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Abstract
Regenerative medicine is a multidisciplinary effort to regenerate or replace a deficiency
of functional cells/tissues, such as deteriorated vasculature in cardiovascular pathologies
or depleted 𝛽-cell mass in diabetes. The transplantation of pro-regenerative progenitor
cell populations has demonstrated therapeutic benefits in pre-clinical models, although
translation to clinical efficacy is limited by the paradoxical balance between cell
expansion ex vivo and loss of regenerative functions in vivo. Herein, this thesis
encompasses two distinct approaches to circumvent translational deficiencies; 1)
prevention of hematopoietic progenitor cell differentiation during ex vivo expansion and
2) utilizing the secretome of pancreas-derived multipotent stromal cell as a biotherapeutic
agent. Across the first two studies, I investigated whether the inhibition of retinoic acid
(RA)-signaling would limit HPC differentiation and retain pro-vascular and islet
regenerative functions in vivo. These studies identified a bias of HPC towards
megakaryopoiesis with prolonged culture; however, also demonstrated that the reversible
inhibition of RA-signaling enhances the expansion of HPC progeny that retain a primitive
phenotype and multifaceted pro-regenerative functions in vivo. Albeit, cell
transplantation is limited by transplanted cell survival and subsequent secretion of proregenerative stimuli. Accordingly, we have demonstrated the transplantation of
conditioned media generated by therapeutic cells by-passes these limitations while
stimulating endogenous mechanisms of tissue regeneration. To this end, I isolated a
heterogenous Panc-MSC population during culture of human islets in vitro. Using labelfree mass spectrometry and flow cytometry analyses, I provide the first in-depth
characterization of human Panc-MSC in comparison to BM-MSC. Specifically, I
demonstrated the proteome of Panc-MSC restricts adipogenesis and RA-signaling; albeit,
is competent to pro-neural stimuli and primed for robust expansion ex vivo. Next, I
determined that Panc-MSC secrete pro-angiogenic and islet regenerative stimuli which
are harbored within extracellular vesicles. Collectively, this body of work provides novel
insights towards multifaceted therapeutic cell populations and lays a foundation to
explore the cell-free biotherapeutics for applications of regenerative medicine.
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Summary
This body of work undertakes a broad experimental approach to identify “stem cell”
populations cells from human post-natal or adult tissues, such as umbilical cord blood,
bone marrow, or pancreas. Specifically, I sought to identify cells which may be used as a
biological agent to activate endogenous (self-) regeneration to treat diabetes and lifethreating complications of blood vessels. In diabetes, a loss or dysfunction of insulinproducing β-cells leads to elevated blood sugars that damage blood vessels in organs
throughout the body. In the first half of this thesis, I developed a method to increase the
number of blood lineage-specific stem cell populations that can regenerate beta-cells and
blood vessels in mouse models. Albeit, I present early evidence that cells of the
megakaryocyte (platelet-producing)-lineage may have therapeutic potential. The second
half of this thesis characterized a mesenchymal progenitor population from human
pancreas tissue using high-sensitive equipment to detect over >7000 proteins in an effort
to establish a “proteomic fingerprint” of therapeutic cell populations. Accordingly, I
proceeded to show that cell transplantation can be avoided, and media conditioned by
mesenchymal progenitors can be concentrated for use as a biological cocktail to stimulate
blood vessel and β-cell regeneration in mouse models. This body of work provides
foundational evidence to further explore the use of post-natal and adult stem/progenitor
cell populations as a therapeutic tool to treat diabetes and/or vascular complications.

Keywords
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Extracellular Vesicles, Proteomics
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Chapter 1

1

Introduction

1.1 Diabetes Mellitus
Over 2000 years ago, physicians in India provided the first ‘clinical’ diagnosis of
“madhumeha” or “honey urine” when excessive urine excretion (polyuria) from patients
attracted an unexpected infestation of insects1,2. Today, madhumeha is diagnosed as
diabetes mellitus (DM) or ‘passing through of honey’ which more accurately segregates
the glucose-rich polyuria of diabetes mellitus from non-related polyuria conditions (i.e.
diabetes insipidus)3. Although DM has challenged scientists and clinicians for over 2000
years, only in the last century has clinical interventions that mitigate early death become
available4. At the root of disease, DM is the dysregulation of blood glucose homeostasis
and/or peripheral insulin sensitivity; ultimately leading to system-wide cardiometabolic
imbalances that contribute to secondary pathologies.
DM can be further segregated based on etiology and central pathology, albeit both
types of DM will ultimately succumb to comparable cardiovascular comorbidities5-9.
Briefly, DM is made-up of individuals with autoimmune Type 1 and insulin-resistant
Type II pathologies; although, other forms of DM, such as gestational diabetes, also
exist10-13. Presently, DM has reached epidemic proportions (>400 million individuals
globally) and has financially burdened the international healthcare system (>700 billion
USD per year) without a foreseeable plateau13. Throughout this chapter, I will discuss the
etiology, pathology and common cardiovascular comorbidities of DM. Specifically, I will
focus on the limitations of therapeutic approaches aiming to provide long-term glucose
control and how regenerative medicine is progressing towards novel therapies to treat
diabetes and vascular comorbidities.
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1.1.1

Human Pancreas Development

Organogenesis of the human pancreas occurs at anatomical region of the endodermderived distal foregut morphogenesis followed by subsequent budding of the FOXA2+
(Forkhead Box A2)/PDX1+ (Pancreatic and Duodenal Homeobox 1) dorsal and ventral
pancreatic epithelium at 4-5 weeks post-conception14,15 (Figure 1.1). Accordingly, the
larger dorsal bud and common bile duct rotate and fuse to the smaller ventral bud,
creating the common pancreatic duct network that drains exocrine secretions towards the
duodenum around embryonic week 7. During these morphological changes, PDX1+
progenitor cells within pancreatic buds undergo robust proliferation and differentiate into
either duct-supported exocrine tissue or endocrine-functioning islets of Langerhans. In a
brief summary, SOX9+ (SRY-box 9)/PDX1+ progenitors will acquire an exocrine fate
through the acquisition of GATA4 (GATA Binding Protein 4) expression defining ‘tip’
progenitor cells committed toward acinar cell fate. In contrast, ‘trunk’ progenitor cells
serve as a bipotent progenitor cell pool which commits to ductal or endocrine-lineage fate
through sustained expression of SOX9 or transient expression of NEUROG3,
respectively15. Exocrine tissue makes up the vast majority of the adult pancreas (>95%)
and provide an essential supply of pro-isoform digestive enzymes that are subsequently
activated in the duodenum of the small intestine. Endocrine tissue makes up ~1-2% of
total pancreas mass despite containing a unique composition of at least 5 hormonereleasing islet cell types. In summary, exclusive expression of lineage specific
transcriptional factors in NEUROG3+ endocrine-lineage progenitors, such as NKX6.1
(NK6 Homeobox 1) and MAFA (MAF BZIP Transcription Factor A) , lead to the
differentiation and maturation of insulin-producing β-cells15. Similarly, the balance
between ARX (Aristaless Related Homeobox) and PAX4 (Paired Box 4) expression
regulates α-cell versus β-cell identity16, respectively. The coordinated development of
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Figure 1.1 Overview of Human Pancreas Development and Lineage-specification.
Organogenesis of pancreas begins in distal foregut endoderm at 3-4 weeks postconception. FOXA2 and PDX1 expression defines Distal Foregut Endoderm commitment
to the pancreatic lineage. High GATA4 expression commits PDX1+ pancreatic bipotent
progenitors towards acinar-cell fate. Sustained NKX6.1 expression commits bipotent
progenitors towards ductal cell fate through sustained expression of SOX9. Alternatively,
endocrine progenitors will lose SOX9 expression and transiently express NEUROG3.
NEUROG3+ progenitors will give rise to endocrine cells, including insulin-secreting βcells and glucagon-secreting α-cells.
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these specialized cell-types bestows the pancreas as a multifunctional organ which
provides central components for nutrient absorption and energy homeostasis.
Acinar cells can be histologically identified by ductal-centric organization, distinct
cytoplasmic zymogen granules, and basolateral nucleus17,18 (Figure 1.2). During
development, acinar cells differentiate from PDX1 pancreatic endoderm progenitors
through the activation of Notch signaling pathways and expression of GATA4, PTF1
(Pancreas Associated Transcription Factor 1a), and CPA2 (Carboxypeptidase A2)15,17,1921

. Pancreatic acini are composed of acinar cells centered around centroacinar cells

located at the terminal end of intercalated ductal epithelium22. Networks of ductal
epithelium converge to form intralobular ducts that transport digestive zymogens released
from acinar cells. Exocrine secretions of the pancreas to lead enzymatic breakdown and
absorption of carbohydrates, lipids, or proteins in the small intestine. Disruption of acinar
homeostasis can lead chronic inflammation of the pancreas, also known as pancreatitis.
Towards this end, acinar cells have been proposed to regenerate exocrine pancreas tissues
via dynamic differentiation and plasticity23,24. Exocrine regeneration by acinar cell
expansion has been thoroughly investigated24,25, however convincing evidence of acinar
cell reprogramming towards an endocrine fate has only been demonstrated using
exogenous vectors26.
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Figure 1.2 Overview of Exocrine and Endocrine Cell Populations of the Pancreas.
The pancreas contains exocrine (acinar and ductal cells) and endocrine (islet of
Langerhans) cell populations, each with unique functions.
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The endocrine compartment of the pancreas is composed several cell-types marked by
specialized hormone secretion27; including ∝-cells (glucagon), 𝛽-cells (insulin), δ-cells
(somatostatin), ε-cells (ghrelin), PP-cells14,28-30. The ratio of cells within islets of
Langerhans is estimated around 35-40% ∝-cells and 40-60% β-cells with infrequent
representation by δ-cells, PP, and ε-cells. Spatial arrangement of endocrine cells within
islets is distinct between rodents and humans, such that β-cells dispersed through the
human pancreas and centered at the islet core in rodent models. Nonetheless, the
architecture of mammalian pancreatic islets is integrated with a dense microvascular
network, that serves to transport secreted hormones to peripheral tissues31. In the context
of diabetes, reciprocal balance of ∝- and β-cell function maintains glucose homeostasis
by controlling the glucose release from the liver and uptake from the circulation32-35.
Briefly, ∝-cells release of glucagon in response hypoglycemic or energy-demanding
conditions. Activation of the glucagon receptor on hepatocytes increases glycogenolysis
and gluconeogenesis to elevate blood glucose levels. In contrast, insulin functions to
reduce blood glucose levels by stimulating glucose uptake into peripheral tissues after
ingestion of food. In the context of diabetes, the loss of functional β-cell mass and/or
peripheral insulin sensitivity leads to damaging hyperglycemia36.

7

1.1.2

Insulin Secretion and Glucose Homeostasis
Following the ingestion of food and absorption of carbohydrates in the small

intestine, systemic blood glucose concentration can rapidly elevate nearly 2-fold in a
healthy adult32. In order to counteract toxicity from prolonged hyperglycemia, β-cells
sense hyperglycemia and rapidly restore normoglycemia (within ~60 minutes) through
the hormonal actions of insulin (Figure 1.3). β-cells are equipped with bidirectional
glucose transporter, GLUT2 (Glucose Transporter 2), that allows β-cells to gauge
systemic glycemia levels and regulate glucose metabolism37,38. Homeostatic blood
glucose levels are maintained by a fine-tuned balance of glucagon or insulin secretion. In
periods of normoglycemia, the low affinity of GLUT2 transporter facilitates glucose
uptake from circulation at concentrations that maintains membrane potential in β-cells38.
In contrast, hyperglycemia elevates glucose uptake via GLUT2 and increases the
production of cytosolic ATP, ultimately leading to insulin secretion (Figure 1.3). ATP
generated by glycolytic activities of the β-cell will inhibit ATP-sensitive K+-channel
function, and in return, indirectly open voltage-gated Ca++ channels38-40. Decreased K+
efflux leads to rapid depolarization of the plasma membrane and increased cytosolic
calcium concentrations mediate insulin release. The initial pool of insulin released via
exocytosis by β-cells is replenished by the glucose-sensitive regulation of pro-insulin
translation. During this period, glucagon secretion from α-cells

8

Figure 1.3 Overview of Insulin Secretion and Glut4 Translocation in Response to
Hyperglycemia. Glucose uptake through GLUT2 transporters leads to increased
cytosolic ATP in beta-cells. Inhibition of ATP-sensitive K+ channels will lead to an
influx of Ca++ and insulin vesicle release and translation. Insulin will activate INSR1/2
on peripheral cells (i.e. adipocytes) and translocation of GLUT4 to the plasma membrane
will occur. Subsequently, glucose will be up taken through GLUT4 transporters to satisfy
metabolic demands.
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is dampened, and glucose storage is promoted within the liver by the inhibition of
glucagon-regulated glycogenolysis enzymes and activation of glycogen synthase to
promote glycogen formation33. Circulating insulin activates insulin-receptors to stimulate
translocation of GLUT4 transporters to the plasma membrane of competent (i.e. liver,
adipose, skeletal muscle) cells to increase the glucose clearance from systemic circulation
and meet the metabolic demands of tissues35,41,42. In type 2 DM, insulin-dependent
GLUT4-translocation is disrupted in peripheral cells.
Insulin secretion and/or function is also regulated by additional effectors which either act
in a positive or negative manner. Incretins hormones including Gastric Inhibitory
Polypeptide (GIP) and Glucagon-like Peptide 1 (GLP-1) are released from the intestinal
mucosa shortly after oral nutrient ingestion43,44. Both GIP and GLP-1 potentiate insulin
secretion from the pancreas, whereas the later also reduces glucagon secretion. Ghrelinsecretion from epsilon-cells also increases insulin secretion from β-cells in rodent model,
although the relevance of this in humans is not completely understood29,30. In contrast,
effectors such as glucagon, catecholamines, growth hormone, cortisol, and free fatty
acids dampen the secretion or peripheral actions of insulin32,34. Intra-islet hormones, such
as somatostatin and PP, also provide overlapping regulation of glucagon and insulin
secretion45,46. In the context of diabetes, disruption of insulin production and/or
peripheral sensitivity leads to dysregulated systemic glucose homeostasis. As a result, a
wide spectrum of cardiometabolic pathologies develop leading to life-threatening
complications.
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1.1.3

Type 1 Diabetes
Accounting for ~10% of individuals with DM, Type 1 DM affects roughly >40

million individuals internationally and is most prominent in populations of Northern
European descent13,47. Type 1 DM is commonly referred to as juvenile diabetes, although
this terminology may be viewed as a misnomer as symptoms occasionally manifest in
adults as latent autoimmune DM or ‘Type 1.5’48. The international rates of Type 1 DM
have gradually increased over time47,49,50, which has only complicated our understanding
of the etiology of Type 1 DM47,50-55. Although genetic mutations (i.e. HLA-DR3/4) have
been identified in a proportion of individuals with Type 1 DM, other studies have
suggested in utero or post-natal environmental insults, combined with genetic
predisposition, may trigger initiation of autoimmunity in Type 1 DM51,54,55. Common
models of Type 1 DM, include NOD mice which spontaneously develop autoimmune
diabetes and reflect the human pathophysiology of inflammatory cell infiltration into
islets56. Other genetic and chemical-induced models have also been used to further our
understanding the pathophysiology of Type 1 diabetes and/or facilitate the transplantation
of human islets and/or regenerative cell populations for the development of novel
therapies57,58.
The underlying pathology of Type 1 DM is targeted T-cell mediated destruction of
pancreatic β-cells (Figure 1.4). Specifically, CD4+ T-helper Cells and CD8+ cytotoxic Tcells are responsible for the targeted destruction of β-cells following the generation of
autoantibodies by activated B cells, respectively54,59. Although mechanisms are not
completely understood, autoantigen presentation is initially mediated by B-lymphocytes
and antigen-presenting cells of the innate immunity, such as macrophages and/or
dendritic cells. Interestingly, 𝛼-cells, 𝛿-cells, PP cells, and 𝜖-cells of the islet are not
targeted by cytolytic CD8+ T-cells, thus suggesting the autoantigen is exclusive to the βcell lineage. Recent studies have suggested early senescence of a β-cell population may
be the root of autoantibody generation60, eventually leading to the destruction of
functional β-cells. The destruction of insulin-generating β-cell leads to systematic
complications, such as neuropathy, nephropathy, retinopathy and gastrointestinal
disorders, as a result of prolonged periods of hyperglycemia8,61-64.
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Figure 1.4 Overview of Autoimmune-induced Type 1 Diabetes and Insulindependent Hyperglycemia. Autoantigens, generated by antigen presenting cells of the
innate and adaptive immune system, activate cytolytic T-cells. Activated T-cells will
selectively induce apoptosis in β-cells, leading to a loss of insulin-producing cell mass.
The loss of β-cell mass will lead to sustained hyperglycemia and insulin-dependence.
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In a clinical setting, individuals with Type 1 diabetes present with a spectrum of
symptoms59; however, the initial diagnosis typically following the rapid onset of severe
hyperglycemia-induced coma. In addition to severe hyperglycemia, patients with Type 1
diabetes may present with sub-average muscle mass, chronic fatigue, polyuria, and/or
secondary infections of oral and genital orifices. Ultimately, individuals diagnosed with
Type-1 diabetes are insulin-dependent and require daily exogenous injection or
automated pump therapies.

1.1.4

Type 2 Diabetes

The prevalence of Type 2 diabetes has increased at an alarming rate. With an estimated
>30% increase of afflicted individuals in next 5 years, Type 2 diabetes continues to
burden the global healthcare system due poor diet, central obesity, and sedentary
lifestyles65-71. In 2015, Type 2 diabetes patients numbered >400-million individuals
globally and despite a notable number of individuals remaining undiagnosed, Type 2 DM
and related health issues caused the global healthcare system >$800 billion13,67,70,71.
Unfortunately, in many cases this financial burden is placed on the afflicted individuals
who struggle to secure and retain employment due to complications of the disease67.
Notably, Type 2 diabetes is largely preventable through proper diet and exercise
regimens, which outlines the importance of public educational programs and individual
care65,66,72-77. Furthermore, both proactive and preventative measures must be taken to
counteract the alarming rate of Type 2 diabetes presently diagnosed in children and
adolescents61. Several genetic pre-dispositions have been proposed by genome-wide
association studies and have correlated variations in genetic loci to the onset and
progression of Type 2 DM in human tissues68,71,78. To this end, evidence from epigenetic
studies following gestational insufficiency have demonstrated important non-genetic
contributions towards β-cell maturation and susceptibility to disease later in life15,79,80.
Without effective management of hyperglycemia, individuals with Type 2 DM will
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eventually become insulin-dependent (Figure 1.5); although, early diagnosis could
prevent this outcome.
Skeletal muscle and adipose tissues are the primary targets for circulating insulin to
stimulate the rapid removal of glucose from the blood35. Insulin binds to insulin receptor
1/2 (INSR1/2) on the membrane of target cells, in return leading to a cascade of
downstream effectors that stimulate translocation of GLUT4 transporter to the plasma
membrane42,81. Chronic activation of INSR1/2 can lead sustained receptor internalization
leading to a global decrease in the expression of GLUT4 on peripheral tissues. As a
result, when β-cells increase the production and secretion of insulin, in an attempt to
combat prolonged periods of hyperglycemia, peripheral tissues, such as skeletal muscle,
become desensitized to chronic exposure of circulating insulin and fail to facilitate the
uptake of glucose from systemic circulation. As a result of concurrent obesity, individuals
with Type 2 DM are prone to elevated level of free fatty acids which additionally
compromise β-cell function82. This paradoxical dysfunction of glucose homeostasis
eventually leads to β-cell exhaustion, free-radical generation, and β-cell death83,84.
Ultimately, the capacity of the pancreas in Type 2 diabetics to produce enough
endogenous insulin is compromised, thus individuals with late-stage Type 2 DM will
require exogenous insulin therapy similar to individuals with Type 1 DM70,71,83.

14

Figure 1.5 Overview of Insulin-resistant Type 2 Diabetes and Insulin-dependent
hyperglycemia. Sustained periods of elevated glucose levels and cardiometabolic
imbalances lead to peripheral insulin desensitization. As a result, insulin demand will
increase and eventually lead to beta-cell exhaustion and apoptosis. In late stages of Type
2 diabetes, the loss of beta-cell mass leads to insulin-dependence.
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1.1.5

Clinical Strategies to Combat Diabetes

Insulin-dependence in Type 1 and Type 2 DM is a result diminished β-cell mass where
insulin secretion is no longer sufficient to maintain glucose homeostasis. Interestingly,
rodent models that received >90% excision of the pancreas did not become insulindependent despite a considerable loss of β-cell mass25,85. In contrast, a 40-50% resection
of the pancreas in human patients has led to insulin-dependence following surgery86.
These differences reflect genetic and physiological differences between species, such as
architectural organization and distribution of islets of Langerhans87-92. Nonetheless,
current therapies must supplement the loss of insulin-secreting β-cells by providing
sufficient exogenous insulin to counteract chronic hyperglycemia93,94. However,
exogenous insulin therapy can lead to fluctuations in blood glucose that lead to diabetic
complications, which reduces the life expectancy of individuals with DM by ~15 years
despite current clinical intervention. Briefly, I will highlight the current clinical strategies
and limitations encountered during the treatment of Type 1 or Type 2 DM.

1.1.5.1

Clinical Therapies for Type 1 Diabetes

From a pioneering studies performed in Canada, the discovery of insulin by Fredrick
Banting, Charles Best, and John McLeod has prolonged the survival of Type 1 DM
patients95,96. Insulin, a 29 a.a. peptide, was first discovered through intravenous
administration of pancreatic extracts which temporary alleviated hyperglycemia in
diabetic dogs. The first human patient to demonstrate clinical improvements was injected
with purified insulin from bovine pancreas97. Today, insulin is primarily synthesized and
purified from bacteria or yeast98,99; although this has not limited the considerable
financial burden placed on insulin-dependent patients67,100,101. Moreover, there exists
several types of insulin that differ based on their pharmacological onset and duration of
therapeutic effect. Endogenous insulin is packages as a hexameric molecule within
cytoplasmic vesicles and cleaved into monomers upon secretion. Exogenous insulin has
exploited these properties to engineering insulin subunits which only exist as monomers
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to longer-lasting insulin subunits. Despite these advancements, insulin therapy fails to
recapitulate the fine-tuned physiological response observed in healthy subjects, thus
replacement of functional β-cell mass is sought to achieve sustained reversal of insulindependence in individuals with Type 1 DM.
The Edmonton protocol provided pioneering evidence that replacement of functional βcell mass could reverse severe Type 1 DM102,103. Specifically, Shapiro and colleagues
demonstrated the infusion of human islets from 2-3 donor pancreas into the portal vein of
the liver could alleviate insulin-dependence for up to 1-year in patients with Type 1
DM104. This procedure is still performed today yet is severely limited by the lack of
donor pancreases and continued autoimmunity and islet rejection despite a parallel
immunosuppressive regimen which leaves patients vulnerable to secondary infections105.
These studies set the foundation for current regenerative medicine approaches which aim
to either replace or regenerate endogenous β-cell mass. Current evidence suggests the
orchestration of endocrine cell regeneration may entail a combination of endocrine-cell
replication, transdifferentiation, and/or islet neogenesis22,23,58,106-110. Therefore, effective
therapies entail a broad activation pro-regenerative signaling pathways, possibly in
multiple cell targets. Albeit, the true effectiveness of either replacement or regeneration
strategies will also depend upon the dampening of autoimmunity111. Accordingly, several
strategies are currently being investigated to mitigate autoimmunity112-114.

1.1.5.2

Clinical Therapies for Type 2 Diabetes

Individuals with Type 2 diabetes are commonly treated with pharmaceutical agents which
aim to lower hyperglycemia independent of exogenous insulin administration. For
example, Metformin is commonly prescribed to reduce blood glucose by dampening
gluconeogenic activity of the liver and increasing peripheral insulin sensitivity115. In
contrast, other pharmaceuticals, such as Sulfonylureas, act to lower blood glucose by
enhancing the secretion of insulin from β-cells116. Recently, pharmaceutical inhibitors of
SLGT2 (sodium-glucose co-transporter 2) aim to reduce glucose reuptake in the proximal
tubule of the kidney117. For example, Empagliflozin administration reduced
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hyperglycemia and Hemoglobin A1c by promoting the excretion of glucose through
urination. Nonetheless, early diagnosis of Type 2 diabetes may permit reversal the
disease through dietary and lifestyle changes65,73,75,76,93,118,119. As previously noted, public
education is crucial to circumvent the epidemic progression of Type 2 DM. In contrast to
Type 1 diabetes, undiagnosed Type 2 DM does not produce an immediate threat to
survival; however, Type 2 DM occurs frequently with hyperlipidemia and leads to lifethreatening cardiovascular comorbidities5-7,9. Therefore, individuals with Type 2 DM
often require therapeutics to simultaneously combat cardiometabolic syndromes and
peripheral insulin-resistance.

1.2 Cardiovascular Comorbidities of Diabetes
Individuals with DM are highly susceptible to developing secondary comorbidities,
including neuropathy, nephropathy, retinopathy and gastrointestinal disorders5-9,63,64.
Notably, prolonged periods of hyperglycemia and/or hyperlipemia leads to irreversible
macrovessel and microvessel damage in 90% individuals with DM. Damage of
microvasculature has be implicated in stroke, myocardial infarction, and peripheral limb
ischemia7,120. Likewise, the disruption to microvascular networks can lead to renal121 and
neurological dysfunction62,122, and loss of vision123. Collectively, loss of vascular
networks reduces the delivery of oxygen and nutrients to tissues leading to system-wide
cardiometabolic dysfunction. Thus, restoration of cardiovascular function using
regenerative medicine approaches are relevant to the treatment of diabetic-related
cardiovascular comorbidities, such as peripheral artery disease.

1.2.1

Vascular Biology and Architecture

Tissues in the human body require dynamic microvascular networks to receive vital
nutrients and oxygen124,125. The cardiovascular system is quickly established during
embryogenesis, such that embryonic tissues rely on paracrine signaling from endothelial
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cells during organogenesis126-129. Development of vasculature is initiated during blood
island formation within the early yolk sac130. Peripheral cells of blood islands generate
angioblasts or endothelial-lineage committed stem cells131, which migrate to the embryo
to establish de novo vasculature structures, a process termed vasculogenesis.
Subsequently, endothelial cell progenitors will undergo extensive proliferation and
mediate sprouting from pre-existing vessels, i.e. angiogenesis, to establish well-defined
vascular networks. Gradients of vessel-supportive cytokines, such as VEGF132,133 or
Angiopoietin family members134-136, are primarily established by secondary cell
populations 137,138, such as circulating hematopoietic cells131,139,140 that provide stimuli
which contribute to vasculature development.
The cardiovascular system is composed of a well-defined hierarchy of macro- and microvessel structures with distinct functions to maintain homeostasis125. At the center of the
cardiovascular system, the heart continuously pumps oxygenated blood from the left
ventricle through aorta141 and downstream arteries (0.1-10mm diameter) and arterioles
(100-300 um diameter) comprised of three distinct anatomical layers142. The tunica
externa is outer most layer of arterial vessels and is primary composed of elastic fibers
which function to support vessel stretching when encountering large volumes of blood
flow. The tunica media is located between the Tunica externa and a basement membrane
that separates the tunica intima. The tunica media is composed of smooth muscle cells
which contribute to hemodynamic regulation throughout the body, such as regulation of
arterial flow142. The tunica intima, found throughout all vessel types, is recognized as the
continuous layer of endothelial cells that interacts with systemic circulation. Capillaries
are the smallest vessels of the cardiovascular system and are the primary site of gas and
nutrient exchange143,144. Depending on the tissue, endothelial cell permeability can
become fenestrated to facilitate filtration (i.e. kidney glomeruli) or selectively
impermeable, as seen in the blood brain barrier145,146. Subsequent networks of venules
and veins return deoxygenated blood from capillaries towards pulmonary circulation for
reoxygenation147. Similar to arteries, venules and veins contain three layers; however,
differ by the relative thinness of the outer tunic layers, increased luminal diameter, and
possess valves that prevent retrograde movement of blood as it is returned through the
vena cava to the right atrium of the heart.
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1.2.2

Endothelial Cells

Endothelial cells line the tunica intima of arterial and venous networks and act as the
functional units of blood vessel to mediate communication between tissue cells and the
systemic circulation. Based on the tissue type, endothelial cells receive extrinsic cues that
guide their phenotype and function, relative to the needs of the tissue145,148. Additionally,
endothelial cells provide paracrine signals that maintain vital cell populations in a variety
of tissues, such as β-cells128,149. The symbiotic relationship between endothelial cells and
adjacent cell populations has been previously demonstrated, such that the depletion of
one population affects the development and survival of the other. Furthermore,
revascularization during organ and tissue transplantation is crucial to the integration and
function of transplanted tissues. Endothelial cells are in constant communication the
hematopoietic system during homeostasis and will release chemotactic and proinflammatory upon injury150. Additionally, endothelial cells are the primary source of
nitric oxide production, a potent vasodilator that acts on adjacent smooth muscle cells
when endothelial cells encounter elevated hemodynamics151,152. Endothelial cells are also
sensitive to elevated lipid and glucose levels in the circulation and succumb to metabolic
dysfunction153. In the context diabetes, injury-induced signals released from endothelial
cells accelerate the infiltration of pro-inflammatory monocytes/macrophages, stimulate
the proliferation and migration of mesenchymal cells, and activate pro-apoptotic
signaling pathways neighbouring cells5,153-158.

1.2.3

Smooth Muscle Cells and Pericytes

Within the Tunica media of large vessels, smooth muscle cells function to maintain
endothelial cell homeostasis and can respond to innervating nervous tissues142,159. Smooth
muscle cells maintain structural integrity of arterial vessels and regulate blood flow
through vasomotor responses. As previously mentioned, endothelial cells release nitric
oxide to stimulate vasodilation through activation of smooth muscle cells, preventing
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downstream damage on fragile capillary networks. Smooth-muscle cells can be identified
by the expression of α-SMA and lack markers of the endothelial lineage.
Related to smooth muscle cells, pericytes also provide structural and paracrine support
with microvessel endothelial networks143,160. Pericytes support capillary homeostasis by
maintaining a delicate balance of growth and regression and are recruited to site of
angiogenesis via a PDGFR𝛽 signaling axis161. Cardiometabolic disorders directly and
indirectly affect pericyte and smooth muscle cell populations, generally leading to
aberrant proliferation and fibrosis in response to elevated metabolic stress159. Pericytes
can be detected by the expression of melanoma cell adhesion molecular (CD146) in the
absence of hematopoietic or endothelial markers161,162. Crisan et al. demonstrated the
selection of CD146+ cells from could establish multipotent stomal cell colony formation
from a variety of postnatal tissues163.

1.2.4

Atherosclerosis

Disruption of endothelial homeostasis and elevated levels of inflammation can lead to
narrowing of blood vessels through the progressive formation of atherosclerotic
plaques138,152,164,165. Specifically, prolonged periods of hyperglycemia or hyperlipidemia
disturb endothelial permeability by increasing reactive oxygen species and decreasing
homeostatic nitric oxide production. Subsequently inflammation initiates a cascade of
monocyte infiltration, proliferation and M1 macrophage specification in response to
excessive lipid deposition within the intimal layers of large vessels (Figure 1.6). Proinflammatory macrophages will readily scavenge excess lipids from interstitial layers of
arterial vessels to generate pathogenic foam cells. Progressive accumulation of foam cells
will develop into the first pathological hallmark of atherosclerosis, the fatty streak. Proinflammatory cytokines stimulate the proliferation and migration of smooth muscle cells
towards the fatty streak. Activated smooth muscle cells will deposit fibrotic extracellular
matrix that lead to the formation of a fibrous cap and de novo plaque formation.
Extensive apoptosis of foam and smooth muscle cells will occur within the core of early
plagues, accelerating the plaque growth through the deposition of lipids, lipoproteins, and
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calcified deposits. Expansion of atherosclerotic plaques can lead to vessel occlusion and
reduction of distal blood flow, as observed in patients with peripheral artery disease.
These processes exacerbate over time until aggregation of platelet aggregation and
infiltration of cytolytic leukocytes disrupts plaque integrity. Spontaneous rupturing of
atherosclerotic plaques and subsequent thrombotic events can impose life-threatening
events, such a myocardial infarction or stroke, by completely occluding arterial blood
flow to the heart or brain164. Common risk factors that lead to atherosclerosis include:
hypertension, hyperlipidemia, sedentary lifestyle, smoking, and diabetes.

1.2.5

Cardiovascular Disease

Cardiovascular disease (CVD) encompasses a broad range of pathophysiological
conditions that primarily affect the function of the heart and/or vasculature5-7,9. These
include a broad spectrum of ailments such as several clinical presentations of cardiac
arrhythmias or myocardial infarction, heart failure, stroke, and peripheral artery disease.
Collectively, CVD remains one of the leading causes of mortality in the world,
accounting for ~30% of deaths 166,167. Furthermore, CVD has placed a crippling burden
on the healthcare system, total costs of $22 billion in Canada per year168. The
manifestation of CVD is multifactorial and commonly presents in parallel with several
cardiometabolic syndromes (i.e. diabetes, obesity, atherosclerosis etc.)158,165,169. Although
genetic pre-dispositions exist, risk factors such as smoking, obesity, etc., are often
avoidable73,76,77,118,119. Nonetheless, escalating rates of diabetes, hypertension, and obesity
globally will inevitably lead to increased prevalence of CVD. It is estimated that nearly
half of the population in the United States will develop CVD in the next decade167,
leading to a >2-fold increase in annual healthcare costs170.
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1.2.6

Peripheral Artery Disease and Critical Limb Ischemia

Atherosclerotic manifestation in the peripheral vasculature can lead to a partial or
complete occlusion of blood flow to distal tissues (Figure 1.6), as observed in individuals
with peripheral artery disease (PAD). 1 in 5 individuals with DM will eventually develop
some form of PAD as a result of diabetes-induced dysfunction of the
microvasculature13,120,171-173. It is estimated 800,000 individuals in Canada and >8 million
individuals in the United States are afflicted with PAD120,174; and many patients with
PAD do not present in the clinic until symptoms are severe. Peripheral artery disease can
be diagnosed with a combination of physical exam, ankle-brachial index (ABI)
measurements, ultrasound, blood tests, and/or angiography172. In many cases, non-healing
wounds or ulcers in diabetic patients lead to diagnosis of PAD, at which point PAD has
progressed beyond reversible stages (i.e. intermittent claudication) and intervention may
be required. Critical limb ischemia (CLI) is the most severe form of PAD. Individuals
with CLI present with resting pain, non-healing ulcers, secondary infections and tissue
necrosis due to the severe ischemia in tissues distal to occluded vasculature. An estimated
1 in 3 patients diagnosed with CLI will require limb amputation; and >60% of patients
will succumb to cardiovascular-related deaths within 5 years175. Current therapeutic
strategies for PAD and CLI aim to target symptoms, slow disease progression, and/or
prevent secondary adverse cardiovascular events176.
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Figure 1.6 Overview of Atherosclerosis and Peripheral Artery Disease.
Cardiometabolic imbalances will disrupt endothelial health and permeability, leading to
subintimal lipid accumulation and monocyte infiltration. Infiltrating monocytes will
rapidly proliferate and differentiate into lipid-scavenging macrophages. Lipid
accumulation within macrophages leads to foam cells formation and apoptosis within the
atherosclerotic plaques. Plaque formation is also mediated by smooth muscle cell
activation, proliferation, and the deposition of collagen and fibrous cap formation. As
atherosclerosis progresses, endothelium is compromised, and platelet aggregation will
occur. Late stages, plaque integrity is comprised and atherothrombosis formation occurs.
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1.2.7

Strategies to Combat Vascular Disease
Currently, patient care for the primary treatment of PAD has two main goals; 1)

management of symptoms to increase quality of life, and 2) mitigate the progression of
atherosclerosis to prevent heart attack and stroke via pharmaceuticals and/or life-style
changes177. Depending on the underlying health of an individual, pharmaceuticals
primarily aim to reduce hyperlipidemia, hyperglycemia, hypertension, or the risk of
platelet aggregation and clot formation65,93. To mitigate limb amputation for CLI, surgical
interventions may be performed to increase the luminal diameter of a restricted artery
(i.e. balloon-catheter angioplasty) or bypass occluded vasculature using autologous or
synthetic grafts which re-establish blood flow from proximal to distal
vasculature176,178,179. Unfortunately, a significant proportion of individuals with severe
PAD are unsuitable surgical candidates due to diffuse microvascular blockage and
underlying comorbidities. Alternative therapies that re-establish blood flow via the
restoration of endothelial homeostasis and function have demonstrated preclinical
potential. The field of regenerative medicine is actively investigating pharmaceutical, and
gene or cell-based therapies to stimulate revascularization and restore tissue
homeostasis180,181.

1.3 Regenerative Medicine: A Historical Perspective
For centuries, scientists and physicians have proposed that the human body possessed
considerable capacity to heal itself through tissue regeneration. For example, Greek
mythology describes the story of Prometheus. As a punishment for stealing fire from the
gods, Prometheus is chained to a rock where his liver is removed daily by an eagle of
Zeus, only to have his liver grow back by the next day. The Greek physician Hippocrates
was quoted as saying “Let food be thy medicine and medicine be thy food”. In the
context of Type 2 diabetes and cardiovascular comorbidities, Hippocrates’ view would
address a critical need to circumvent these pathologies through individual nutrition and
lifestyle habits. Hippocrates’ philosophy could also translate to the foundation of current
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approaches which aim to discover therapeutic strategies that enhance regeneration and reestablish tissue homeostasis by activation of endogenous signaling networks. Within the
following section, I will provide a foundational overview on the field regenerative
medicine; specifically focusing on the applications of post-natal regenerative cell sources
to develop biotherapeutics for DM and/or comorbid CVD pathologies.

1.3.1

Regenerative Medicine
Regenerative medicine encompasses a broad spectrum of therapeutic approaches

and multidisciplinary efforts to restore physiological tissue function in the face of
disease182. For example, regenerative medicine approaches to treat vascular
complications of diabetes encompass efforts including: pro-angiogenic gene therapies183,
pro-vascular stem/progenitor cell transplantation184, pharmaceutical or biological
activation of pro-angiogenic pathways185, biological and synthetic scaffold
transplantation186 and related efforts of tissue engineering187. At the core of regenerative
medicine, is the aim to reverse deficiencies in tissue mass, cell function, and/or
homeostatic signaling networks which underlie the pathophysiology of a disease. Stem
cells hold undetermined potential to replace or regenerate damaged tissues; albeit, further
research is critical to realize this potential. Accordingly, many labs are investigating the
use of stem cells to treat chronic ailments, such as Type 1 DM and CLI.

1.3.2

Stem Cell Biology

First discovered by Canadian scientists, James Till and Ernest McCulloch188, stem cells
are defined by their capacity to undergo symmetric division without differentiation (selfrenewal) while also demonstrating the capacity to differentiate into cells of multiple
lineages (potency)189. Self-renewal is necessary for the long-term survival of stem cell
pools throughout the lifetime of an individual so that expendable and functionally mature
cells can be continuously replaced when damage or senescence occurs. The hierarchy of
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cell potency apexes with totipotency (the ability to generate cells of the embryo and
extraembryonic tissue) represented at fertilization and subsequent generation of a zygote.
As embryogenesis proceeds and the morphogenesis of the blastocysts occurs, and cells of
the inner cell mass (i.e. embryonic stem cells) are pluripotent (Figure 1.7). Pluripotency
is the capacity of a cell to differentiate to all 3 germ layers of the embryo proper; i.e.,
ectoderm, mesoderm, endoderm. Embryonic stem cells are the only native tissue that
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Figure 1.7 Working Model of Pluripotency and Multipotency in Stem Cells
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demonstrate pluripotency in the human body, as adult stem cells exhibit multipotency
generating multiple cell types within a specific germ layer. Notably, these barriers in
potency have been shattered by Yamanaka’s generation of induced-pluripotent stem cells
from differentiated cells that may represent a potential source of patient specific-stem
cells190.
The turnover of cell in the human body requires compartmentalized differentiation of
lineage-specific stem and progenitor cells that demonstrate multipotency, or the capacity
to differentiate into multiple lineages of a single germ-layer191,192. For example,
mesoderm-derived hematopoietic stem cells give rise to multipotent progenitor cells that
are committed to differentiation of myeloid or lymphoid lineages of the hematopoietic
system; moreover, these cells do not readily differentiate into related lineages such as
endothelial or multipotent stromal cells. These stem and progenitor cells of the
mesodermal lineage have been targeted in pre-clinical and clinical studies to treat
diabetes and related cardiovascular complications57,193-197. The phenotypic identity of
stem cell populations can be differentiated according to surface marker expression, such
as CD34 expression on hematopoietic stem cells198,199. However, cell surface marker
expression is dynamic and changes in response to injury or culture in vitro.
Molecular functions unique to stem and progenitor that provide protection from
cytotoxic insults can be used alone or in combination with surface markers to identify
long-lived stem cell populations in a variety of fetal, postnatal, and adult cancerous
tissues200. As an example, aldehyde dehydrogenase activity has been used as a conserved
self-protective enzymatic function that protects against oxidative damage within multiple
stem and progenitor cells lineages in tissues including blood201, pancreas202, brain, and
colon203. In general, as cells differentiate toward functional maturity, ALDH-activity is
reduced. Despite these protective mechanisms, accumulating evidence has demonstrated
a microenvironment of chronic metabolic disease such as type 2 diabetes can lead to the
depletion of stem and progenitor numbers, in addition to perturbation of regenerative
function74. In the context of regenerative medicine, tissue specific stem and progenitor
cells possess the potential to replace damaged or dysfunctional cells (i.e. β-cells or
microvessels) through directed differentiation ex vivo204 or through the activation of
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dormant tissue-resident-progenitor cells via paracrine signaling mechanisms in situ205.
To exemplify the latter, umbilical cord blood (UCB)-derived hematopoietic progenitor
cells (HPC) with high aldehyde dehydrogenase activity demonstrate a multifaceted
secretome that can stimulate β-cell and endothelial cell proliferation in vivo following cell
transplantation without long-term engraftment or differentiation into damaged cell
phenotypes58,206.

1.3.3

Aldehyde Dehydrogenase and Retinoic Acid Signaling Pathway

Aldehyde dehydrogenase (ALDH) plays an essential role in embryogenesis and provides
post-natal stem and progenitor cell populations long-term protection from cytotoxic
insults207. The aldehyde dehydrogenase enzyme family contains 19 isoforms, with
localization to cytosolic or mitochondrial compartments. Previously studies have
demonstrated that ALDH2 is the main isoform expressed during early embryogenesis,
whereas ALDH1 and ALDH3 isoforms are primarily expressed throughout post-natal
tissues. In addition to providing cytosolic protection to reactive aldehyde species, ALDH
is a rate-limiting step in the metabolism of retinol to retinoic acid (Figure 1.8).
Retinol (Vitamin A) is a cholesterol derivative taken up from circulation through Retinoic
Acid 6/STRA6 expression at the plasma membrane of competent cells. Cytosolic retinol
is metabolized by alcohol dehydrogenase family members (i.e. ADH10/11) to generate
retinaldehyde (retinal). ALDH1A1 or ALDH1A3 oxidizes retinaldehyde to produce the
lipophilic morphogen retinoic acid (RA). Following production, RA can be rapidly
translocated from the cytosol to the nucleus by cellular retinoic acid-binding protein 2
(CRBP2) and presented to RA-receptor complexes to regulate transcriptional and
epigenetic events. RA receptors exist as heterodimers consisting of one retinoic acid
receptor (RARα, RARβ, RARγ) in conjunction with a retinoid X receptor isoform
(RXRα, RXRβ, RXRγ)208. The binding of RA to the RAR alters the conformation of the
complex from a transcriptional repressor to a transcriptional activator of numerous targets
containing retinoic acid receptor elements (RAREs). Furthermore, induction by RAsignaling pathways regulates the transcription of several important genes that code for
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proteins involved in RA-signaling including CRBP1/2 (cellular retinol binding protein),
CRABP1/2 (cellular retinoic acid binding protein), and CYP26 (Cytochrome P450
family).
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Figure 1.8 Working Model of Canonical Retinoic Acid Signaling Pathway. Retinol is
imported through STRA6 (Stimulated by Retinoic Acid Receptor 6) and metabolize by
ADH (Alcohol Dehydrogenase) to Retinal. Retinal is further metabolized by ALDH
(Aldehyde Dehydrogenase) into RA (Retinoic Acid). RA is bound by CRABP (Cytosolic
Retinoic Acid Binding Protein) which will translocate to the nucleus and present RA to
RAR/RXR (Retinoic Acid Receptor/Retinoid X Receptor) heterodimer complexes bound
to RARE (Retinoic Acid Response Element) which will regulate the transcription of
downstream targets.
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RA signaling was has been shown to function together with several other mitogens for
the proper development and segmentation of the hindbrain, forebrain, upper limb buds,
and foregut207. Previous studies have demonstrated that RA forms an opposing
concentration gradient with CYP26 expression to set developmental boundaries during
tissue patterning and organogenesis. RA gradients also play a crucial role during foregut
development, more specifically, the proper development of the insulin-producing
pancreas. Interestingly, xenopus models have demonstrated retinoic acid signaling to
induce the endocrine-specification of ventral and dorsal buds209. Collectively, there exists
a paradoxical and complex balance between the maintenance of high ALDH-activity in
primitive stem cell populations while preventing differentiation through RA-signaling
pathways.

1.3.4

Hematopoietic Stem and Progenitor Cells

Cells of the hematopoietic system serve multifunctional roles to maintain homeostasis in
the body, overseeing processes such as immunity, tissue remodeling, wound response and
delivery of oxygen. Therefore, maintenance of hematopoietic stem and progenitor cells is
crucial and requires an intricate balance between self-renewal and differentiation210.
Hematopoietic stem cells are originally derived from the blood islands of the yolk sac,
before repopulating the aorta-gonad mesonephros regions of the developing
embryo131,210. Subsequently, hematopoiesis takes place in the fetal liver before
establishing permanent residence within the bone-marrow microenvironment211.
Hematopoietic stem cells reside within the endosteal niche of the bone marrow that
allows communication via endothelial and mesenchymal stromal cell populations.
Accordingly, hematopoietic stem cells will receive signals that influence progenitor cell
production and commitment towards myeloid or lymphoid lineages.
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Figure 1.9 Overview of Hierarchy of Hematopoiesis with a specific focus on
megakaryopoiesis. Working model of human hematopoiesis/megakaryopoiesis beginning
with quiescent LT-HSC (Long-term Hematopoietic Stem Cell) and transiting to common
myeloid progenitor cells. Unipotent MEP (Megakaryo-erythocyte progenitors) will give
rise to CD41+ megakaryoblasts Megakaryopoiesis will continue with the emergence of
CD41+/CD42+ megakaryocytes capable of platelet generation.
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Several phenotypic markers have been used to purify hematopoietic stem cells from fetal
and adult tissues, such as CD34 and CD133198,199. Similarly, functional characteristics
such a high ALDH-activity also identifies hematopoietic cells with primitive phenotypic
and progenitor cell functions. The collective efforts of the Dick laboratory have primarily
advanced our understanding of human hematopoiesis, including demonstrate single-cell
HSC transplants can repopulate irradiated murine bone marrow198. Extending from this
knowledge, members of the Bonnet laboratory have demonstrated that the apex of adult
hematopoiesis may be a cell which lacks CD34 and co-expresses a phenotypic profile
including CD90+/CD49f+/CD45RA-/CD38-199 (Figure 1.9). Nonetheless, FACS
purification based on CD34 expression and/or high ALDH-activity enriches for primitive
hematopoietic cells capable of long-term hematopoietic reconstitution in
immunodeficient mice (i.e. NOD/SCID)212. As hematopoietic stem and progenitor cells
differentiate towards maturity the loss of CD34 expression occurs, combined with the
acquisition of mature hematopoietic cell markers such as CD38213. Common myeloid
progenitor cells will extensively proliferate and give rise to a bipotent progenitor that
generates cells of the erythroid and megakaryocytic lineages, or a unipotent progenitor
that generates neutrophils and monocytes. Conversely, select cell types may be derived
from myeloid and/or lymphoid lineages (i.e. Dendritic cells)214-216, rendering the
phenotypic identification of intermediate stages of differentiation challenging. Towards
this end, ALDH-activity is uniformly dampened as differentiation occurs across multiple
hematopoietic lineages201, suggesting sustained stem cells functions may be more
indicative of primitive identity compared to the transient nature of cell surface marker
expression212,217.
Hematopoietic stem/progenitor cells (HSPC) have been used in a diverse range of clinical
studies, including bone marrow transplantation for blood disorders218 and
revascularization strategies for CLI193,194. HSPC are readily isolated from a post-natal
tissue, such as bone marrow, peripheral blood, and umbilical cord blood219.
Unfortunately, therapeutic HSPC are rare, thus ex vivo expansion may be required for
clinical translation for many potential applications. The expansion of HSPC has been met
with multiple challenges such as tissue source, primitive cell selection, and culture
conditions. Expansion of HSPC is challenged by the rapid induction of differentiation
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due to intrinsic signaling networks, such as RA-signaling pathways. Previous studies
have demonstrated the pharmacological inhibition or activation of select signaling
pathways can enhance the expansion of therapeutic HSPC220,221. Furthermore, the
Zandstra lab has demonstrated the dynamic regulation of microenvironmental signaling
networks can lead to robust expansion of HSPC populations experimentally model in
silico222-225. Finally, HSPC can be used in alternative therapies for their multifaceted
therapeutic functions such as the stimulation of islet regeneration57,58 or blood vessel
formation206,226. Collectively, HSPC harbour multifunctional therapeutic potential that is
limited by differentiation and loss of regenerative functions during expansion ex vivo.
Further research is required to identity targetable signaling pathways which may retain or
expand therapeutic HSPC.

1.3.5

Mesenchymal/Multipotent Stromal Cells

Since initial clinical use in 1995, multipotent stromal cells (MSC) has been the focus of
over 200 clinical trials world-wide227-229. MSC, as known as mesenchymal stem cells,
possess unique characteristics and can be enriched from several tissues according to the
guidelines established by the International Society of Cellular Therapies (ISCT)230.
According to these guidelines, MSC must demonstrate 1) plastic adherence 2)
mesodermal multipotency (into adipose, bone, cartilage lineages), and 3) exhibit a
distinct surface marker profile (Figure 1.10), which distinguishes it from related
mesodermal cell contaminants (i.e. hematopoietic and endothelial). Specifically, MSC
must express surface marker CD90 (Thy-1), CD73 (Ecto-5'-nucleotidase), and CD105
(Endoglin) after plastic adherent culture; meanwhile, lack the expression of CD45, CD31,
CD14, HLA-DR, CD19, CD79a and CD34. MSC demonstrate a fibroblast-like
morphology when cultured ex vivo, which has brought controversy to whether the
fibroblasts and MSC are interchangeable231-233. Despite several groups reporting that
select fibroblast lines can satisfy the ISCT guidelines232-234, other studies have reported
transcriptional and/or functional differences that may distinguish MSC from committed
fibroblasts231,235,236. For example, MSC are highly proangiogenic and contribute to tissue
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regeneration and immunomodulation via paracrine signaling networks. Therefore, the
capacity for MSC to initiate tissue regeneration may be a defining characteristic to
segregate MSC from fibroblasts235, especially considering the well-established role of
fibroblast activation during aging and many forms of pathogenesis237,238.
MSC can be obtained from a variety of adult and fetal tissues, each with a unique
phenotype and functional characteristics attributed to the tissue of origin239,240. For
example, MSC classically isolated from BM express higher levels of pericyte marker
CD146 and alkaline phosphatase compared to placental-derived MSC241; which reflects
differences in osteogenic potential. Nonetheless, MSC should be considered highly
heterogeneous and possess distinct subsets with unique surface marker expression
(CD271, CD56, CD146), enzymatic expression (ALDH) and functional characteristics in
vitro or in vivo242,243. For example, it has been reported that two distinct populations of
BM MSC may exist244,245. A CD271+/CD146+ population that regulates the endosteal
niche and hematopoiesis, while a 271+/CD146- population that serves as a progenitor
pool to generate osteoblasts of the skeletal bone. We have recently reported that the
selection of high ALDH-activity ex vivo enriches for a BM-MSC with enhanced proangiogenic secretome243. Collectively, MSC are an attractive cell type with a safe
therapeutic history and multifaceted regenerative functions, that may be further
modulated by the selection of tissue-specific MSC and/or MSC subsets within
heterogeneous expansion cultures.
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Figure 1.10 Working model of MSC phenotype, multipotency, and pro-regenerative
secretome.
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1.3.6

Cellular Therapies for Diabetes

The clinical demonstration that diabetes could be reversed via the restoration of
functional β-cell mass103,105, prompted researchers to discover novel methods to either
replace or regenerate lost β-cell in situ. Currently, the leading approach to restore
functional β-cell mass is through the transplantation of an exogenous β-cell source246-248.
Whole pancreas transplantation has reversed diabetes in human patients, however the
scarcity of donor pancreas tissue and a necessity for HLA-matching and/or
immunosuppression has limited this approach249. Likewise, islet transplantation can
reverse diabetes for prolonged periods, however, this approach is met with the same
limitations as pancreas transplantation. The potential use of pluripotent stem cell (ESC or
iPSC) technologies has promoted many laboratories to focus their efforts on ex vivo
generation of an unlimited number of β-cells for transplantation246. Notably, Kieffer and
colleagues have demonstrated that transplantation of ESC-derived PDX1+ pancreatic
progenitors was sufficient to reverse diabetes in rodent models (Ref). Transplanted
PDX1+ cells differentiated in vivo to generate a mixture of endocrine cell phenotypes,
with significant representation by insulin-secreting 𝛽-like cells204,250. However, careful
characterization of cell function revealed insulin secretion from PDX1+ progenitors were
~10% of native β-cells, which highlights further work is needed to guide β-cell
maturation either ex vivo or in vivo. In addition, the suppression of the autoimmune
destruction of the transplanted β-like cells is necessary to sustain euglycemia. In
pioneering efforts, bioengineering approaches have been tested to encapsulate
transplanted PDX1+ cells in a device that is permeable to the release of insulin while
preventing immune cell infiltration248.
In 2010, the Joslin “Medalist” study demonstrated residual β-cell mass and functional
insulin secretion within individuals who have lived with Type 1 DM for >50 years251.
Moreover, histological analysis of post-mortem patients has identified the presence of
proliferating β-cells coinciding with β-cell apoptosis. Collectively, this study provided
two foundational concepts; 1) residual β-cell mass is present in individuals with longstanding Type 1 DM and 2) β-cell proliferation can occur in the face of ongoing
autoimmunity. Considering the destruction of β-cell mass is heterogeneous across the
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pancreas and select regions may promote immune cells invasion, these results suggest
that the stimulation of endogenous β-cell regeneration in situ may be feasible approach in
T1 DM patients if autoimmunity can be controlled107. Towards this goal, our lab has
pioneered studies demonstrating the transplantation of blood-derived progenitor cell
populations can stimulate the regeneration of endogenous islets in murine models of
DM57,58,195,196,205. Specifically, human HSPC and MSC populations derived from human
UCB and/or BM can reduce hyperglycemia in NOD/SCID mice subjected to
streptozotocin-induced β-cell ablation. The Prochymal trial was the first to attempt to
alleviate early-onset Type 1 DM through the infusion of allogeneic BM-derived MSC
harvested from a healthy donor252. Despite promising preclinical results, therapeutic
efficacy observed in this study was transient and modest. Recently, we have
demonstrated the secretome of expanded human MSC can act as an injectable
biotherapeutic to potently stimulate islet regeneration205, potentially circumventing the
limitations encountered by direct cell transplantation, discussed below.

1.3.7

Cellular Therapies for Vascular Disease

The therapeutic goal for treating ischemic damage induced by vascular disease is to
promote angiogenesis to revascularize and restore cardiometabolic homeostasis253. Initial
trials for treating critical limb ischemia with progenitor cell transplantation, have
primarily entailed the infusion of mononuclear cells derived from autologous
sources254,255. Collectively, the efficacy of this approaches has been variable, showing
improvements in ankle brachial index measurements and improved quality of life scores
(Rutherford index), yet amputation rates were not improved in patients with severe CLI.
Therefore, refined the cell selection, expansion, or transplantation of therapeutic cell
populations is currently under intense investigation. Accordingly, Perin et al. recently
concluded a clinical trial which explored the transplantation of autologous BM-cells
purified for high ALDH-activity in patients with both critical limb ischemia and
intermittent claudication193,194. The results of these studies did not show improved clinical
efficacy over the transplantation of unpurified mononuclear cells. It is becoming evident
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that the microenvironment of cardiometabolic disorders (i.e. diabetes, obesity, etc.) and
cardiovascular disease can deplete progenitor cell numbers and diminish regenerative
functions of pro-angiogenic cell types256-259. Thus, autologous progenitor cell
transplantation carries severe limitations in the clinical setting.
Pre-clinical studies have demonstrated the therapeutic potential of progenitor cell
transplantation for treating vascular disease, yet the translational rate to clinical efficacy
has been notably underwhelming. In addition to the limitations linked to progenitor cell
biology, current murine models of CVD and PAD do not accurately reflect
pathophysiological observations observed in human studies260. Despite mice sharing
~95% of the protein-coding genome, there exists a measurable distinction between the
regulatory or non-protein coding regions of the genome. These regions generate nucleic
acid effectors that provide post-transcriptional/translational regulation of homeostatic and
inflammatory pathways (i.e. micro-RNAs). As a result, cardiometabolic disorders and
pathophysiology of vascular disease are not completely recapitulated in current murine
models261,262. Specifically, transgenic models lack pathological hallmarks of human CVD
such as lesion development, atherosclerotic plaque complexity, localization to coronary
arteries, intimal thickening, and thrombotic plaque rupturing observed in human patients.
Recently, vascular organoids have been generated from both adult263-265 and pluripotent
stem cell sources266 that organize into a hierarchical arrangement and can be induced to
exhibit characteristics of human pathology. The Penninger lab recently demonstrated
organoids derived from human iPSC produced a physiologically-relevant arrangement of
mesenchymal, endothelial, and hematopoietic cell that could self-assemble, and these
vessels could mimic diabetic vasculopathy in vitro and in vivo266. From a speculative
point-of-view, the use of vascular organoids to refine our understanding of vessel
assembly will lead to development of novel therapies to treat vascular complications of
diabetes169.
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1.3.8

Limitations of Cell Transplantation and the Development of Cellfree Biotherapeutics

Limitations of progenitor cell transplantation to treat diabetes and vascular disease
primarily center around progenitor cell source and extensive expansion required for
clinical application in humans. We have recently demonstrated additional 3-days of ex
vivo culture significantly diminished primitive progenitor cell marker expression and
provascular functions of UCB-derived HPC transplanted into in a murine model of
hindlimb ischemia226. Our previous studies indicate that the regenerative function of
transplanted progenitor cells may vary on an individual basis, such as donor health, body
composition, co-morbidities and/or age267,268. Accumulating evidence has demonstrated
the chronic diseases such as diabetes can disrupt progenitor cell homeostasis leading to
the generation of a pro-inflammatory and pro-fibrotic secretome in mesenchymal cell
populations269-273. The engraftment of transplanted progenitor cell populations is often
transient274, thus prolonging engraftment of transplanted cells may enhance therapeutic
outcomes in vivo. Although, it is difficult to track the biodistribution of transplanted cells
in human patients275, recent advancements of biomedical imaging is allowing for highresolution mapping of transplanted cell populations276. Collectively, current cell
transplantation strategies are in need of approaches to enhance the expansion of
therapeutic cell populations ex vivo or prolong engraftment in vivo without the loss of
regenerative functions.
We have recently demonstrated that the secretome of BM-MSC can be concentrated to an
injectable volume and used to stimulate human islet cell proliferation in vitro277 and
murine islet neogenesis in vivo205. Combining the benefits of protein and cell-based
approaches are now warranted to: 1) identify therapeutic effectors and their recipient cell
populations, 2) to determine if therapeutic secretome are progenitor cell-specific, and 3)
investigate the generation of ‘designer cells’ to tailor the secretome of progenitor cell
populations toward a treatable disease.
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1.3.9

Extracellular Vesicles

The secretome of MSC contains regenerative stimuli secreted in the form of both protein
and nucleic acids (miRNA and mRNA), which can contribute to pro-regenerative and
pathological responses in vivo278-282. These regenerative cargoes can be packaged into
extracellular vesicles (EVs) that signal in an autocrine and paracrine fashion to initiate
tissue regeneration. EVs are lipid bi-layered vesicles which facilitate intercellular
communication by protecting and transporting a unique set of cargo distinct from
traditional cytokine secretion. Specifically, EVs contain protein, nucleic acids, and
bioactive lipids each with a unique role in cellular communication (Figure 1.11). EVs can
be subclassified based on their size and cellular-origin into exosomes and microparticles.
Moreover, EVs are distinct from cell remnants, such as apoptotic bodies. Exosomes
(30nm-100nm) are the smaller of the two EV sub-classifications and are derived from the
endosomal pathway. Multivesicular bodies of the endosomal pathways are either shuttled
to the lysosome for degradation or are repackage with unique cargo and released as
exosomes via exocytosis283. In contrast, microparticles are larger in size (from 100nm1μm) and are generated by blebbing of the cytoplasm and pinching of the cell membrane,
leading to the direct release of microparticles to the environment surrounding the cell284.
The generation of exosomes and microparticles is a highly regulated, although the
mechanism of this organization remains obscure. Nonetheless, EVs contain cargo which
can activate signaling pathways to significantly alter the physiology of recipient cells285.
With these properties in mind, the contribution of EVs towards the MSC-generated
secretome needs to be further investigated to develop novel regenerative therapies.
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Figure 1.11 Overview of Extracellular Vesicle Secretion, Detection, and Applications
of Regenerative Medicine
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1.3.10

Designer Cells and the Future of Regenerative Medicine

Recent advancement in genetic engineering strategies, such as CRISPR286-288, and indepth molecular analyses (i.e. Mass Spectrometry, Single-cell RNAseq) hold the
potential to be used as vital tools of regenerative medicine. More specifically, global
transcriptional and translational analyses provide us with a better understanding of the
molecular characteristics within 1) therapeutic donor cell populations, 2) targeted
endogenous cell populations for tissue regeneration, 3) dysfunctional/depleted cell
populations during disease. In return, this insight will permit the directed activation of
pro-regenerative pathways within therapeutic donor and target cell populations, in an
attempt to combat disease. As an example of this concept, we have recently demonstrated
that canonical Wnt-signaling within MSC is dampened as regenerative functions are lost
during ex vivo culture277. Accordingly, the activation of Wnt-signaling during cell
propagation enhanced the therapeutic efficacy of the BM-MSC secretome following
intrapancreatic delivery of this ‘designer’ biotherapeutic. Other examples of current
designer cell strategies to advance the field of regenerative medicine, include the
generation of 𝛽-cells from pluripotent stem cell sources246, modelling of human diabetes
and/or cardiovascular disease within cultured organoid systems266, and T cell289 or NK
cell290 engineering to target tumor cells. On the horizon of regenerative medicine is the
advancement of biological scaffold design186,291, 3D tissue engineering292, and in silico
experimentation with machine learning293. Therefore, this is an exciting time for
regenerative medicine approaches yet there currently exists a need to characterize the
molecular properties of regenerative cell populations with multifaceted therapeutic
potential.
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1.4 Thesis Overview and Hypotheses
Patients with diabetes are burdened with an increased risk of developing life-threating
cardiovascular comorbidities. Regenerative medicine and cellular therapies possess the
potential to develop curative therapies for diabetes and/or cardiovascular complications.
Unfortunately, the depletion and dysfunction of therapeutic cell populations occurs as a
result of chronic disease, limiting the clinical efficacy of autologous cell transplantation.
Allogenic sources, such as UCB, offer an alternative source of therapeutic progenitor
cells that are untouched by chronic inflammation and oxidative stress; but require
extensive expansion ex vivo to generate clinically relevant cell numbers without the loss
of regenerative functions. Similarly, MSC represents another therapeutic cell population
which requires extensive expansion for clinical applications. In addition, the secretome of
MSC may be used as cell-free biotherapeutic278-282, although further research is necessary
to refine this approach. During the course of my thesis, I focused on addressed two major
challenges faced by direct cell transplantation; 1) the limitations of progenitor cell
expansion ex vivo, and 2) directed delivery of pro-regenerative stimuli to damaged
tissues. First, I demonstrated that the inhibition of RA-signaling could enhance the
expansion of UCB-derived HSPC with multifaceted therapeutic potential. Second, I
demonstrated that MSC derived from human pancreatic tissue generate extracellular
vesicles with both vascular and islet regenerative stimuli. Throughout these studies, I
utilized mass spectrometry and multiparametric flow cytometry to identify novel
proteomic characteristics of both HPC and MSC subsets. Additionally, I performed
xenotransplantation studies to investigate tissue regeneration induced by human cells
after femoral artery ligation-induced hindlimb ischemia or streptozotocin-induced 𝛽-cell
ablation.
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1.4.1
1.

Chapter 2: Objective & Hypothesis
To characterize proteomic changes during the expansion of UCB ALDHhi cells
using label-free mass spectrometry and multiparametric flow cytometry.

2.

To assess whether inhibition of ALDH-activity will enhance the expansion of
UCB ALDHhi cells while retaining primitive surface marker and hematopoietic
functions in vitro.

3.

To determine whether inhibition of ALDH-activity will expand hematopoietic
progeny that stimulate vascular regeneration in a murine model of hindlimb
ischemia.

In chapter 2, I hypothesized that reversible inhibition of ALDH-activity, using
diethylaminobenzaldehyde (DEAB), will enhance expansion of UCB-derived
hematopoietic progenitor cells while retaining primitive surface marker phenotype and
pro-angiogenic functions in vivo.

1.4.2
1.

Chapter 3: Objective & Hypothesis
To investigate the enrichment of the megakaryocyte-lineage during expansion of
UCB ALDHhi cells.

2.

To determine whether FACS purification of ALDHhi cells, after ex vivo
expansion under DEAB-treated conditions, reselects for cells with proangiogenic functions in vitro.

3.

To determine whether FACS purification of ALDHhi cells, under DEAB-treated
conditions, reselects for cells retaining islet regenerative functions.

In chapter 3, I hypothesized that reversible inhibition of ALDH-activity, via
diethylaminobenzaldehyde (DEAB), will enhance the expansion of UCB-derived
hematopoietic progenitor cells retaining a primitive surface marker phenotype and islet
regenerative functions in vivo.
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1.4.3
1.

Chapter 4: Objective & Hypothesis
To determine fibroblast-like cells derived from human islet cultures demonstrate
MSC-like phenotype and multipotent functions in vitro.

2.

To conduct proteomic comparison of Panc-MSC to BM-MSC using mass
spectrometry

3.

To determine the competency of Panc-MSC to respond to pro-neural or proadipogenic stimuli

In chapter 4, I hypothesized that fibroblast-like cells established from human islets will
demonstrate phenotypic and functional characteristics of MSC with tissue-specific
functional characteristics.

1.4.4
1.

Chapter 5: Objective & Hypothesis
To characterize the protein content within extracellular vesicle versus the soluble
fraction generated by Panc-MSC

2.

To determine whether pro-vascular stimuli within extracellular vesicles
generated by Panc-MSC can improve revascularization after injection into
ischemic hindlimbs.

In chapter 5, I hypothesized that extracellular vesicles generated by Panc-MSC would
contain pro-vascular stimuli capable that accelerate the recovery of hindlimb blood
perfusion and revascularization in a murine model of hindlimb ischemia.

1.4.5
3.

Chapter 6: Objective & Hypothesis
To characterize the protein content within extracellular vesicle versus the soluble
fraction generated by Panc-MSC

48

4.

To determine whether islet regenerative stimuli within extracellular vesicles
generated by Panc-MSC can improve hyperglycemia after injection into
pancreas of streptozotocin-treated NOD/SCID mice.

In chapter 6, I hypothesized that the secretome of Panc-MSC contains islet-regenerative
stimuli that can reduce hyperglycemia in NOD/SCID subjected to STZ-induced β-cell
ablation.
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Chapter 2

2

Inhibition of Aldehyde Dehydrogenase‐Activity Expands
Multipotent Myeloid Progenitor Cells with Vascular
Regenerative Functioni

i A version of this chapter has been published: Cooper, T.T., Sherman, S.E., Kuljanin,
M., Bell, G.I., Lajoie, G.A. and Hess, D.A., 2018. Inhibition of Aldehyde
Dehydrogenase‐Activity Expands Multipotent Myeloid Progenitor Cells with Vascular
Regenerative Function. Stem Cells, 36(5), pp.723-736.
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2.1 Introduction
Systemic atherosclerosis results in impaired blood vessel architecture and function1,
leading to peripheral arterial disease (PAD) characterized by obstructed blood flow
within the peripheral vasculature, limiting delivery of oxygen and nutrients to afflicted
tissues2. Clinical presentation of PAD ranges from asymptomatic ischemia to exerciseinduced intermittent claudication, which may progress toward critical limb ischemia
(CLI), the most severe manifestation of PAD. Patients with CLI suffer from pain at rest,
non-healing tissue ulceration, and life-threatening infections. Current pharmaceutical
therapies target risk factors to reduce cardiovascular events, whereas endovascular or
surgical bypass interventions aim to recover perfusion to afflicted tissues. Unfortunately,
these therapies provide only short-term benefit and are not offered to individuals with
diffuse CLI3-6. As a result, 25%–30% of CLI patients require limb amputation within the
first year of diagnosis7, and>60% of CLI patients will succumb to death within 5 years8.
There is a need to develop effective therapies for the 8–12 million North Americans and
>200 million individuals worldwide afflicted with advancing PAD7,8. Tissue
revascularization via “therapeutic angiogenesis” has been proposed as a potential target
for combating severe PAD. Robust angiogenesis can occur in skeletal muscle following
ischemic injury; however, this requires activation of several cell types to orchestrate
vascular remodeling or to activate flow within collateral vessels9,10. Pro-angiogenic
cytokine/chemokine secretion by hematopoietic progenitor cells (HPCs) direct sprouting
by vessel-forming endothelial progenitor cells (EPC) and encourage infiltration by vessel
wrapping pericytes, respectively; two processes essential for stable neovessel
formation10. Thus, cellular therapies to induce revascularization uses the secretory
properties of transplanted blood-derived progenitor cells to generate a pro-angiogenic
microenvironment and restore revascularization within ischemic tissues11. We have
previously demonstrated the vascular regenerative potential of HPC isolated from healthy
human bone mar-row (BM) and umbilical cord blood (UCB)12,13. Notably, purification of
cells with high aldehyde dehydrogenase (ALDH)activity (ALDHhi), a detoxification
function conserved in pro-genitor cells of multiple lineages, promoted revascularization
following transplantation into mice with hind-limb ischemia, by stimulating endogenous
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capillary formation at the site of injury without permanent incorporation into regenerating
murine neovessels13. Moreover, ALDHhi cells from BM or UCB are also enriched for rare
non-HPCs (EPC and multipotent stromal cells), with a larger representation of myeloid
HPC12-15. In 2011, a randomized Phase I clinical trial by Perin et al. demonstrated that
intramuscular (i.m.) transplantation of autologous BM ALDHhi cells significantly
improved Rutherford’s Category scores and ankle-brachial index measurements from
baseline in patients with non-operational CLI but did not improve ischemic ulcer
healing16. These results provided rationale for a Phase II trial (PACE trial) which aimed
to stimulate revascularization in patients with intermittent claudication, thereby
mitigating progression toward end-stage CLI17. This double-blinded multicenter study
recently reported that transplantation of autologous BM-derived ALDHhi cells was unable
to effectively improve exercise performance or blood perfusion via collateral vessel
formation after6 months18. Although the preclinical data used to initiate early clinical
studies were promising13, several factors may explain why preclinical efficacy in murine
models does not accurately predict clinical efficacy in humans. The preclinical
experiments were performed using healthy human BM ALDHhi cells trans-planted into
immunodeficient mice with surgically induced limb ischemia. Femoral artery ligation
(FAL) in mice has been the gold-standard preclinical model to assess therapeutic
angiogenesis elicited by pharmaceuticals or cells; however, the model does possess
several limitations which need to be addressed to improve clinical translation.
Specifically, this model mimics an acute ischemic injury occurring in young and healthy
animals and does not reflect the chronic ischemic microenvironment occurring in human
patients due to the buildup of atherosclerotic plaques over an extended period of time. In
addition to physiological differences between species (i.e., heart rate and plasma
cholesterol), patients with PAD commonly demonstrate other influential factors, chronic
inflammation, smoking, and sedentary lifestyles, which are difficult to mimic in a murine
model. Furthermore, emerging preclinical evidence also indicates autologous BM
mononuclear cells (MNC) harvested from patients with chronic atherosclerosis and
associated comorbidities exhibit severe functional impairments19,20. Endothelial cells
derived from healthy animals exhibited vascular regenerative functions in a diabetic
model of myocardium ischemia, whereas, cells harvested from diabetic animals failed to
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induce vasculogenesis21. Several studies have aimed to increase clinical efficacy by
purification of select subpopulations (CD341) derived from autologous BM-MNC 22;
however, this approach has provided a modest benefit over transplantation of unpurified
BM-MNC. Alternatively, using healthy allogenic sources may improve the efficacy of
cell-based therapies, by limiting the exposure of therapeutic cells to the damaging
microenvironment of chronic disease23,24. ALDH provides protection to long-lived stem
and progenitor cell populations from cytotoxic insults25. Representing a conserved stem
cell function and coinciding with primitive surface marker expression (CD341), ALDHhiactivity rapidly diminishes as multipotent HPC differentiate toward more expendable
lineage-restricted phenotypes15. ALDH also rep-resents the rate-limiting enzyme in the
production of retinoic acid (RA), a potent driver of hematopoietic differentiation. RA
activates the retinoic acid receptor (RAR) - retinoid X receptor (RXR) nuclear receptor
complex that regulates mRNA transcription and epigenetic modifications26, resulting in
hematopoietic cell differentiation. For example, activation of RAR/RXR induces the
expression cyclic-ribose ADP hydrolase (CD38), a membrane-bound enzyme implicated
with hematopoietic cell differentiation27. Therefore, the ex vivo expansion of UCB
ALDHhi cells represents a paradoxical challenge to increase primitive and pro-angiogenic
ALDHhi cell numbers while limiting RA-induced hematopoietic differentiation. We have
recently shown that UCB ALDHhi cells can be efficiently expanded under serum-free
conditions to generate hematopoietic progeny retaining vascular regenerative functions in
vivo28. However, as culture time was increased from 6 to 9 days, expanded progeny failed
to retain vascular regenerative functions. In addition, reducing RA-production by
inhibition of ALDH-activity during ex vivo expansion augmented the number of CD34
HPC with SCID-repopulation capacity29,30. Therefore, we sought to determine whether
inhibition of ALDH-activity, using diethylaminobenzaldehyde (DEAB) treatment, would
enhance the expansion of UCB ALDHhi cells without loss of vascular regenerative
functions assessed after i.m. transplantation into mice with FAL-induced unilateral hindlimb ischemia
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2.2 Methods
2.2.1

Isolation of Human UCB ALDHhi Cells

Human UCB samples were obtained with informed consent by venipuncture of the
umbilical vein following Ceasarian section at Victoria Hospital Birthing Centre, London,
ON, Canada. The Human Studies Research Ethics Board (HSREB) at Western University
approved all procedures. Within 24 hours of collection, UCB samples were initially
depleted of mature myeloid, lymphoid and red blood cells (RosetteSep Human Cord
Blood Progenitor Cell Enrichment Cocktail, Stem Cell Technologies, Vancouver, BC,
Canada). Lineage-depleted (Lin-) mononuclear cells were isolated by Hypaque Ficoll
centrifugation and incubated with Aldefluor regent prior to purification by FACS (FACS
Aria III, BD Biosciences, Mississauga, Ontario, Canada). UCB ALDHhi cells were
selected based on low side scatter and high ALDH-activity with >98% purity, as
previously described12,15,28.
.

2.2.2

Expansion of UCB ALDHhi Cells in Culture

UCB ALDHhi cells were plated on fibronectin‐coated flasks and expanded in serum‐free
X‐vivo 15 (Lonza, Basel, Switzerland) supplemented with 10 ng/ml thrombopoietin
(TPO), Fms‐like tyrosine kinase 3 ligand (FLT‐3L), and stem cell factor (SCF) for up to
9 days, herein referred to as Basal conditions. All growth factors were purchased from
Life Technologies (Carlsbad, CA). To inhibit ALDH‐activity and limit cell
differentiation, 1.0 × 10−5 mol/l diethylaminobenzaldehyde (DEAB) (Stem Cell
Technologies, Vancouver, Canada) was added to Basal conditions between days 3 and 6
of ex vivo expansion, herein referred to as DEAB‐treated conditions. DEAB dose and
treatment kinetics were optimized based on maximal retention of ALDHhi cells at
endpoint. Complete media change was performed every 3 days.
.
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2.2.3

Generation of HPC‐Conditioned Media and Cell Lysates for
Proteomic Analyses

Expanded cells were harvested and washed with phosphate‐buffered saline (PBS) to
remove residual growth factors and resuspended in fresh RPMI 1640 + 10 ng/ml of SCF,
TPO, and FLT‐3L for 24 hours to generate conditioned media (CM) in biological
triplicate. CM was centrifuged to remove cellular debris and concentrated using 3 kDa
molecular weight cutoff filter units (Millipore, Bedford, MA). Concentrated CM was
lyophilized overnight and resuspended in 8 mol/l urea, 5.0 × 10−2 mol/l ammonium
bicarbonate, 1.0 × 10−2 mol/l dithiothreitol, and 2% SDS solution before secreted protein
quantitation and fractionation. Expanded cell pellets were lysed in 8 M urea buffer, and
sonicated (20 × 0.5 second pulses; level 1) to shear DNA. Protein concentrations were
estimated using the Pierce 660 nm protein assay (ThermoFisher Scientific, Waltham,
MA).

2.2.4

Chloroform/Methanol Precipitation and Protein Digestion

Cell lysates or CM were reduced in 1.0 × 10−2 mol/l dithiothreitol for 30 minutes and
alkylated in 1.0 × 10−1 mol/l iodoacetamide for 30 minutes. Samples were precipitated in
chloroform/methanol in 1.5 ml microfuge tubes31; 50 μg aliquots of each sample were
topped up to 150 μl with 5.0 × 10−2 mol/l ammonium bicarbonate, 600 μl of ice-cold
methanol, followed by 150 μl of chloroform; 450 μl of water was added before vortexing
and centrifugation at 14,000g for 5 minutes. The upper/aqueous methanol phase was
removed and 450 μl of ice-cold methanol was added before vortexing and centrifugation.
Precipitated protein pellet was air dried before protein digestion. For on‐pellet protein
digestion, 100 μl of 5.0 × 10−2 mol/l ammonium bicarbonate (pH 8.0) trypsin/LysC (1:50
ratio, enzyme:sample) (Promega, Madison, WI) solution was added before incubation
overnight at 37°C in water bath shaker. Trypsin (1:100 ratio) was added for 4 hours
before acidifying with 10% formic acid (pH 3–4). Digests were centrifuged at 16,000g to
remove insoluble material. Peptide concentrations were estimated using a BCA assay
(ThermoFisher Scientific).
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2.2.5

SCX Peptide Fractionation

Tryptic peptides recovered from chloroform/methanol precipitation of cell lysates or CM
(50 μg) were fractionated using SCX StageTips32. Peptides were acidified using 1%
Trifluoroacetic acid and loaded onto a 12‐plug StageTips. Six SCX fractions were
collected by eluting in 7.5 × 10−2, 1.25 × 10−1, 2.0 × 10−1, 2.50 × 10−1, and 3.0 × 10−1
mol/l ammonium acetate/20% acetonitrile/0.5% formic acid (FA) solutions followed by
elution with 5% (w/v) ammonium hydroxide/80% ACN. Fractions were dried in a
SpeedVac, resuspended in double distilled water and dried again to remove residual
ammonium acetate. All samples were resuspended in 0.1% FA before liquid
chromatography–tandem mass spectrometry (LC‐MS)/MS analysis.

2.2.6

Liquid Chromatography–Tandem Mass Spectrometry

One microgram of sample was injected into a Waters nanoAcquity HPLC system
(Waters, Milford, MA) coupled to an ESI Orbitrap mass spectrometer (Orbitrap Elite or
QExactive, ThermoFisher Scientific). Buffer A consisted of water/0.1% FA and buffer B
consisted of ACN/0.1% FA. All samples were trapped for 5 minutes at a flow rate of 10
μl/minute using 99% Buffer A, 1% Buffer B on a Symmetry BEH C18 Trapping Column,
5 μm, 180 μm × 20 mm (Waters). Peptides were separated using a Peptide BEH C18
Column, 130Å, 1.7 um, 75 um × 250 mm operating at a flow rate of 300 nl/minute at
35°C (Waters). Cell lysate samples were separated using a nonlinear gradient consisting
of 5%–7.5% B over 1 minute, 7.5%–25% B over 180 minutes and 25%–60% B over 240
minutes before increasing to 98% B and washing. CM samples were separated using a
nonlinear gradient consisting of 1%–7% B over 3.5 minutes, 7%–19% B over 90 minutes,
and 19%–30% B over 120 minutes before increasing to 95% B and washing. Settings for
data acquisition on the Orbitrap Elite and QExactive are provided in Table 2.1.
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Table 2.1 Overview of parameters used for data acquisition on a Q Exactive and LTQ
Orbitrap Elite.

.
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2.2.7

Proteomic Data Analyses

Data analysis was performed using PEAKS 8.0 software (Bioinformatics Solutions Inc.,
Waterloo, ON, Canada). Raw data files were refined using correct precursor mass and de
novo sequencing was performed using the following parameters: parent mass tolerance
20 ppm; fragment ion tolerance 0.80 Da; enzyme was set to trypsin. Data analyses were
searched against the Uniprot human sequence database (20,178 entries). Quantitative data
analysis was performed using MaxQuant version 1.5.2.833. Protein and peptide false
discovery rate were set to 0.01 (1%), while the decoy database was set to revert. All
parent and fragment tolerances were set as described above. The match between runs was
enabled and all other parameters left at default. Data were analyzed using label free
quantitation and intensity‐based absolute quantification as described previously34.
Bioinformatic analysis was performed using Perseus version 1.5.0.8 and proteins
identified by site, reverse and contaminants were removed manually. When using the
match between runs feature, datasets were filtered for proteins containing a minimum of
one unique peptide in at least two biological replicates. Missing values were replaced
using data imputation by using a width of 0.3 and a downshift of 1.235.

2.2.8

Flow Cytometry

Expanded HPC were harvested following 6- or 9-day expansion and enumerated by trypan blue
exclusion using hemocytometer counts. Cells were labelled with Aldefluor to assess ALDHactivity and co-stained with 7-amino-actinomycin D to determine viability. Cells also were
labeled with anti-human antibodies for CD45 (pan-hematopoietic marker), CD33 (myeloid),
CD14 (monocytes), CD31 (PECAM), CD41 (ITGA2), and CD42 (megakaryocyte). Cells were
assessed for the retention of primitive HPC phenotypes using CD34 and differentiation of
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expanded cells was determined using CD38 (cyclic ADP ribose hydrolase). Cell surface marker
expression for total cells, as well as ALDHhi versus ALDHlo subsets was determined using an
LSRII flow cytometer (BD Biosciences) at the London Regional Flow Cytometry Facility.
Analyses were performed using FlowJo software v8.2.

2.2.9

Hematopoietic Colony Formation

To assess the retention of hematopoietic colony forming function following expansion, day 9
expanded HPC were harvested and seeded in semi-solid methylcellulose media (H4434, Stem
Cell Technologies) at 500 cells/well in 12-well plates, in duplicate. Hematopoietic colonies were
enumerated after 12-14 days in vitro and scored based on morphological characteristics.

2.2.10

qRT-PCR analysis of Retinoic Acid Signaling Pathway

Total mRNA was extracted from Day 9 Basal or DEAB-expanded HPC using PerfectPure RNA
Purification kits (5Prime, Beverly, MA). NanodropTM was performed to establish mRNA
concentration and purifty at the London Regional Genomics Facility prior to production of 500ng
of cDNA using iScript cDNA conversion kits (Bio-Rad; Hercules, CA), according to
manufactures protocol. qRT-PCR was performed using the Sofast Evagreen Supermix detection
system (Bio-Rad) in conjunction with a CFX384 (Bio-Rad, Hercules, CA). Validated primers for
ALDH1A3 (HQP005252), CYP26A1 (HQP003919), RARA (HQP016114) and RARG
(HQP016118) were purchased from Genecopoeia (Rockville, MD). Quantification of transcripts
was assessed using the housekeeping gene GUSB and normalized to Day 9 HPC harvested from
Basal conditions.

2.2.11

Femoral Artery Ligation and Transplantation

Unilateral hind limb ischemia was induced in anesthetised (100mg/kg ketamine/xylazine,
maintain with 2% isoflurane, 0.8L/min) NOD/SCID mice via surgical ligation and excision of the
femoral artery and vein (FAL), as previously described206. NOD/SCID mice with unilateral hindlimb ischemia (perfusion ratio <0.1, 24-hours after surgery (Day 0) were transplanted with a total
of 5.0x105 expanded cells from Basal or DEAB-treated conditions, or non-cellular vehicle
control, by intramuscular (i.m) injection (20uL) at three sites between ligation landmarks. To
serve as a non-cellular vehicle control, mice received i.m.-injections of 60𝜇l of PBS in a similar
fashion to cell-transplanted mice.
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2.2.12

Laser Doppler and Catwalk

Anesthetised NOD/SCID mice were warmed to 37ºC for 5 minutes and hindlimb blood perfusion
was measured using Laser Doppler perfusion imaging (LDPI). Recovery of blood flow was
quantified on 3, 7, 14, 21, 28, and 35 days post-transplantation by comparing the perfusion ratio
(ischemic/non-ischemic) of transplanted mice. Recovery of limb usage in transplanted mice was
determined by the ratio of paw print area in transplanted limb versus the contralateral control was
assessed at Day 7 and 35 using the Noldus Catwalk Imaging system, as previously described28.

2.2.13

Immunofluorescent Microscopy

Adductor muscle) from both ischemic and non-ischemic thighs were harvested, embedded in
OCT, and cryosectioned (12𝜇m) to obtain three sections per slide ≥50𝜇m apart. Cryosections
were fixed in 10% formalin (Sigma) and blocked with 5% serum. Capillary density was
quantified at 7 and 35-days post-transplantation using rat anti-mouse CD31 (BD Biosciences;
1:100) detected with fluorescein-labeled rabbit anti-rat secondary antibodies (Vector; 1:200).
CD31+ cells were enumerated from 4 randomly selected fields of view per section of murine
thigh muscles, totaling 12 images per limb. EdU+ proliferating cells were detected using the
Click-iT imaging kit (Alexafluor 594; Life Technologies), co-stained with CD31 to allow
quantification of proliferating endothelial cells. Functional vessel density was also visualized
using rabbit anti-mouse von Willebrand factor (1:100) detected with goat anti-rabbit fluoresceinlabeled secondary antibodies (1:200). DAPI was used as counterstain to label nuclei.

2.2.14

Determination of Human Cell Engraftment into Murine Tissues

Serial cryosections (25 𝜇m) were obtained across 150𝜇m of ischemic adductor muscles harvested
7 days post-transplantation (n=4). Cryosections were fixed in 10% formalin and blocked mouseon-mouse reagent (Vector Labs, Burlingame, CA, USA). Human cell engraftment was visualized
by staining muscle sections with mouse anti-human HLA-A,B,C (1:100) detected with horse antimouse fluorescein-labelled secondary antibodies (1:200). DAPI was used as counterstain to label
nuclei.

75

2.2.15

Statistical Analyses

A multiple sample t test was performed in Perseus comparing the cell lysates for day 9
Basal versus DEAB for proteomic analysis; and day 6 Basal versus day 9 Basal for
secretome analysis. Statistical analysis for flow cytometry, quantitative polymerase chain
reaction (qPCR), hematopoietic colony forming‐cell analyses was performed using a
student's t test within each time point. Analysis of significance was performed by one‐
way analysis of variance with Tukey's multiple comparisons tests for all in vivo
experiments and enumeration of myeloid‐specific colony formation. Outliers were
identified using Grubb's test; p < .05.

2.3 Results
2.3.1

Basal Conditions Promoted Expansion of Cells with
Megakaryocyte Secretory Profile

We have recently demonstrated UCB ALDHhi cells expanded under Basal conditions for
6 but not 9 days, accelerated the recovery of hindlimb perfusion after transplantation28.
This led us to investigate whether additional culture time (3 days) changed the secretory
profile of expanded hematopoietic progeny, thereby limiting vascular regenerative
function in vivo. Mass spectrometry proteomic analysis was used to determine changes in
the secretome of cells harvested after culture under Basal conditions (N = 3) at day 6 or
day 9. A total of 5,404 unique proteins were detected, with 3,636 proteins identified in
CM generated by both day 6 and day 9 expanded cells; 325 proteins or 1443 proteins
were exclusively contained within CM generated from day 6 or day 9 cells, respectively.
Major cytokines associated with angiogenesis were present in CM generated from both
expanded cell populations. Therefore, we focused on the relative quantity of proteins
commonly secreted. Of the 3,636 common proteins secreted, 144 and 317 proteins were
significantly increased in day 6 and day 9 CM, respectively. Distinct patterns of
expression were identified reflecting widespread changes in protein expression as culture
time was increased (Fig. 2.1A). Although day 6 and day 9 cells demonstrated polarized
regenerative function in vivo28, the secretion of proangiogenic proteins, such as vascular
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endothelial growth factor (VEGF)‐A and angiopoietin 1 (ANGPT1), was comparable
between expanded cell populations. Interestingly, proteins involved in inflammation and
platelet activation were enriched within CM generated from day 9 cells (Figure 2.1B).
For example, platelet activation‐associated proteins significantly increased in CM
generated from day 9 cells included integrin α‐IIb (ITGA2B, CD41), glycoprotein Ib
(GP1B, CD42), glycoprotein IX (GP9), and platelet endothelial aggregation receptor 1
(Fig. 2.1C). Flow cytometry was used to validate expression of CD41 and CD42, classic
markers of megakaryocyte‐lineage differentiation (Fig. 2.1D). These analyses
demonstrated that expansion of UCB‐derived ALDHhi cells under Basal conditions
enriched for cells with a committed megakaryocyte (CD41+/CD42+) phenotype as
culture time progressed from 6 to 9 days (25.76 ± 5.14% vs. 54.7 ± 6.50%; *, p < .05;
Figure 2.1E). Importantly, this end‐stage megakaryocyte differentiation was also
associated with the loss of vascular regenerative capacity after transplantation28.
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Figure 2.1 Umbilical Cord blood ALDHhi cells differentiated toward a
megakaryocyte phenotype when cultured under Basal conditions. Viable day 6 (N=3)
or day 9 (N=3) cells expanded under basal conditions were replated in RPMI 1640+ stem
cell factor, thrombopoietin, Fms-like tyrosine kinase 3 ligand for 24 hours to generate
conditioned media (CM). (A) Mass Spectomtery analyses of CM revealed distinct
secretome profiles. (B) Secretory profile of day 9 cells was highly enriched with proteins
implicated in platelet activation. (C) Day 9 cells significantly upregulated the expression
of CD41 (ITGA2B) and CD42 (GPIB), compared with day 6 cells. (D, E) Increased
culture time under Basal conditons enriched for cells with a megakaryocyte phenotype
(CD41+/CD42+). Data represented as mean + SEM (*, p <.05; N=5-7). Statistical analyses
were determined by paired Student’s t test.
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2.3.2

DEAB‐Treatment Augmented ALDHhi Cell Expansion

ALDHhi cells represented only 2.47 ± 1.33% Lin– cells (Fig. 2.2A) correlating to <0.5%
of total MNC collected. In addition, UCB ALDHhi cells rapidly reduce ALDH‐activity
(Fig. 2.2B) during ex vivo expansion 28. Therefore, ALDHhi cells were expanded with or
without DEAB‐treatment, to inhibit ALDH‐activity and limit RA‐induced differentiation
during culture (Fig. 2.2B). Exposure of cells to DEAB‐treatment at days 3–6 was selected
based on the optimal preservation of ALDHhi cells during 6- and 9-days expansion ex
vivo (Figure 2.3). Temporal DEAB‐treatment from days 3 to 6 increased expanded
ALDHhi cell frequency at day 6 (40.98 ± 8.43% vs. 13.85 ± 2.38%; **, p < .01) and at
day 9 (31.04 ± 5.48% vs. 6.58 ± 1.03%; **, p < .01; Fig. 2.2C). Total cell expansion
kinetics were equivalent over 9 days with or without DEAB‐treatment (82.62 ± 9.51‐fold
vs. 79.22 ± 16.49‐fold increase; Fig. 2.2D). Taken together, DEAB‐treatment led to a
25.42 ± 4.35‐fold increase in ALDHhi cell numbers obtained after 9 days; a significant
increase compared with Basal conditions (5.40 ± 1.27‐fold increase; ***, p < .001; Fig.
2.2E). Therefore, DEAB‐treatment from days 3 to 6 during a 9‐day expansion protocol
was selected for further assessment of primitive progenitor cell phenotype and function.
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Figure 2.2 Diethylaminobenzaldehyde (DEAB)-treatment augmented the expansion
of early myeloid progenitors with high ALDH-activity. (A) Umbilical cord blood
ALDHhi cells were isolated by fluorescence-activated cell sorting and expanded with or
without DEAB-treatment between days 3 and 6. (B) Representative flow cytometry plots
showing DEAB-treatment enhanced (C) the frequency of ALDHhi cells retained after 9
days (N=7). (D) Total cell expansion was not affected by DEAB-treatment, whereas (E)
total ALDHhi cell number was increased ~25-fold under DEAB-treated conditions. (F)
DEAB-treatment increased hematopoietic colony forming capacity of expanded cells
seeded in methylcellulose media (N=5). (G) DEAB-treatment enhanced the production of
colonies with multiple myeloid phenotypes. Data represented as mean + SEM (*, p<.05;
**p<.01;***p<.001). Statistical analyses were determined by paired Student’s t test.
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Figure 2.3 Temporal DEAB-treatment increases the retention of ALDHhi cells
during ex vivo expansion. (A) UCB ALDHhi cells were cultured under Basal
conditions (X-vivo 15 + 10ng/mL TPO, SCF, FLT-3L) for 6 days and treated with
10uM of DEAB between days 0-3, 0-6, or 3-6. (B) DEAB-treatment occurring
between Days 3-6 increased enrichment of ALDHhi cells. (C-D) Extending on these
results, DEAB-treatment was either removed (DEAB 3-6) or extended (DEAB 3-9)
for an additional 3 days of culture. Interestingly, temporal DEAB-treatment (DEAB
3-6) increased the frequency of ALDHhi cells retained after 9 days of culutre,
compared to Basal conditions. Data represented as Mean ± SEM (**p<0.01,
***p<0.001; N=3-13). Statistical analyses were determined by ANOVA with
Tukey’s multiple comparisons test.
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2.3.3

RA‐Signaling Was Modified following DEAB‐Treatment

ALDH‐activity leads to the production of RA, a potent driver of hematopoietic
differentiation. To validate that DEAB‐treatment modulated RA‐signaling during
expansion, we first performed reverse transcriptase‐qPCR on transcriptional targets of the
RAR/RXR complex. Activation of the RAR/RXR complex was expected to increase
transcription of target genes such as CYP26A1, ALDH1A3 isoform, and RAR25. DEAB‐
treatment significantly reduced transcription of ALDH1A3, CYP26A1, and RAR
subunit while transcription of RAR was increased (Figure 2.4). Collectively, this
suggested RA‐signaling networks were modified following DEAB‐treatment.
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Figure 2.4 Transcriptional analysis of Day 9 cells cultured under Basal or DEABtreated conditions. RT-qPCR was performed on cell lysates (n=3) of UCB ALDHhi cells
cultured under Basal or DEAB-treated conditions for 9 days. Fold changes are relative to
Day 9 Basal cells. DEAB-treated conditions decreased the transcription of (A) Aldehyde
Dehydrogenase 1A3, (B) Cytochrome P450 Retinoic Acid-Inactivating 1, (C) Retinoic
Acid Receptor-Alpha, (D) Whereas, DEAB-treated conditions increased the transcription
of (G) Retinoic Acid Receptor-Gamma. β-glucuronidase (GUSB) was used as a
housekeeping gene. Data represented as Mean ± SEM. (*p<0.05, **p<0.01). Statistical
analyses were determined by Student’s t-test.
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2.3.4

DEAB‐Treatment Enriched for Cells with Multipotent Myeloid
Progenitor Function

To determine whether expanded cells retained hematopoietic colony forming unit (CFU)
functions in vitro, day 9 cultured cells were seeded in methylcellulose media and
enumerated for myeloid‐lineage colony formation after 14 days. DEAB‐treated cells
demonstrated a significantly higher frequency (*, p < .05) of total colony formation (1
CFU in 7.4 cells) compared with cells expanded under Basal conditions (1 CFU in 13.3
cells; Fig. 2.2F). DEAB‐treatment enriched specifically for early HPC with myeloid
multipotency; enumerated by colonies demonstrating multiple myeloid morphologies
(Fig. 2.2G). Thus, DEAB treatment augmented the expansion of ALDHhi cells that
retained multipotent hematopoietic CFU capacity in vitro.

2.3.5

DEAB‐Treatment Enriched for Cells with Primitive Surface
Marker Expression

To determine whether DEAB‐treatment also prevented the loss of primitive cell surface
phenotype (ALDHhi/CD34+/CD38–) during expansion, cells were analyzed using
multicolor flow cytometry (Table 2.2). At day 9, expanded cells were exclusively
hematopoietic determined by pan‐leukocyte marker (CD45) expression (>99%), and the
majority of Basal or DEAB‐treated cells expressed the early myeloid cell surface marker
CD33 (96.1 ± 0.85 and 94.5 ± 1.53%, Table 2.3). Monocyte‐specific marker (CD14)
expression was comparable between Basal and DEAB‐treated conditions (2.96 ±1.23 vs.
4.08 ± 1.64% of total cells). compared with Basal conditions, expression of the
hematopoietic differentiation marker CD38 was significantly reduced following DEAB‐
treatment (31.06 ± 2.52 vs. 21.16 ± 2.56% of total cells; **, p < .01; Table 1).
Futhermore, DEAB‐treatment enriched for cells with primitive ALDHhi/CD34+ (2.18
± 0.42 vs. 6.20 ± 0.73% of total cells; *, p < .05) and ALDHhi/CD34+/CD38– (2.29 ±
0.35 vs. 5.46 ± 0.59% of total cells; ***, p < .001) phenotypes (Table 2.2). Collectively,
DEAB‐treatment generated 5‐ and 10‐fold increase in the total number of ALDHhi
CD34+ or ALDHhi CD34+/CD38– after 9 days, respectively (Table 2.3). In contrast,
Basal conditions generated a modest 1.7‐ and 4.1‐fold increase in the number of ALDHhi
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CD34+ or ALDHhi CD34+/CD38–, respectively. Basal conditions highly enriched for
cells with mature hematopoietic cell (ALDHlo/CD38+) phenotype (24.59 ± 2.70% of
total cells; ***, p < .001; Table 2.2). Collectively, DEAB‐treatment enhanced the
expansion of hematopoietic cells retaining ALDHhi‐activity and primitive cell surface
marker expression patterns.

.
Table 2.2 DEAB‐treatment enhanced the expansion of cells with a primitive surface
phenotype
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Table 2.3 UCB ALDHhi cell expansion under Basal or DEAB-treated conditions generates
myeloid-specific cell progeny.

Table 2.4 . DEAB-treatment enhanced the number of expanded cells with primitive
surface phenotype
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2.3.6

DEAB‐Treatment Reduced Megakaryocyte Lineage Maturation

Basal culture conditions led to UCB ALDHhi cell differentiation toward a megakaryocyte
phenotype as culture time progressed (Fig. 2.1). Therefore, we sought to determine
whether DEAB‐treatment delayed differentiation of expanded ALDHhi cells toward the
megakaryocyte lineage (Fig. 2.5A). Although we did not observe differences in the
frequency of expanded cells acquiring mature megakaryocyte phenotype (CD41+/CD42+)
at day 9 (Fig. 2.5B), DEAB‐treatment significantly reduced the frequency of CD41+ cells
that coexpressed CD38 (17.3 ± 2.7 vs. 26.2 ± 6.4% of CD41+ cells; Fig. 2.5C; *, p < .05,
and Table 2.5). Furthermore, DEAB‐treatment significantly reduced the expression of
CD38 on CD41+/CD42+ megakaryocytes, compared with Basal conditions (*, p < .05;
Fig. 3D). Previous reports have also suggested that expanded CD41+/CD42–
hematopoietic cells retain myeloid multipotency in vitro and SCID‐repopulating
capacities in vivo when coexpressing a CD34+/CD38– phenotype36. At day 9, DEAB‐
treatment enriched the CD41+/CD42– megakaryoblast fraction with primitive
CD34+/CD38– phenotype (13.1 ± 2.4% vs. 8.2 ± 2.0%; *, p < .05; Table 2.5).
Collectively, these results suggested that DEAB‐treatment delayed the maturation of
CD41+/CD42– megkaryoblasts by delaying CD38 acquisition and loss of CD34
expression.
.
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Figure 2.5 DEAB-treatment reduced differentiation towards megakaryocyte
phenotype. Schematic of megakaryopoiesis and acquisition of mature megakaryocyte
phenotype (CD41+/CD42+/CD38+). (B) DEAB-treatment did not alter CD41 and CD42
expression patterns at 6 or 9 days. (C) Representative flow cytometry plots showing
reduced expression of CD38 on CD41+/- cells generated under DEAB-treated conditions.
(D) CD38 expression was reduced on megakaryocytes (CD41+/CD42+) under DEABtreated conditions. Data represented as Mean ± SEM (*p<0.05; N=5-8). Statistical
analyses were performed by paired Student’s t-test.
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Table 2.5 DEAB-treatment retains primitive progenitor cells within CD41+/subpopulations coinciding with reduced CD38 expression.
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2.3.7

DEAB‐Treated Cells Demonstrated a Pro‐Survival and Pro‐
Angiogenic Proteome

We used highly sensitive mass spectrometry to compare global proteome changes after 9
days expansion under either Basal (N = 3) or DEAB‐treated (N = 3) conditions. Expanded
UCB ALDHhi cells generated a heterogeneous cell population comprised of several
hematopoietic cell types after 9 days28; therefore, detectable changes in the global
proteome should reflect changes within influential signaling networks. The proteomic
profiles of these expanded cell populations were remarkably similar. Of the 6,804 unique
proteins detected, only 121 proteins were unique to cells harvested from DEAB‐treated
conditions, and 164 were unique to cells harvested from Basal conditions, (Fig. 2.6A).
Proteins exclusively expressed under DEAB‐treated conditions were largely associated
with anti‐apoptotic activity (i.e., NEMO, IKBKG; Caspase Recruitment Domain‐
containing protein 6, CARD6; Table 2.6). Conversely, proteins exclusive to Basal
conditions included drivers of apoptosis, including Fas cell surface death receptor (FAS)
(Table 2.7). Several proteins implicated with mature hematopoietic cell functions (i.e.,
plasminogen activator; platelet‐activating factor receptor; dendritic cell‐associated lectin
2; integrin subunit beta 7) were exclusively produced under Basal conditions.
Of the 6,519 proteins common to cells from Basal and DEAB‐treated conditions, only
117 proteins demonstrated a >1.2‐fold or <1.2‐fold difference comparing DEAB‐treated
to Basal conditions (Fig. 2.6B, C). Common angiogenic factors (ANGPT1; von
Willebrand factor, vWF; and transforming growth factor beta 1) were comparable in the
proteome of Basal and DEAB‐treated cells. Interestingly, DEAB‐treatment primarily
upregulated intracellular proteins involved in the prevention of apoptosis (i.e., BCL2
family apoptosis regulator, MCL1), in the preservation of progenitor cell function
(thrombopoietin receptor, MPL), or with cell motility such as proto‐oncogene C‐Crk
(CRK) and leucine rich repeat containing 16A. Cells harvested from Basal conditions
upregulated proteins primarily associated with HPC differentiation; including Fibronectin
(FN1), Serpin family B member 8 (SERPINB8), lymphocyte antigen 75 (LY75), and
adenosine deaminase 2 (CECR1). Validating our flow cytometry data, CD38 protein
levels were decreased 1.68‐fold in cells harvested after DEAB‐treatment compared with
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Basal conditions. Collectively, these analyses suggest that DEAB‐treatment increased the
production of pro‐survival proteins and decreased the production of proteins associated
with hematopoietic differentiation.
.
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Figure 2.6 Distinct proteomic
profiles for DEAB-treated
versus Basal cells. (A) Mass
spectrometry identified 6804
individual proteins across cell
lysates. Out of 6519 proteins
were detected in both Basal and
DEAB-treated cells (N=3), only
137 proteins were found to be
(B) differentially expressed (red
circles, *p<0.05). (C) DEABtreatment increased production
of anti-apoptotic proteins,
including myeloid cell leukemia1 (MCL1) and thrombopoietin
receptor (MPL). Decreased
detection of differentiation
factors including CD38, CECR1,
SERPINB8, and Fibronectin
(FN1) was also observed in
DEAB-treated cells. Statistical
analyses were performed by
students t-test.
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Table 2.6 Proteins exclusively found in the cell lysate of DEAB-treated cells

Table 2.7 Proteins exclusively found in the cell lysate of Basal cells

93

2.3.8

Transplantation of DEAB‐Treated Cells Accelerated the Recovery
of Perfusion

We have previously shown that extended culture of UCB ALDHhi cells resulted in the
loss of vascular regenerative functions after transplantation in vivo28. Therefore, we
sought to determine whether DEAB‐treatment could generate cells that retained vascular
regenerative function following transplantation into mice with hind‐limb ischemia. After
unilateral FAL surgery, non‐obese diabetic/severe combined immunodeficient
(NOD/SCID) mice with hind‐limb ischemia (Perfusion Ratio, PR; PR < 0.1) received i.m.
injection of UCB ALDHhi cells expanded for 9 days under Basal or DEAB‐treated culture
conditions. Transplantation of 5.0 × 105 cells generated under Basal conditions failed to
improve limb perfusion from baseline recovery observed with PBS‐injected controls
(PR = 0.58 ± 0.04 vs. 0.49 ± 0.05 at day 35, respectively; Fig. 2.7A, B). However, i.m.‐
transplantation with 5.0 × 105 cells generated under DEAB‐treated conditions
significantly increased limb perfusion as early as day 21, compared with PBS controls
(0.70 ± 0.04 vs. 0.43 ± 0.03; **, p < .01), and improved limb perfusion persisted until
day 35 post‐transplantation (0.76 ± 0.06; **, p < .01). Limb usage assessed by Catwalk
paw print area measurements for all groups were equivalent at day 35. However, at 7
days post‐transplantation mice that received DEAB‐treated cells showed modestly
improved limb usage compared with PBS‐controls (p = .17) (Figure 2.7C).
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Figure 2.7 DEAB-treated cells accelerated the recovery of limb perfusion after
transplantation. (A) Representative LDPI following FAL and intramuscular
transplantation of PBS (n=7), 5x105 Basal cells (n=11), or 5x105 DEAB-treated cells
(n=11). Perfusion ratio (PR) in the ischemic (orange box) versus non-ischemic (yellow
box) limbs are shown in white text. (B) NOD/SCID mice i.m.-injected with Basal cells
showed similar recovery of perfusion compared to PBS controls (Day 35 PR=0.58±0.04
vs. 0.49±0.06; respectively). Transplantation of DEAB-treated cells enhanced the
recovery of limb perfusion compared to PBS vehicle controls or Basal cells at days 2135. (C) Paw area ratio of ischemic vs. non-ischemic limb measure at 7- and 35-days posttransplantation (n=5-7). DEAB-treated cells modestly increased limb usage at 7 days
post-transplantation, albeit limb usage was equal across transplantation conditions at day
35 post-transplantation. Data represented as Mean ± SEM (*p<0.05, **p<0.01).
Statistical analyses were performed by ANOVA with Tukey’s multiple comparisons test
relative to PBS-injected mice.
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2.3.9

Transplantation of DEAB‐Treated Cells Stimulated Endothelial
Cell Proliferation and Increased Capillary Density within Ischemic
Limbs

To investigate potential mechanisms by which DEAB‐treated cells accelerated the
recovery of limb perfusion, vascular density was assessed alongside human cell
engraftment kinetics at day 7 and day 35 post‐transplantation in ischemic thigh muscle
tissue sections. Human cell engraftment was detected within ischemic thigh muscles at 7‐
days post‐transplantation with either Basal or DEAB‐treated cells (Figure 2.8). Compared
with Basal cells, DEAB‐treated cells demonstrated a trend toward increased engraftment
within the ischemia thigh muscle (1.25 ± 0.21 vs. 0.83 ± 0.11 HLA+ cells/mm2, n = 4,
p = .13). Moreover, transplanted cells were not detected after 35‐days post‐
transplantation. Mice were injected with EdU 24 hours before euthanasia to allow
quantification of proliferating CD31+ endothelial cells. At day 7 post‐transplantation,
mice transplanted with DEAB‐treated cells showed an increased number of EdU+/CD31+
cells/mm2 within ischemic thigh muscle, compared with mice injected with cells
generated under Basal conditions (3.06 ± 1.08 vs. 0.67 ± 0.27, *, p < .05) or PBS (0.11
± 0.11, **, p < .01; Fig. 2.9A, B). Augmented endothelial cell proliferation corresponded
to increased CD31+ capillary density at day 35 with DEAB‐treated cells (*, p < .05; Fig.
2.9C). In addition, mice transplanted with DEAB‐treated cells increased the number of
larger vessels expressing vWF at day 35 (Figure 2.10), compared with PBS‐injected
controls. Collectively, DEAB‐treated cells survived for at least 7 days post‐
transplantation and stimulated endothelial cell proliferation leading to increased vascular
density in the ischemic limb
.
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Figure 2.8 Human cell engraftment detected in the ischemic thigh muscle 7 days posttransplantation. Representative confocal photomicrograph (20x) of a thigh muscle cryosections
stained for HLA-A, B,C, detecting human cells 7 days after the intramuscular transplantation of
(A) Day 9 Basal cells or (B) Day 9 DEAB-treated cells. Arrows indicate location of detected
human cells. Scale bar = 50𝝁m
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Figure 2.9 Transplantation of DEAB-treated cells increased capillary density via
increasing murine endothelial cell proliferation. NOD/SCID mice transplanted with either PBS
(n=5), Basal cells (n=6), or DEAB-treated cells (n=6) were injected with EdU 24-hrs prior to
euthanasia at 7 days post-transplantation. (A) Representative confocal images (10x) of
cryosectioned thigh muscles stained for endothelial cell marker (CD31) and EdU-incorporation
(Alexafluor 594). (B) Representative confocal image (40x) of endothelial cell proliferation
(EdU+/CD31+) in the ischemic limb of mice transplanted with DEAB-treated cells. (C) Mice
transplanted with DEAB-treated cells had a significantly increased number of proliferating
endothelial cells within the ischemic limb, compared to PBS-injected or Basal cell transplanted
mice. (D) Intramuscular transplantation of DEAB-treated cells increased CD31+ capillary density
in ischemic limbs of mice sacrificed at day 35 (n=7-11). Data represented as Mean
± SEM.(*p<0.05, **p<0.01). Statistical analyses were performed by ANOVA with Tukey’s
multiple comparisons test. Scale bar = 150μm.
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Figure 2.10 Intramuscular transplantation of DEAB-treated cells prevented the loss of von
Willebrand factor-positive blood vessel networks after femoral artery ligation-induced CLI.
(A) Representative immunofluorescent images (20x) of cyrosectioned thigh muscles harvested 7days post-transplantation and stained for von Willebrand factor (vWF). (B) DEAB-treated and
Basal cells increased the number of vWF+ vessels 35 days post-transplantation, compared to PBS
control. Data represented as Mean ± SEM (*p<0.05; n=5-7). Statistical analyses were determined
by ANOVA with Tukey’s multiple comparisons relative to PBS-injected mice. Scale bar = 50𝝁m
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2.4 Discussion
Blood‐derived progenitor cells with ALDHhi‐activity demonstrate multifaceted
regenerative functions in preclinical studies12, 15. However, it is becoming well accepted
in preclinical studies that harvesting autologous cells from the BM of individuals with
diffuse atherosclerosis19 and associated comorbidities such as obesity and type 2
diabetes20, 37, results in the accrual of progenitor cells with depleted numbers and
dysfunctional vascular regenerative capacity. The use of allogenic UCB cells with limited
exposure to damaging metabolic by‐products of chronic disease24 may mitigate
progenitor cell exhaustion and facilitate the development of cellular therapies with
improved efficacy. UCB represents a readily accessible source of regenerative cells,
usually considered discarded material, and is easily harvested with no risk to either the
newborn or mother. Recent establishment of national cord blood banking programs
generates a renewable multi-donor pool with increased diversity for HLA‐matching and
subsequent use in allogeneic therapeutic applications. A phase I clinical trial
(NCT01019681) was recently initiated to determine the safety and efficacy of UCB‐
MNC; however, these results have yet to be reported. We have previously demonstrated
enhanced vascular regenerative functions of UCB‐derived ALDHhi cells compared with
unpurified UCB‐MNC12. However, ALDHhi cells only represent <0.5% of total UCB‐
MNC and require ex vivo expansion to increase the number of progenitor cells needed to
support early preclinical studies. Herein, we demonstrate an expansion strategy and early
preclinical evidence which indicates expanded allogeneic UCB ALDHhi cells could be
used for treating severe ischemic disease16.

UCB ALDHhi cells are primarily comprised of early myeloid HPC12 that can be
efficiently expanded in short‐term culture under serum‐free conditions28. Unfortunately,
when culture time was extended from 6 to 9 days, the vascular regenerative function of
expanded progeny was diminished after i.m.‐transplantation into NOD/SCID mice with
hind‐limb ischemia23. This led us to speculate that prolonged culture time under serum‐
free (Basal) conditions reduced pro‐angiogenic growth factor production and/or secretion,
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such as VEGF‐A, from expanded progeny. Despite robust differentiation toward the
megakaryocyte lineage between days 6 and 9, we did not observe significant decrease in
secreted levels of common pro‐angiogenic growth factors (VEGF‐A, ANGPT1, CCL5).
In contrast, we observed an increased expression of megakaryocyte lineage‐specific
proteins, including CD41 (ITGA2B) and CD42 (GPIB). Specifically, flow cytometry
analyses demonstrated a reduction of primitive surface marker (CD34) expression
alongside diminished ALDH‐activity, which coincided with the acquisition of a mature
megakaryocyte phenotype (CD41+/CD42+/CD38+).

Megakaryocytes represent large hematopoietic cells (50–100 𝜇m) which release platelets
into systemic circulation through the fragmentation of proplatelet extensions that protrude
into vascular sinuses of the BM niche. The turnover of circulating platelets is frequent
(<9 days); therefore, the consistent production of platelets is necessary to ensure vessel
hemostasis and injury repair38,39. Platelet‐derived CD42 binds to vWF on exposed
subendothelium collagen during vascular injury, the subsequent activation of platelets
will stimulate soluble protein and extracellular vesicle secretion into the local
microenvironment and systemic circulation. These stimuli recruit and activate biological
processes within endothelial or hematopoietic cells38, 40,41. Specifically, platelet‐derived
stimuli (i.e., VEGF‐A) influence both angiogenic and inflammatory pathways during
wound healing and vascular regeneration in vitro and in vivo39, 40,42. To our knowledge,
this is the first study to characterize and investigate the vascular regenerative potential of
a culture‐expanded, megakaryocyte‐enriched cell population for treating ischemic
disease. Indeed, the acquisition of a mature megakaryocyte phenotype
(CD41+/CD42+/CD38+) and concomitant loss of ALDHhi‐activity under Basal conditions
diminished the vascular regenerative capacity of UCB‐derived ALDHhi cells.

Chute et al. were the first to show that DEAB‐treatment enhanced the expansion of UCB‐
derived CD34+ CD38– cells with SCID repopulating capacity. Specifically, DEAB‐
treated cultures were enriched 11.6‐fold with cells retaining primitive CD34+/CD38–
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phenotype after 7 days. The benefit of DEAB‐treatment was reversed after RA‐
supplementation, suggesting that inhibition of ALDH‐activity promoted HSC self‐
renewal via reduced RA‐production. Our study extends these findings to show that
inhibition of ALDH‐activity and RAR/RXR complex activation could modify the
transcription of downstream targets (i.e., CYP26A1)29. Despite equal expansion of
CD34+ cells compared with Basal conditions, DEAB‐treated progeny better retained a
primitive phenotype, with a 15‐fold expansion in CD34+ CD38– cells and an 11‐fold
expansion of the most primitive ALDHhi/CD34+/CD38– cells. Importantly, DEAB‐
treatment significantly increased multipotent myeloid colony formation in vitro,
suggesting that ALDHhi activity can segregate multipotent CD34+ cells from committed,
unipotent ALDHlo CD34+ cells43.

Under Basal conditions, rapid loss of ALDHhi‐activity coincided with the acquisition of
mature hematopoietic surface marker, CD38. In contrast, DEAB‐treatment enhanced
retention of ALDHhi phenotype and reduced CD38 expression. CD38 (Cyclic Ribose
ADP Hydrolase) is a multifunctional enzyme implicated with intracellular Ca+ signaling,
platelet aggregation, and adhesion of leukocytes to CD31+ endothelial cells44,45. CD38 is
also a direct target of RA‐signaling27, suggesting that DEAB‐treatment limited CD38
expression by modifying RA‐signaling networks. Furthermore, DEAB‐treated cell lysates
exhibited increased levels of MCL1 and MPL, cellular proteins implicated with
progenitor cell maintenance46,47. Conversely, Basal conditions, increased the expression
of proteins implicated with hematopoietic differentiation (i.e., CECR1, FN1, SERPINB8,
and LY75). Collectively, flow cytometry and proteomic data confirmed DEAB‐treatment
enhanced the expansion of multipotent HPC by limiting RA‐induced differentiation.

We next investigated whether differentiation toward the megakaryocyte lineage was
delayed by the inhibition of RA‐production. Commitment to the megakaryocyte lineage
is marked by the acquisition of CD41 (ITGA2B), whereas CD42 (GP1B) expression
occurs later in megakaryopoiesis48. However, acquisition of CD41 and CD42 expression
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was not altered by DEAB‐treatment. This was not a surprise considering treatment with
TPO and FLT‐3L is known to drive early megakaryopoiesis and increase CD41
expression during ex vivo expansion49. Several reports have suggested that cells with the
immature megakaryoblast phenotype (CD34+/CD38–/CD41+/CD42–) retain multipotency
in vitro and in vivo 36, 50,51.DEAB‐treatment increased the accumulation of CD34+/CD38–
progenitor cells and delayed the acquisition of CD38 within the megakaryoblast lineage
(CD41+/CD42–). DEAB‐treatment also limited the production of mature megakaryocytes
(CD41+/CD42+/CD38+); suggesting that inhibition of RA‐production delayed
differentiation at multiple stages of megakaryopoeisis.

Although the secretome and proteome of day 9 Basal cells showed similar expression of
pro‐angiogenic stimuli (i.e., VEGF‐A), day 9 Basal cells did not support the recovery of
perfusion after i.m. transplantation into the ischemic limb of NOD/SCID mice. In
contrast, DEAB‐treated cells accelerated the recovery of blood perfusion by increasing
endothelial cell proliferation in ischemic muscle tissue. Both Basal and DEAB‐treated
cells were detected 7‐days post‐transplantation but were absent at day 35. DEAB‐treated
cells demonstrated a trend toward increased engraftment and were found to be closely
associated with proliferating endothelial cells, however, did not engraft into murine
vasculature. Thus, we predict that survival and/or migration to a regenerative niche is
compromised in day 9 Basal cells following i.m.‐transplantation. In support of this
interpretation, day 9 Basal cells exclusively expressed proteins implicated with the
induction of apoptosis, including FAS52. In contrast, DEAB‐treated cells exclusively
expressed several pro‐survival molecules (i.e., CARD6, MCL1, KRT18, etc.), in addition
to retaining the cytoprotective functions of ALDHhi‐activity. Further studies are
warranted to determine the role of apoptotic and pro‐survival pathways identified in this
study. Several studies have demonstrated increased regenerative cell function by pre‐
treating cells with small molecules to enhance survival following transplantation53,54. Our
data suggest DEAB‐treatment generated heterogeneous myeloid cell progeny with pro‐
angiogenic secretory capacity that were more likely to survive i.m.‐transplantation into a
harsh ischemic microenvironment. Furthermore, our data suggest ALDHhi ‐activity and
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reduced CD38 expression may be a characteristic of vascular regenerative hematopoietic
cells. Especially considering day 9 DEAB‐treated, day 6 Basal, and fresh UCB ALDHhi
cells 12 share these characteristics (ALDHhi/CD38lo), in contrast to day 9 Basal cells with
diminished vascular regenerative functions (ALDHlo/CD38hi).

Both Basal and DEAB‐treated cells were identified by proteomics to equally express
integrin complexes including CD41, CD61, CD18, and CD29 after culture on fibronectin.
Activation of integrin signaling is expected to increase transplanted cells survival and/or
migration. In contrast, detachment induced apoptosis could negatively impact
transplanted cell engraftment. In addition, UCB ALDHhi cells cultured under Basal
conditions for 9 days increased the production of extracellular matrix (ECM) molecules
(fibronectin and collagen), compared with DEAB‐treated cells. The increased production
of ECM molecules is characteristic of cells within the megakaryocyte lineage that could
potentially limit bio‐distribution throughout the ischemic muscle. Additional studies are
needed to specifically address whether pre‐exposure to a matrix influences the
engraftment and bio‐distribution of transplanted progenitor cells. Interestingly, Whiteley
et al. demonstrated UCB‐derived CD34+/CD45+ cells cultured for 8 days, engrafted
ischemic murine muscle tissue at a higher rate than uncultured CD34+ cells or MNC,
suggesting that ex vivo culture may benefit cellular therapies for PAD55. Several early
trials have reported modest clinical benefits following the i.m. transplantation of
expanded progenitor cells from autologous BM or peripheral blood56,57; however, these
trials were unable to improve limb amputation rates.

In summary, our previous studies established that UCB ALDHhi cells and day 6 expanded
progeny temporally engraft ischemic muscle tissues and induce neovascularization in
NOD/SCID mice with hind‐limb ischemia28. Unfortunately, the low number of
transplantable cells would limit or impede a controlled clinical study to effectively
investigate currently unestablished parameters of expandable UCB‐cells, such as clinical
efficacy and cell dose. This study demonstrates limiting RA‐induced differentiation
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during UCB‐cell expansion can expand total cell number by ∼80‐fold, and total ALDHhi
cells by ∼25‐fold, without a significant loss of vascular regenerative function. Therefore,
we consider these results early preclinical evidence that reasonable cell numbers can be
generated from a single UCB sample to assess currently undetermined parameters leading
to improved efficacy, such as cell dose, phenotype (ALDH, CD34, CD38, etc.), or
therapeutic cell source (BM vs. UCB). Collectively, (a) advanced understanding of
signaling pathways which drive progenitor cell differentiation, (b) identification of
vascular regenerative cell subpopulations, and (c) improving culture conditions to
facilitate cell type specific expansion is warranted for the development of effective
vascular regenerative therapies.
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Chapter 3

3

Inhibition of retinoic acid production expands a
megakaryocyte-enriched subpopulation with islet
regenerative functionii

ii A version of this chapter has been published: Cooper, T.T., Bell, G.I. and Hess, D.A.,
2018. Inhibition of retinoic acid production expands a megakaryocyte-enriched
subpopulation with islet regenerative function. Stem cells and development, 27 (20),
pp.1449-1461.

3.1 Introduction
The current ‘‘epidemic’’ status of diabetes mellitus (DM) is expected to increase from
425 million individuals in 2017 to >625 million individuals by 2045, amplifying the
surging financial burden on the healthcare system1. Two classifications of DM exist, each
with a distinct etiology and pathology2,3. Type 1 DM represents *10% of reported cases
and is associated with the autoimmune destruction of insulin-secreting β-cell s. Type II
DM accounts for *90% of reported cases and is associated with insulin resistance in
peripheral tissues. In both Type I or long-standing Type II DM, exogenous insulin is used
for treatment of unregulated glycemic control. Unfortunately, current treatments do not
mimic homeostatic insulin secretion, which leads to extreme fluctuations of blood
glycemic levels. As a result, >80% of individuals with DM will develop life-threatening
cardiovascular complications3. There is accumulating evidence that demonstrates human
pancreas contains resident stem/progenitor cell populations4-6 and DM may be effectively
treated by the restoration of physiologically functional β-cell mass6,7. As a result, cellbased therapies have become a focus of translational research aiming to restore depleted
β-cell mass be either replacement or regeneration strategies8,9. Recent phase I/II clinical
investigations to replace (NCT02239354) or regenerate (NCT00690066) β-cell mass are
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currently underway or have reported early results. In 2010, the Joslin Medalist study
reported measurable C-peptides levels and actively proliferating β-cell mass in the
pancreata of individuals with Type I DM for >50 years10.
This encouraged the idea that transplantation of appropriate cell types and/or stimuli may
boost endogenous β-cell regeneration in the islets of a diabetic individual5. We initially
demonstrated human bone marrow (BM) and umbilical cord blood (UCB)-derived
progenitor cells selected for high aldehyde dehydrogenase (ALDH) activity could
stimulate endogenous β-cell regeneration and reduce hyperglycemia in streptozotocin
(STZ)-treated NOD/ SCID mice11,12. We have recently demonstrated the secretome of
blood-derived progenitor cells such as multipotent stromal cells or hematopoietic
progenitor cells (HPC) can stimulate human β-cell proliferation in vitro13,14. It has also
been demonstrated that mature hematopoietic cells, such as platelets, may have β-cell
supportive functions during the clinical treatment of Type 1 DM autoimmunity15.
Collectively, identifying phenotypic characteristics islet-regenerative cell populations and
the effectors used to orchestrate robust islet regeneration is crucial to effective treating or
reversing DM. UCB represents an accessible source of hematopoietic, endothelial, and
mesenchymal progenitor cells and collection imposes no risk to either the newborn or
mother. The worldwide establishment of public and private cord blood banking registries
has generated a renewable pool with increased diversity for human leukocyte antigen
(HLA)-matching for use in therapeutic applications. We view UCB as a favorable source
of progenitor cells compared to autologous bone marrow, as accumulating evidence
demonstrates loss of progenitor cell number and function when cells are harvested from
the microenvironment of chronic diseases16-19. Cells harvested from healthy allogenic
sources (i.e., UCB) are untouched by damaging metabolites that circulate throughout the
body of diabetic individuals18. Further research is warranted to determine the full
potential of UCB cell progeny for therapeutic strategies to treat DM and common
cardiovascular comorbidities. The selection of UCB ALDHhi cells isolates an HPCenriched cell population with multifaceted regenerative functions11,20. Unfortunately,
UCB ALDHhi cells represent a rare subpopulation (70-fold after 9 days; >1.0 · 107 viable
cells); however, a primitive cell phenotype and regenerative function are rapidly lost21-23.
We have recently identified that UCB ALDHhi cells preferably differentiate toward the
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megakaryocyte lineage as culture time was increased22. Specifically, we detected
increased expression of megakaryocyte-specific lineage markers, including CD41
(ITGA2) and CD42 (GP1B), by global proteomic analyses and validated by
multiparametric flow cytometry. UCB ALDHhi cells became enriched for a
megakaryoblast phenotype (CD41+/CD42-) during ex vivo expansion and subsequently
acquired a committed megakaryocyte phenotype (CD41+/CD42+); coinciding with loss of
high ALDH-activity (UCB hematopoietic progeny capable of robustly stimulating islet
regeneration. ALDH is rate limiting enzyme in the production of retinoic acid (RA), a
potent driver of HPC differentiation via the activation of the RAR/RXR nuclear receptor
complex (RAR/ RXR)24. Activation of the RAR/RXR complex will increase the
production of downstream products that initiate hematopoietic differentiation and/or cell
proliferation25-27. This imposes a paradoxical challenge to efficiently expand ALDHhi
HPC while limiting the intrinsic propensity for hematopoietic differentiation in vitro.
Reversible inhibition of ALDH1A-activity, using diethylaminobenzaldehyde (DEAB)
supplementation, limited HPC differentiation during 9-day culture and generated an
ALDHhi cell-enriched population (>20% of day 9 progeny; >20-fold increase of ALDHhi
cells) that retained vascular regenerative function in vivo22. Herein, we investigated the
islet regenerative capacity of expanded UCB ALDHhi cells reselected for high versus low
ALDH-activity following 9 days culture under previously described DEAB-treated
culture conditions. We hypothesized expanded ALDHhi cells reselected from DEABtreated conditions would demonstrate islet regenerative function following
intrapancreatic transplantation into STZ-induced hyperglycemic NOD/SCID mice.
Surprisingly, this study identified that only a CD41+ megakaryocyte-lineage enriched
ALDHlo cell population harvested from DEAB-treated conditions supported islet
regeneration, albeit modestly. Collectively, this study provides evidence that the retention
of high ALDH-activity, via DEAB-treated conditions, does not coincide with islet
regenerative function.
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3.2 Methods
3.2.1 UCB ALDHhi cell isolation and expansion
3.2.2 Human UCB samples were obtained with informed consent by venipuncture of
the umbilical vein following Caesarian section at Victoria Hospital Birthing
Centre, London, ON, Canada (REB No. 12934). The Human Studies Research
Ethics Board (HSREB) at Western University approved all procedures. Within
24 h of collection, UCB samples were initially depleted of mature myeloid,
lymphoid and red blood cells using RosetteSep Human Cord Blood Progenitor
Cell Enrichment Cocktail (Stem Cell Technologies, Vancouver, BC, Canada).
Lineage-depleted (Lin-) mononuclear cells were isolated by Hypaque Ficoll
centrifugation and incubated with Aldefluor regent before purification by FACS
(FACS Aria III; BD Biosciences, Mississauga, ON, Canada). UCB ALDHhi cells
were selected based on low side scatter and high ALDH-activity with >98%
purity (n = 5). Purified UCB ALDHhi cells were cultured on fibronectin-coated
plates for 9 days under untreated (X-vivo 15 + 10 ng/mL SCF, TPO, FLT-3L) or
DEAB-treated (Untreated+10 mM DEAB on days 3–6), as previously described
(Figure 3.1A)22.

3.2.3 Flow cytometry
UCB ALDHhi cells expanded under untreated or DEAB-treated conditions were
harvested at day 9 and enumerated by trypan blue exclusion using hemocytometer counts.
Cells were labeled with Aldefluor to assess ALDH-activity. and co-stained with 7-aminoactinomycin D to determine viability. Fresh UCB Lin- MNC and expanded UCB ALDHhi
cell progeny were co-labeled with anti-human antibodies for CD41 (ITGA2), and CD42
(GP1B; megakaryocyte). Expanded cells were assessed for a primitive HPC phenotype
using anti-human CD34 and hematopoietic lineage differentiation was determined using
anti-human CD38 (cyclic ADP ribose hydrolase). Cell surface marker expression for
fresh cells, and expanded ALDHhi versus ALDHlo subsets was determined using an
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LSRII flow cytometer (BD Biosciences) at the London Regional Flow Cytometry
Facility. All analyses were performed using FlowJo software v8.2.

3.2.4 Hematopoietic colony formation
Day 9 expanded cells were harvested from untreated or DEAB-treated conditions and
reselected for high or low ALDH-activity before being seeded in semi-solid
methylcellulose media (H4434; Stem Cell Technologies) at 500 cells/mL in 12-well
plates, performed in duplicate (Figure 3.2C). Hematopoietic colonies were enumerated
after 12–14 days in vitro and scored based on morphological characteristics of burst
forming unit erythrocyte (BFU-E), colony forming unit granulocyte (CFU-G), colony
forming unit macrophage (CFU-M), colony forming unit granulocyte/macrophage (CFUGM), or colony forming unit mixed (CFU-Mixed)20. CFU/100 cells were calculated by
number of colonies formed per 100 cells seeded in the assay. Furthermore, the frequency
of lineage-specific colony formation was calculated by dividing the number of a lineagespecific colony (i.e., BFU-E) by the total number of colonies enumerated.

3.2.5 Transplantation of expanded ALDHlo and ALDHhi cells
Pancreatic β-cell ablation was induced in NOD/SCID mice aged 8- to 10-weeks ( Jackson
Laboratories, Bar Harbor, ME; www.jax.org) by intraperitoneal injection of STZ (35
mg/kg/ day) for 5 consecutive days11 (Figure 3.3A). All animal procedures were
approved by the Animal Care Committee at Western University Canada (AUP 2015033). On day 10, hyperglycemic (15–25 mM) mice were sublethally irradiated (300 cGy)
and transplanted in a blinded fashion by intrapancreatic injection of phosphate-buffered
saline (PBS), or 105 expanded (bulk) cells, 2.0 x 105 ALDHlo cells, or 2.0 x 105 ALDHhi
cells harvested from untreated or DEAB-treated conditions. Systemic blood glycemic
levels were monitored weekly in a blinded fashion for 42 days. Twenty-four hours before
sacrifice, mice were i.p.- injected with 200 µg 5-ethynyl-20-deoxyuridine (EdU;
Invitrogen) to label proliferating cells in situ. In addition, glucose tolerance tests were
performed over 120 min after i.p.-injection of 2 g/kg glucose bolus at day 41, as
previously described (Figure 3.4A)23.

115

3.2.6 Immunohistochemistry and immunofluorescent analyses
Pancreata were harvested, embedded in OCT, and cryosectioned (12 µm) to obtain three
sections per slide ± 200 µm apart. Cryosections were fixed in 10% formalin (Sigma) and
blocked with 5% serum before immunohistochemical staining for insulin to determine
islet number, size, and β-cell area as previously described23. Additionally,
immunofluorescent co-staining for insulin with EdU, CD31, Nkx6.1, and/or HLA-A,B,C
was performed. EdU+ proliferating cells were detected using the Click-iT imaging kit
(Alexafluor 488; Life Technologies). Intra-islet capillary density was enumerated posttransplantation using rat anti-mouse CD31 (1:100; BD Biosciences) detected with FITClabeled rabbit anti-rat secondary antibodies (1:200; Vector). Nxk6.1+ cell nuclei were
enumerated using anti-rabbit (1:2000; AbCam) and detected using goat anti-rabbit FITClabeled secondary antibodies (1:200; Vector). Human cell engraftment was enumerated
by staining pancreas sections with mouse anti-human HLA A,B,C (1:100; AbCam)
detected with horse anti-mouse FITC-labeled secondary antibodies (1:200; Vector).
DAPI was used as counterstain to label nuclei. Quantification and analyses were
performed using Fiji (Image J v2.0).

3.2.7 Quantification of islet number, size, and β-cell mass
Islet number was quantified across four random images per tissue section (12 images per
mouse) by enumerating the presence of insulin+ islet structures containing more than 20
nuclei. Islet size was determined by measuring the circumference of each islet identified
in the previous quantification using Fiji (Image J v2.0). Lastly, β-cell mass of each mouse
was calculated:
𝐼𝑠𝑙𝑒𝑡 𝐴𝑟𝑒𝑎 (𝐼𝑛𝑠𝑢𝑙𝑖𝑛 +)
𝑃𝑎𝑛𝑐𝑟𝑒𝑎𝑠 𝑊𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔) 𝑥 (
) = 𝛽 − 𝑐𝑒𝑙𝑙 𝑚𝑎𝑠𝑠
𝑁𝑜𝑛 − 𝑖𝑠𝑙𝑒𝑡 𝐴𝑟𝑒𝑎

3.2.8 Statistical analyses
Statistical analysis for flow cytometry and colony analyses was performed by one-way
ANOVA with Tukey’s multiple comparisons tests. Analysis of significance was
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performed by one-way ANOVA with Tukey’s multiple comparisons tests for all in vivo
experiments and enumeration of histological analyses. Outliers were identified using
Grubb’s test; P < 0.05.

3.3 Results
3.3.1

High ALDH-activity does not select for the megakaryocyte lineage
in fresh UCB cells

We have previously demonstrated that purified UCB Lin− ALDHhi cells represent a
heterogeneous progenitor cell population with multifaceted regenerative functions11,20.
However, the robust expansion of UCB Lin− ALDHhi cells (>70-fold) under serum-free
conditions containing SCF, Flt-3L, and TPO generated a megakaryocyte-enriched
population with diminished ALDH-activity and progenitor cell surface marker
expression22. To understand the propensity of UCB Lin− ALDHhi cells to differentiate
toward the megakaryocyte lineage, we sought to determine whether the initial selection
of primitive cells based on high ALDH-activity also enriched for committed precursors
within the megakaryocyte lineage. Therefore, we first compared fresh UCB Lin− MNC,
or FACS-purified ALDHhi and ALDHlo cells for megakaryoblast (CD41+/CD42−) and
megakaryocyte (CD41+/CD42+) cell surface marker expression (Figure 3.11A). The
frequency of cells with CD41+/CD42− megakaryoblast phenotype was equivalent
between freshly isolated UCB Lin− MNC (28.8% ± 6.12%), or purified ALDHhi
(26.9% ± 2.1%) versus ALDHlo cell subpopulations (29.1% ± 6.4%; Figure 3.1B).
Moreover, the frequency of committed CD41+/CD42+ megakaryocytes was also
equivalent within the fresh UCB Lin− cell subsets (Figure 3.1C). Thus, selection of UCB
Lin− cells based on high ALDH-activity did not enrich for cells of the megakaryocyte
lineage; although ∼60% of UCB ALDHhi cells expressed early megakaryocyte marker
CD41.

117

118

Figure 3.1 Expansion of UCB ALDHhi cells generated cells of the megakaryocyte
lineage in vitro. (A) Schematic for the initial FACS-purification of cells with low sidescatter (SSC-A) and high aldehyde dehydrogenase (ALDH) activity from lineagedepleted (Lin-) human umbilical cord blood (UCB) and subsequent expansion under
serum-free conditions with or without DEAB-treatment. The frequency of (B)
CD41+/CD42- megakaryoblasts, and (C) CD41+/CD42+ megakaryocytes was equivalent
within fresh UCB Lin- mononuclear cells, and purified ALDHhi or ALDHlo cell subsets.
Following expansion of UCB ALDHhi cells for 9 days with or without DEAB-treatment,
(D) expanded cells re-selected for high ALDH-activity were enriched for CD41+/CD42megakaryoblasts compared to the ALDHlo cell subset. Conversely, (E) expanded cells reselected for low ALDH-activity were enriched for CD41+/CD42+ megakaryocytes,
compared to the ALDHhi cell subset. Data represented as Mean ± SEM (*p<0.05, N=35). Statistical analyses were determined by one-way ANOVA with Tukey’s post-hoc test.
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3.3.2

The expanded ALDHhi cell subpopulation was enriched for a
megakaryoblast phenotype and the ALDHlo cell subpopulation was
enriched for a megakaryocyte phenotype

The ex vivo expansion of UCB Lin− ALDHhi cells under DEAB-treated culture
conditions robustly increased the total number of viable ALDHhi cells for preclinical
studies (>20-fold)22. Despite the retainment of ALDHhi cells under DEAB-treated
conditions, the frequency of CD41+/CD42+ megakaryocytes in the total cell population
was comparable to untreated conditions. It is currently unreported whether ALDHhi cells
reselected from DEAB-treated conditions are enriched for specific subpopulations of the
megakaryocyte lineage, compared to untreated conditions. Following ex vivo expansion
of UCB Lin− ALDHhi cells under untreated or DEAB-supplemented conditions, cell
progeny that retained high ALDH-activity was enriched (*p< 0.05) for early
megakaryoblast (CD41+/CD42−) phenotype, compared to the ALDHlo cell subpopulation
(Figure 3.1D) from either condition. Conversely, the ALDHlo cell subpopulation
generated under untreated and DEAB-treated conditions was significantly enriched
(**P < 0.01) for a committed CD41+/CD42+ megakaryocyte phenotype, compared to the
ALDHhi cell subpopulation (Figure 3.1E). Collectively, DEAB-treated conditions
generated CD41+/CD42− megakaryoblasts that retained ALDHhi progenitor cell
characteristics and reduced the commitment of UCB Lin− ALDHhi cells toward an
ALDHlo CD41+/CD42+ megakaryocyte phenotype.

3.3.3

Reselection of ALDHhi cells enriched for primitive phenotypes and
increased multipotent hematopoietic colony formation in vitro

Multipotent HPC with colony formation function in vitro and SCID-repopulating
capacity in vivo can be enriched from fresh UCB samples by the selection of
CD34+/CD38− or ALDHhi cells28,29. To determine whether multipotent HPC remained
after 9-days culture, we assessed expanded UCB Lin− ALDHhi cells for a primitive
progenitor cell phenotype and for clonal colony formation in vitro. Following ex vivo
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expansion of UCB Lin− ALDHhi cells under untreated or DEAB-supplemented
conditions, reselected ALDHhi cells were significantly enriched (**p < 0.01) for primitive
CD34+/CD38- cell surface marker expression (20.8% ± 7.3% or 15.1% ± 3.9%),
compared to the ALDHlo cell subpopulation (1.7% ± 0.7% or 1.7% ± 0.5%; Figure 2A).
The frequency of CD34+/CD38- cells in the ALDHhi subset was comparable between
culture conditions (Figure 2A). Regardless, we have previously reported that the
enrichment of ALDHhi cells under DEAB-treated conditions induced a more than twofold
increase in the number of ALDHhi/CD34+/CD38- cells, compared to untreated
conditions22. Importantly, DEAB-treated conditions induced a significant decrease in
frequency of ALDHhi or ALDHlo cells with CD38+ expression (Figure 3.2B), a marker of
hematopoietic maturation27. To determine hematopoietic colony forming capacity in
vitro, ALDHhi and ALDHlo cells were reselected after expansion under untreated and
DEAB-treated conditions and seeded in methylcellulose media. Hematopoietic colony
formation was manually enumerated after 14 days (Figure 3.2C). Notably, ALDHhi cells
from either untreated or DEAB-treated conditions were significantly enriched for colony
forming cells compared to ALDHlo cells (Figure 3.2D). ALDHhi cells from DEAB-treated
cultures also demonstrated a higher frequency (*p < 0.05) of colony formation (1 CFU in
10.5 cells, *p < 0.05) compared to ALDHhi cells expanded under untreated conditions (1
CFU in 30.0 cells). The frequency of myeloid colonies formed was found to be similar to
cells expanded under untreated or DEAB-treated conditions (Figure 2E). Within the
ALDHhi or ALDHlo subsets only ALDHhi cells demonstrated myeloid multipotency by
the formation of CFU-mixed colonies, whereas ALDHlo cells largely contained
progenitors restricted to the macrophage (CFU-M) or granulocyte (CFU-G) lineages
(Figure 2E). Collectively, these results demonstrate DEAB-treated conditions reduced the
acquisition of mature marker CD38 and augmented the expansion of ALDHhi cells that
retained multipotent hematopoietic colony forming capacity in vitro.
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Figure 3.2 Re-selection of expanded cells with high ALDH-activity enriched for cells
retaining primitive (CD34+/CD38-) phenotype and multipotent colony forming
capacity in vitro. (A) Following expansion for 9 days with or without DEAB-treatment,
primitive (CD34+/CD38-) cell phenotype was enriched within the expanded ALDHhi cell
subset compared to the ALDHlo cell subset. (B) CD38 expression was significantly
decreased following DEAB-treatment. Specifically, CD34-/CD38+ cell frequency was
reduced in both the ALDHhi and ALDHlo cell subpopulation of cells harvested from
DEAB-treated conditions. (C) Following expansion for 9 days with or without DEABtreatment, expanded cells re-purified for low or high ALDH-activity were seeded in
methylcellulose media and colony formation was enumerated after 14 days. (D) Total
hematopoietic colony formation was increased within expanded cells re-selected for high
ALDH-activity and was also increased for re-selected ALDHhi cells generated under
DEAB-treated conditions compared to re-selected ALDHhi cells generated untreated
conditions. (E) Only ALDHhi cells from either Untreated or DEAB-treated conditions
demonstrated full myeloid-specific multipotency, compared to re-selected ALDHlo cells
that did not form mixed colonies. Data represented as Mean ± SEM (*p<0.05, **p<0.01,
***p<0.001; N=3-5). Statistical analyses were determined by one-way ANOVA with
Tukey’s post-hoc test.

122

3.3.4

Intrapancreatic transplantation of ALDHlo cells from DEABtreated conditions reduced hyperglycemia in STZ-treated
NOD/SCID mice

We have shown that ex vivo expansion of UCB Lin− ALDHhi cells rapidly diminishes
islet regenerative function as culture time was increased13. Therefore, we sought to utilize
previously reported culture conditions that increase the number (two-fold) of ALDHhi
cells following 9-day expansion, compared to untreated conditions22. On day 10, STZtreated, hyperglycemic (>15 mM) NOD/SCID mice received intrapancreatic
transplantation (Figure 3.3A) of PBS or 5.0 × 105 bulk cells harvested from either
untreated or DEAB-treated conditions. Similar to PBS-injected controls, mice
transplanted with untreated bulk cells remained hyperglycemic up to 42 days (Figure
3.3B, C). Compared to PBS-injected controls, transplantation of DEAB-treated bulk cells
reduced hyperglycemia on day 17 (*p < 0.05); however, a sustained reduction of
hyperglycemia was not observed at later time points out to day 42 (*p = 0.17; Figure
3.3B, C). In a recent publication, we also demonstrated that sustained reduction in
hyperglycemia was only achieved when 6-day expanded cells were reselected for high
ALDH-activity before intravenous transplantation23. Therefore, we reselected our
expanded cell populations for high versus low ALDH-activity before direct
intrapancreatic transplantation. Hyperglycemic mice received an intrapancreatic
transplantation of 2.0 × 105 ALDHhi or ALDHlo cells harvested from either untreated or
DEAB-treated conditions. ALDHhi cells harvested from either untreated or DEAB-treated
conditions at 9 days were unable to reduce hyperglycemia, compared to PBS-injected
controls (Figure 3D, E). Interestingly, the ALDHlo cell subset from DEAB-treated
conditions significantly reduced hyperglycemia at days 14, 17, and 28 (*p < 0.05; Figure
3.3D). More importantly, hyperglycemia was significantly reduced by measurement of
area under the curve (*p < 0.05; Figure 3.3E), compared to PBS-injected controls. After
performing glucose tolerance tests 24-h before euthanasia, mice transplanted with bulk,
ALDHhi, or ALDHlo cells from either untreated or DEAB-treated conditions did not
demonstrate an improved physiological response to i.p. injection of a glucose bolus
(Figure 3.4). Thus, DEAB-treated conditions generated ALDHlo cells that modestly
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reduced resting glycemia levels in STZ-treated NOD/SCID mice following
intrapancreatic transplantation. However, the reduction in hyperglycemia was modest,
transient, and mice were unable to respond to glucose bolus in a physiological manner at
a later time point.
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Figure 3.3 Intrapancreatic transplantation of re-selected ALDHlo cells from DEABtreated conditions reduced hyperglycemia in STZ-treated NOD/SCID mice. (A)
Hyperglycemia was induced in NOD/SCID mice by serial injections of STZ
(35mg/kg/day) between days 0-4. Hyperglycemic mice (>15.0 mmol/L at day 10) were
sublethally irradiated (300 cGy) on Day 10 and received intrapancreatic transplantation
of 5.0x105 bulk cells, 2.0x105 ALDHhi cells or 2.0x105 ALDHlo cells harvested after 9
days expansion using either Untreated or DEAB-treated conditions. To serve as a vehicle
control (PBS), mice received an intrapancreatic injection of phosphate buffered saline at
an equivalent volume (20µl). (B) Resting blood glucose levels of mice transplanted with
vehicle control (PBS), or bulk cells expanded under untreated or DEAB-treated
conditions. (C) Mice transplanted with untreated (n=10) or DEAB-treated (n=11)
expanded cells did not show reduced glycemia area under the curve (AUC), compared to
PBS-injected (n=8) controls. (D) Mice transplanted with ALDHlo cells from DEABtreated conditions (n=7) showed reduced resting blood glucose levels (Day 14, 17 and 28)
compared to PBS-injected controls (n=10). (E) Mice transplanted with ALDHlo cells
from DEAB-treated conditions (n=7) showed reduced glycemia area under the curve
(AUC), compared to PBS-injected (n=8) controls. Data represented as Mean ± SEM
(*p<0.05, n=6-11 mice per group). Statistical analyses were determined by one-way
ANOVA with Tukey’s post-hoc test compared to PBS control.
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Figure 3.4 Mice transplanted with expanded cells do not respond to intraperitoneal
injection of glucose. (A) On Day 41, transplanted mice were fasted (4h) and received
intraperitoneal injection of 2.0mg/kg dextrose followed by serial serum glucose
measurements up to 120 min. (B, C) Mice transplanted with expanded cells from
untreated or DEAB-treated conditions did not demonstrate a physiological response to
glucose bolus. (D, E) Similarily, mice transplanted with expanded cells from untreated or
DEAB-treated conditions reselected for low or high ALDH-activity did not demonstrate a
physiological response to glucose bolus. Data represented as mean + SEM (n= 3-8).
Statistical analyses were determined by one-way ANOVA with post-hoc Tukey’s t-test.
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3.3.5

Intrapancreatic transplantation of expanded ALDHlo cells from
DEAB-treated conditions increased islet number

To investigate the mechanisms by which expanded ALDHlo cells generated from DEABtreated conditions modestly reduced hyperglycemia in NOD/SCID mice, pancreas
sections were analyzed for islet size, number, and total β-cell mass (Figure 3.5A–D).
Histological analysis revealed a significant increase in the number of insulin+ islets in
mice receiving intrapancreatic transplantation of DEAB-treated ALDHlo cells, compared
to PBS-injected mice (*p < 0.05; Figure 3.5B). In contrast, islet circumference remained
comparable between all transplantation conditions (Figure 3.5C). Ultimately, mice
transplanted with DEAB-treated ALDHlo cells demonstrated an increased trend in total β
cell mass, compared to PBS-injected controls (p = 0.14; Figure 3.5D). Thus, expanded
DEAB-treated ALDHlo cells did not robustly increase β cell mass and transplanted mice
demonstrated a failed physiological response to a glucose challenge, despite modestly
improved resting glycemic levels
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Figure 3.4 Mice transplanted with ALDHlo cells from DEAB-treated conditions
showed modestly increased islet number and beta-cell mass. (A) Representative
photomicrographs of islets stained for insulin (brown) at day 42 in STZ-treated
NOD/SCID mice transplanted with vehicle control or ALDHlo cells harvested from
Untreated or DEAB-treated conditions. Compared to vehicle control, mice transplanted
with DEAB-treated ALDHlo cells demonstrated (B) increased islet number without (C)
measurable changes in islet size. (D) Mice transplanted with ALDHlo cells from DEABtreated conditions did not show significantly (p=0.14) increased β-cell mass, compared
to mice injected with vehicle control. Data represented as Mean ± SEM (n=6-10).
Statistical analyses were determined by one-way ANOVA with Tukey’s post-hoc test
compared to PBS control. Scale bar = 100µm.
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3.3.6

Expanded ALDHlo cells increased intra-islet cell proliferation but
did not increase intra-islet vascularity or Nxk6.1+ expression

To better understand regenerative processes induced by intrapancreatic ALDHlo cell
xenotransplantation, we assessed intra-islet cell proliferation in mice pulsed with EdU for
24 h before sacrifice at day 42. Pancreata transplanted with ALDHlo cells harvested from
DEAB-treated conditions demonstrated an increase in the number of proliferating (EdU+)
cells within islets at day 42 (Figure 3.6A). Although increased proliferation was
observed, intra-islet vascular density (CD31+ cells/Islet Area; Figure 3.6B) and β cell
identity marker expression (Nkx6.1; Figure 3.6C) were equivalent to PBS-injected mice.
Thus, indicating proliferating cells were likely not of an endothelial or β cell phenotype.
HLA-A,B,C+ human cells were not detected in the pancreas of transplanted mice at day
42, despite detectable engraftment at day 14 (Figure 3.7). Collectively, ALDHlo cells
from DEAB-treated conditions transiently engrafted the murine pancreas and modestly
increased islet cell proliferation without significantly increasing islet-vascularity or
functional β cell mass.
.
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Figure 3.5

Intrapancreatic transplantation of ALDHlo cells from DEAB-treated

conditions increased intra-islet cell proliferation. (A) Representative photomicrograph of
EdU+ cells within insulin-expressing islets at day 42 in an STZ-treated mouse transplanted
with DEAB-treated ALDHlo cells. Compared to PBS-injected control mice (n=9), mice
transplanted with DEAB-treated ALDHlo cells (n=7) showed an increased number of
proliferating cells (EdU+) within islets. (B) Representative photomicrograph of murine
CD31+ cells within insulin-expressing islets at Day 42 in an STZ-treated mouse transplanted
with DEAB-treated ALDHlo cells. Intra-islet vascularization (CD31+) was equivalent for all
transplanted groups. (C) Representative photomicrograph of murine Nkx6.1+ nuclei with
insulin-expressing islets at day 42 in a STZ-treated mouse transplanted with DEAB-treated
ALDHlo cells. Intra-islet Nkx6.1+ cells per islet area was equivalent for all transplanted
groups. Data represented as Mean ± SEM (*p<0.05; n=6-10). Statistical analyses were
determined by one-way ANOVA with post-hoc Tukey’s post-hoc test compared to PBS
control. Scale bar = 100µm.
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A

Figure 3.6 Mice transplanted with expanded cells re-selected for low ALDH-activity
showed human cell engraftment at 4-days post-transplantation. (A) Representative
photomicrographs of human cell engraftment in the pancreas of mice transplanted with
expanded cells re-selected for low ALDH-activity at 4 days post-transplantation. HLA-A,
B, C-expressing cells were detected in mice transplanted with ALDHlo cells generated
under untreated (n=2) and DEAB-treated conditions (n=2). Scale bar = 100µm.
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3.4 Discussion
Restoration of β cell mass for the treatment of diabetes has recently become an intense
focus of translational research, yet many of the mechanisms facilitating the regeneration
of endogenous β cell mass remain elusive. For example, identifying hematopoietic cell
subtypes that stimulate islet regenerative mechanisms has largely been unexplored. We
have demonstrated selection of UCB Lin− ALDHhi cells enriched for a HPC population
capable of reducing hyperglycemia in STZ-injected NOD/SCID mice11. Unfortunately,
UCB ALDHhi cells are rare and expansion will be required to collect enough cells to
potentially treat human subjects. Our recent work and this study demonstrate the
challenge in expanding these cells with concurrent retention of islet regenerative
capacity13. The selection of UCB Lin− ALDHhi cells biases HPC differentiation by active
RA-induced differentiation under serum-free conditions that promoted the acquisition of
a megakaryocyte phenotype (CD41+/CD42+) and loss of regenerative function (Figure 6).
On the other hand, we have recently reported that DEAB-induced inhibition of RAproduction enhanced the expansion of HPC that retained vascular regenerative paracrine
functions in vivo22. With these properties in mind, we initially hypothesized that
reversible inhibition of ALDH-activity could enhance the expansion of UCB-derived
hematopoietic progeny with islet regenerative function by preventing differentiation from
an ALDHhi cell phenotype. Herein, we show the robust islet regenerative function of
UCB Lin− ALDHhi cells is lost during ex vivo culture; however, beneficial functions
were partially retained by inhibiting RA-induced differentiation and paradoxically
reselecting for CD41+ enriched ALDHlo cells.
The islet regenerative function of uncultured UCB Lin− ALDHhi cells was rapidly lost
under clinically applicable, hematopoietic selective serum-free culture conditions. With
this in mind, we first sought to determine whether the megakaryocyte content of
uncultured UCB Lin− ALDHhi cells could provide help elucidate the phenotype of an
islet regenerative cell population, as expanded cells are largely committed to the
megakaryocyte lineage. CD41+/CD42+ cell content was equivalent between uncultured
UCB Lin− cells, or Lin− ALDHhi or Lin− ALDHlo cell subsets. These results provided
indirect evidence that CD41+/CD42+ megakaryocyte content likely played a minimal role
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in the islet regenerative function of transplanted uncultured UCB Lin− ALDHhi cells and
the enrichment of a megakaryocyte phenotype is a result of subsequent culture
conditions. Interestingly, Gentry et al. previously reported that the selection of ALDHhi
cells enriched for megakaryocyte progenitors by >2000-fold, compared to the ALDHlo
subpopulation30. We attributed our conflicting results observed in this study to our use of
a lineage-depletion cocktail, which does not deplete cells of the megakaryocyte lineage
from UCB MNC. Furthermore, megakaryoblast and megakaryocyte phenotype in UCB
cells was assessed by flow cytometry in our study, as opposed to the use of a clonogenic
assay that would assess the megakaryocyte potential of selected subpopulations.
Nonetheless, our results corroborate the findings by Gentry et al., such that UCB ALDHhi
cells robustly generated cells of the megakaryocyte lineage in vitro.

Megakaryocytes are large cells (>50 𝜇m) that primarily reside within the bone marrow31
or lungs32 and are derived from a common megakaryocyte/erythroid myeloid progenitor
cell33. Considering our culture conditions are supplemented with TPO, a known driver of
megakaryopoiesis and paradoxically required for effective progenitor cell expansion, it is
likely that the expansion of CD41+/CD42+ cells from ALDHhi cells can be attributed to
active TPO-signaling. Future research would need to determine the role exogenous TPO
and/or extracellular matrix molecules have on UCB ALDHhi cell differentiation toward a
CD41+/CD42+ phenotype, an area that has been extensively studied with other HPC
subpopulations34-36. Moreover, TPO produced by cells of the megakaryocyte lineage
could signal in an autocrine fashion to stimulate the expression of CD41 and CD4236.
Considering that >60% of freshly isolated UCB Lin− ALDHhi cells express CD41, we
propose that UCB Lin− ALDHhi cells are primed to respond to drivers of differentiation,
including the RA- and TPO-signaling pathways. Collectively, the expansion of ALDHhi
cells and modulation of megakaryopoiesis in vitro is complex and future studies would
need to consider several parameters including (1) progenitor cell purification, (2) culture
conditions, and (3) culture duration.
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For nearly 2 decades, high ALDH-activity has served as an enzymatic marker to identify
and enrich for hematopoietic progenitor subtypes in fetal and adult tissue37-39. Our recent
publication demonstrated DEAB supplementation and subsequent inhibition of RAproduction enriched for ALDHhi cells progeny (>2-fold) during UCB HPC expansion24,
leading to a >20-fold increase in viable ALDHhi cell number. Supporting our previous
studies, we report that CD34+/CD38− cell surface expression was enriched within the
ALDHhi cell subset following expansion23; moreover, reselected ALDHhi cells
demonstrated enhanced multipotent hematopoietic colony formation, compared to
ALDHlo cells23. Importantly, ALDHhi cells reselected from DEAB-treated conditions
showed enhanced hematopoietic colony formation, compared to untreated conditions.
Considering CD34+/CD38− enrichment within the ALDHhi subset was comparable
between untreated and DEAB-treated conditions, our results support previous reports that
high ALDH-activity further enriches for multipotent HPC from the CD34+/CD38−
subpopulation29. These results indicate that the loss of high ALDH-activity coincides
with the loss of multipotent progenitor capacity and hematopoietic colony formation can
be retained by temporarily inhibiting RA-production in vitro. The loss of ALDH-activity
has been associated with HPC differentiation and here we add that the ALDHlo cell
subsets were enriched for a CD41+/CD42+ megakaryocyte phenotype (>50%) following
ex vivo expansion. On the other hand, ALDHhi cells were enriched for CD41+/CD42−
megakaryoblasts compared to ALDHlo cells. Therefore, we propose a model where high
ALDH-activity is gradually diminished during culture as uncommitted multipotent
myeloid progenitors lose a primitive CD34+/CD38− phenotype and transition toward a
CD41+/CD42− megakaryoblast phenotype, before commitment toward a CD41+/CD42+
megakaryocyte phenotype and acquisition of CD38 expression (Figure 6).

In the current study, we observed a modest improvement of glycemia levels in STZtreated NOD/SCID mice receiving intrapancreatic transplantation of expanded cells
harvested from DEAB-treated conditions. However, our histological analysis revealed
minimal regeneration of β cell mass had occurred following direct transplantation of bulk
expanded cells. These results lead us to predict the reselection of cells based on high
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versus low ALDH-activity would be required to purify regenerative cells with enhanced
engraftment and/or migration. Intrapancreatic transplantation of expanded cells reselected
for high versus low-activity surprisingly revealed that only ALDHlo cells harvested from
DEAB-treated conditions (DEAB ALDHlo) reduced hyperglycemia. The capacity of
ALDHlo cells harvested from DEAB-treated conditions to reduce hyperglycemia and
improve islet function after intrapancreatic transplantation was highly variable, with 3 of
7 mice showing notable recovery. Although we observed increased islet number within
the pancreas of mice transplanted with DEAB ALDHlo cells, the size of murine islets and
total β cell mass were comparable between all conditions. Our previous reports
demonstrated that transplanted fresh UCB ALDHhi cells transiently engrafted the
pancreas yet demonstrated sustained regeneration of β cell mass12. Similarly, we detected
engraftment of transplanted expanded cell progeny at day 14 but not day 42; suggesting
that expanded ALDHlo cell engraftment is also transient while islet regenerative function
is modest. Nonetheless, DEAB-treated ALDHlo cells modestly reduced hyperglycemia,
by increasing islet number through unidentified mechanisms. The results of this study
contrast our previous HPC transplantation studies that reported increased β cell mass as a
result of increased islet size not islet number23. We observed an increased rate of
proliferating cells within murine islets at day 42 following direct transplantation of
DEAB ALDHlo cells, however, it was concluded that EdU+ cells were not of an
endothelial (CD31) or β cell (Nkx6.1) phenotype. Collectively, we provided preliminary
evidence that transplanted DEAB ALDHlo cells temporarily engraft the pancreas to
support β cell function via unidentified and likely multifactorial mechanisms.

Highly vascularized networks within islets of Langerhans facilitate the release and
transport of blood glucose regulating hormones, including insulin and glucagon, through
systemic circulation40. Seneviratne et al. demonstrated increased intra-islet vascularity
islet size and β cell mass after intravenous transplantation of 6-day expanded ALDHhi
HPC23. Considering DEAB-treated cells robustly stimulate angiogenesis in the ischemic
hindlimb, we investigated whether islet vascularity was increased following
intrapancreatic transplantation; in return increasing the efficiency of systemic insulin
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delivery. Immunofluorescent analysis revealed intra-islet vascularity was equivalent
between all transplantation conditions. This was anticipated, considering islet size was
not increased following DEAB-treated ALDHlo cell transplantation. These collective
results suggest that intra-islet vascularity may increase only when robust recovery β cell
mass occurs. Previous studies have demonstrated a “symbiotic” relationship between
endothelial cells and pancreatic β-cells41,42. Specifically, the proliferation and survival of
β-cells was dependent on paracrine signaling from the neighboring vascular network. In
this study, DEAB ALDHlo cell transplantation increased islet number and not size.
Therefore, we suggest the modest reduction of hyperglycemia was likely a result of
increasing the number of endogenous islets capable of releasing insulin into systemic
circulation. We propose that DEAB ALDHlo cells likely provided unidentified supportive
stimuli to surviving islets following STZ-induced β-cell ablation. Nonetheless,
identification of these stimuli will require future proteomic studies using cell populations
with more robust and consistent islet regenerative function in vivo.

In summary, we provide preliminary evidence that expanding ALDHhi cells while
retaining islet regenerative function is complex and the loss of islet regenerative function
is likely multifactorial. Specifically, we have identified several important findings that
may benefit future research aiming to expand HPC ex vivo for therapeutic applications.
These include results such as the following: (1) FACS purification of UCB Lin− MNC
based on ALDH-activity does not enrich for megakaryocytes, (2) inhibition of RAproduction generates multipotent ALDHhi cells in vitro, and (3) retainment of a primitive
ALDHhi phenotype does not coincide with islet regenerative function following
intrapancreatic transplantation. Collectively, these results indicate that cellular therapies
using expanded HPC to accelerate endogenous islet regeneration require further studies
to prevent the loss of islet proliferative and vascularizing function.
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Figure 3.7 UCB Lin- ALDHhi cells acquire megakaryocyte phenotype during
expansion that coincide with reduced islet regenerative function. UCB ALDHhi
cells efficiently expand under serum-free conditions; however, UCB ALDHhi cells will
rapidly lose an ALDHhi phenotype and acquire a committed megakaryocyte phenotype.
The differentiation of UCB ALDHhi cells coincides with the loss of islet regenerative
function.
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Chapter 4

4

The Proteome of Human Pancreas-derived Multipotent
Stromal Cells Restricts Adipogenesis, Drives Cell Division
and Defines a Unique Surface Marker Profile

4.1 Introduction
Since initial clinical use for cellular therapy in 1995, human multipotent stromal
cells (MSC) has been used in over 400 clinical trials reported by the US National
Institutes of Health (http://www.clinicaltrial.gov/), a reflection of the diverse therapeutic
potential of MSC 1. Specifically, MSC have demonstrated beneficial therapeutic
characteristics including proangiogenic, immunomodulatory, and tissue-regenerative
functions after transplantation in an diverse array of pre-clinical studies and clinical
applications. Unfortunately, MSC possess phenotypic and functional characteristics
modified by selective culture conditions in vitro. The absence of a unique molecular
fingerprint has led to establishment of heterogenous MSC populations as a result of
different tissue sources, isolation protocols, and culture techniques 2-4.
In a collective effort to unify the field, the International Society of Cellular
Therapies (ISCT) established a set of minimal criteria that MSC must demonstrate: 1)
growth after plastic adherence, 2) a surface marker profile during culture that
distinguishes MSC from related mesodermal cell lineages (i.e. hematopoietic and
endothelial), and (3) mesodermal multipotency into bone, cartilage and adipose tissue in
vitro 5. Specifically, MSC must express stromal cell markers CD90 (Thy-1), CD73 (Ecto5'-nucleotidase), and CD105 (Endoglin) during culture; and lack the expression of CD45,
CD31, CD14, HLA-DR, CD19, CD79a and CD34. However, several studies have
reported conflicting heterogeneity regarding proposed surface markers expression 6.
Cultured MSC are dynamically heterogenous and can be segregated into distinct
subsets based on surface marker expression 7,8, enzymatic activity 9 and/or multipotency
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in vitro 10. The use of various adult and fetal sources has amplified the complexity of a
standardized MSC-identity generating tissue-specific MSC populations with unique
phenotypic, molecular, and functional characteristics in vitro. For example, MSC isolated
from bone-marrow (BM) express higher levels of CD146 and alkaline phosphatase
compared to placental-derived MSC; which reflected inherent transcriptional and
epigenetic differences resulting in enhanced osteogenic potential of BM-MSC in vitro 10.
Intracellular markers such as vimentin have been utilized to identify MSC populations in
vitro and in vivo 11, however comparative levels of vimentin and surface marker
expression between MSC and progeny prevent culture-independent isolation of pure
MSC populations. Considering MSC are the precursors to ECM-modeling fibroblasts and
vessel stabilizing pericytes in vivo, a hierarchy of MSC identity an function, akin to the
hematopoietic system, likely exists in vitro.
Bone marrow-derived MSC (BM-MSC) is arguably the most widely utilized MSC
populations in vitro and in vivo, however a limited number of in-depth proteomic and
functional comparisons between MSC populations from distinct tissue
microenvironments have been reported. This has limited our understanding of molecular
and functional diversity across MSC derived from various tissue sources. Therefore,
insightful experimentation, such as global proteomic characterization, are warranted to
obtain a foundation of knowledge to support the identification of MSC with robust
scalability, reduced heterogeneity, and biotherapeutic potential. Herein, we consider BMMSC the “gold-standard” of therapeutic MSC populations and utilize the phenotypic and
molecular fingerprint of BM-MSC to characterize a previously understudied human
pancreas-derived MSC population 12-14. To our knowledge, this is the first in-depth
proteomic characterization of human (Pancreas-derived) Panc-MSC combined with
multiparametric flow cytometry and functional testing in comparison to BM-MSC.
Specifically, we revealed unique phenotypic, molecular, and functional characteristics of
Panc-MSC, such as accelerated growth kinetics and restricted adipogenic potential.
Overall, this study provides novel insights into MSC population that has been previously
understudied for applications of stem cell biology and regenerative medicine.
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4.2
4.2.1

Methods
MSC Culture, Expansion and Growth Dynamics

BM-MSC Establishment:
Human BM aspirates were obtained from healthy donors with informed consent from the
London Health Sciences Centre (London, ON). BM-MSC were established as previously
described 9.

Panc-MSC Establishment:
Ricordi-chamber isolated human islets were obtained through the Integrated Islet
Distribution Program (IIDP, USA). 200 islet equivalents were plated in RPMI 1640 +
10% FBS for up to 7 days. Between days 5-7, adherent fibroblast-like cells were
separated from non-adherent islets by media aspiration followed by trypzination and
filtration using a 40𝜇m cell strainer. Single cell suspensions were subsequently reseeded
on tissue culture plastic at 4,000 cells/cm2 and expanded in Amniomax-C100TM with
AmniomaxTM E100 Supplement (Life Technologies).

MSC Culture and Growth Dynamics:
Panc-MSC and BM-MSC were utilized for experimentation between passage 2-4. In
order to investigate the growth dynamics of Panc-MSC and BM-MSC, manual
hemocytometer counts were performed every 24 hours over a 96-hour period.
Microenvironmental Stiffness:
To determine how microenvironmental stiffness (kPa) affects the phenotype or
adipogenic potential of MSC, 24-well silicone-based soft substrate plates coated with
fibronectin were used to culture MSC under growth or adipogenic conditions (see below).
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Specifically, MSC were seeded on substrates at 2, 10, 30, 100 kPA stiffness (ExCellness,
Switzerland).

4.2.2

Flow Cytometry

Panc-MSC and BM-MSC were stained with anti-human antibodies for MSC markers
(CD73, CD105, CD90; BD Biosciences), hematopoietic markers (CD34, CD14, CD45,
CD133; BD Biosciences), endothelial marker CD31 (BD Biosciences), and the pericyte
marker CD146 (BD Biosciences). MSC were also co-stained with AldeflourTM (Stem
Cell Technologies) reagent to determine ALDH-activity and cell viability was assessed
by co-staining with 7-amino-actinomycin D (7AAD; 5μl; BD Biosciences). Additionally,
MSC were stained using antibodies for α-SMA, vimentin, adiponectin, STRO-1, and
HLA-DR (BD Biosciences). Adiponectin and α-SMA (AbCam) were detected using antimouse or anti-rabbit Cy5 secondary antibody (BD Biosciences), respectively. Neural
lineage markers TUBB3, MBP, and GFAP (AbCam) were also measured on cultured
MSC and detected using an anti-mouse FITC secondary antibody (Vector). Data was
acquired using a LSRII flow cytometer at the London Regional Flow Cytometry Facility.
All data was analyzed using FloJo software (v8.2).

4.2.3

Immunohistochemistry and Immunofluorescent Analyses

MSC were cultured on glass coverslips until 60% confluency was achieved. MSC were
washed twice with PBS prior to fixation with 10% formalin and permeabilization with
0.1% Triton X-100. Coverslips were stained with hematoxylin and eosin, rinsed with
deionized water and embedded in an aqueous mounting media. Additional coverslips
were co-stained with PE-conjugated anti-human CD146 (BD Biosciences) and primary
rabbit anti-human ALDH1A1 (1:500, AbCam) detected by a goat anti-rabbit FITC
secondary antibody (1:200, Vector). Additional coverslips were co-stained with APCconjugated anti-human STRO-1, PE-conjugated anti-human vimentin (BD-Biosciences)
and BV421-conjugated anti-human HLA-DR antibodies. Immunofluorescent images
were counterstained with DAPI (1:1000) or DRAQ5. Colorimetric images were acquired
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at 40x using an Olympus (BX50) and confocal images were acquired under oilimmersion at 40x and 63x using a Leica TCS SP8.

4.2.4

Determination of Mesodermal Multipotency

Adipogenesis Differentiation Assay:
MSC were seeded at a density of 1 x 104 cells/cm2 in supplemented Amniomax C100 for
24 hours. Media was replaced with Complete Adipogenesis Differentiation Medium with
Adipogenesis Supplement (Life Technologies). Complete media changes occurred every
3 days. After 10 days, MSC were stained for lipid accumulation using Oil Red O
(Sigma).

Osteogenesis Differentiation Assay:
MSC were seeded at a density of 5 x 103 cells/cm2 in Amniomax C100 + supplement for
24 hours. Media was replaced with Complete Osteogenesis Differentiation Medium with
Osteogenesis Supplement (Life Technologies). Media was changed every 3 days. After
21 days, MSC were stained for calcium deposits using Alzarian Red (VWR).

Chondrogenesis Differentiation Assay Protocol:
MSC were seeded as 5𝜇l micro-masses at a density of 2 x 104 cells/𝜇l in Amniomax
C100 + supplement for 2 hours. Media was replaced with Complete Chondrogenesis
Differentiation Medium with Chondrogenesis Supplement (Life Technologies). Media
was changed every 3 days. After 21 days, chondrocyte pellets were embedded and OCT
and cryosectioned prior to staining glycosaminoglycans using Alcian Blue (Sigma).
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4.2.5

Label-free Mass Spectrometry

Lysate protein was subjected to 1D SDS-PAGE fractionation using 12% gels. All MS
data was collected using a Q Exactive Plus Orbitrap (ThermoFisher Scientific, Waltham,
MA, USA), as previously described15. Full MS parameters are outlined in the
Supplementary Table 1. Data analysis was performed using PeaksStudio 7.5 and
MaxQuant 1.5.2.8.

4.2.6

RT-qPCR Analysis

RNA was collected using RNAeasy purification kit (Qiagen) and quantified using the
Nanodrop ND-100 Spectrophotometer at the London Regional Genomics Center at
Robarts Research Institute. RNA was converted to 1µg of cDNA per sample using the
iScriptTM cDNA Synthesis Kit (Bio-Rad, London, Canada) on the Eppendorf Master
Cycler (Thermo Fisher). cDNA was stored at -80⁰C. RT-qPCR was performed using the
SSofast kit (Bio-rad) along with primers ALDH1A1 (Cat#HQP005075), ALDH1A3
(Cat#HQP005252), MCAM (Cat#HQP011099) and housekeeping gene, GUSB
(Cat#HQP008583) from GeneCopoeia. Information regarding, PPARG, CEBPA, LPL
primers used for adipogenesis studies are listed in Table 4. 1. The relative quantification
of mRNA was acquired using the CFX96 Real-Time PCR Detection System.
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Table 4.1 Primer for Adipogenesis RT-qPCR Analyses

Full Name/ Gene Name

Primer Sequences

Peroxisome Proliferator-activated

FWD: TTCAGAAATGCCTTGCAGTG

Receptor Gamma/PPARG

REV: CCAACAGCTTCTCCTTCTCG

CCAAT/enhancer-binding Protein

FWD: CAGAGGGACCGGAGTTATGA

Alpha/CEBPA

REV: TTCACATTGCACAAGGCACT
FWD: GTCCGTGGCTACCTGTCATT

Lipoprotein Lipase/LPL
REV:TGGCACCCAACTCTCATACA

4.2.7

Statistical Analyses

The majority of statistical analyses were performed by unpaired student’s t-test between
BM- and Panc-MSC. Phenotypic analyses during culture on soft substrates were analyzed
using repeated measures one-way ANOVA with post-hoc Tukey’s t-test. Outliers were
identified using Grubb’s test; p<0.05.
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4.3 Results
4.3.1

Panc-MSC robustly expand ex vivo and express a classical MSClike phenotype.

We have recently reported that the secretome of human BM-MSC stimulated human βcell proliferation in vitro 15. During these studies we observed emergence of fibroblastlike cells that formed colonies adherent to plastic from islets cultured with media
supplemented with FBS or MSC-generated CM. Fibroblast-like cells were subcultured
into supplemented AmnioMax C-100 media and compared to BM-MSC for phenotypic,
functional, and molecular characteristics. Herein, we refer to this cell population as
pancreatic-MSC (Panc-MSC).
After colony establishment, Panc-MSC were adherent to tissue culture plastic
(TCP) and demonstrated spindle-like morphology (Supplemental Figure 1A), albeit the
size (forward-scatter area) of Panc-MSC was smaller than BM-MSC (Supplemental
Figure 1B). Panc-MSC underwent robust expansion across several passages under typical
BM-MSC growth conditions in AmnioMax C-100. Notably, when each MSC subtype
were seeded at an equal density between passages 2-4, Panc-MSC demonstrated a 2-fold
increase (*p<0.05) in cell growth kinetics over 4 days compared to BM-MSC, (Figure
1A). Panc-MSC also expressed classical MSC surface markers, including CD73, CD105,
and CD90 (Figure 1B-C). Importantly, Panc-MSC did not express surface markers of the
endothelial (CD31, or PECAM-1) or hematopoietic (CD45, pan-leukocyte) lineages
(Figure 1D-E). Overall, Panc-MSC demonstrated a classical MSC phenotype and robust
growth kinetics in plastic adherent culture.

4.3.2

The multipotency of Panc-MSC is skewed away from
adipogenesis.

BM-MSC harbor tri-lineage differentiation potential under pro-differentiation culture
conditions in vitro 5. Panc-MSC were found to efficiently undergo chondrogenesis and
osteogenesis marked by the positive identification of glycoprotein (Alcian Blue) and
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calcium deposition (Alazarian Red), respectively (Figure 1F). Compared to BM-MSC,
the capacity of Panc-MSC to make adipocytes was restricted, albeit lipid droplet
formation was consistently detected across all Panc-MSC cell lines. We performed
transcriptional analysis of adipogenesis-associated mRNA transcripts Peroxisome
Proliferator-activated Receptor Gamma (PPAR𝛾; PPARG), CCAAT/enhancer-binding
protein α (CEBP𝛼; CEBPA), and Lipoprotein Lipase (LPL) 10 days after induction in
differentiative adipogenic media (Figure 1G) and compared to mRNA expression levels
to MSC harvested before induction. Interestingly, BM-MSC robustly increased
transcription of PPAR𝛾, CEBP∝, and LPL mRNA (15.8±6.52, 172.6±142.1,
4549.0±3072.0 fold-increase, respectively); whereas transcriptional adipogenic induction
was significantly lower in Panc-MSC (1.27±0.29, 0.71±0.33, 2.30±1.44 fold-increase,
respectively; *p<0.05). Furthermore, the frequency of adiponectin+ cells, detected by
flow cytometry, generated from Panc-MSC was significantly reduced compared to BMMSC (4.40±1.43 versus 22.47±5.02 % of MSC, *p<0.05; Figure 1H). Thus, Panc-MSC
demonstrated mesodermal multipotency with robust osteogenic and chondrogenic
potential; however, adipogenesis was transcriptionally and functionally restricted in
response to pro-adipogenic stimuli.
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Figure 4.1 Panc-MSC demonstrate spindle-like morphology and decreased forward
scatter area compared to BM-MSC. (A) Representative photomicrographs of BM-MSC
and Panc-MSC stained with hematoxylin and eosin. (B) Panc-MSC are significantly
smaller than BM-MSC under MSC-growth conditions or under adipogenic conditions as
microenvironmental stiffness is decreased, measured by forward scatter area. Data
represented as Mean ± SEM (*p<0.05; N=3). Statistical analyses were determined by
Student’s t-test.
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Figure 4.2 Panc-MSC demonstrated robust growth kinetics, classical MSC surface
marker expression and restricted adipogenic potential. (A). Panc-MSC demonstrated
robust cell expansion kinetics in vitro and generated increased cell number after 96 hours
in vitro, compared to BM-MSC. (B-C) Representative flow cytometry plots showing
comparable expression (>95%) of CD73, CD90, and CD105 in BM-MSC and PancMSC. (D) Panc-MSC did not express endothelial or endothelial (CD31) or hematopoietic
(CD45) lineage markers, respectively. (E) Panc-MSC demonstrated osteogenic and
chondrogenic differentiation in vitro; however, adipogenic differentiation was
qualitatively less pronounced than observed in BM-MSC. (F) BM-MSC robustly
increased transcription of PPARG, CEBPA, and LPL following adipogenic induction for
14 days. In contrast, Panc-MSC demonstrated a minimal increase of adipogenesis-related
transcriptional targets after adipogenic induction. β-glucuronidase (GUSB) was used as a
housekeeping gene. (G) The frequency of Panc-MSC acquiring adiponectin expression
after adipogenic induction was ~5-fold less than BM-MSC. Data represented as Mean ±
SEM (*p<0.05; n=3-5). Statistical analyses were determined by unpaired Student’s t-test.
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Figure 4.3 Panc-MSC exhibit comparable STRO-1 membrane-surface expression
compared to BM-MSC. (A) Representative confocal images of vimentin and STRO-1
expression by BM-MSC and Panc-MSC. (B) Representative flow cytometry plots (insert)
demonstrated comparable expression of STRO-1 between Panc-MSC and BM-MSC,
measured by MFI. Data represented as Mean ± SEM (*p<0.05; N=3). Statistical analyses
were determined by Student’s t-test.
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4.3.3

Selection of 500 highest expressed proteins generates a unique
fingerprint for Panc-MSC.
Proteomic technologies provide a unique opportunity to characterize global

protein content between related cell types. Using label-free mass spectrometry, we
identified >7500 unique proteins in the proteome of both BM-MSC or Panc-MSC (Figure
2A). Principle component analyses of the entire dataset generated a unique signature that
tightly clustered BM-MSC samples distinct from Panc-MSC samples (Figure 2B). We
focused our initial analyses on the top 500 (T-500) identified proteins based on
expression intensity (LFQ). Vimentin was the most abundant protein detected in both
MSC subtypes and was expressed at comparable levels (BM/Panc; Log10 p=1.14, Figure
2C). We additionally detected STRO-1 expression on both BM-MSC and Panc-MSC at
comparable expression levels (Supplemental Figure 2A-B). Furthermore, Panther
pathway enrichment analysis of the T-500 proteome identified that both MSC-types
robustly expressed components of integrin signaling (P00034), including ITGB1 and
ITGA1 (Figure 2D-E). Moreover, both MSC-types produced several secreted ECM
molecules at comparable levels, although fibronectin-1 (FN1) expression was
significantly increased in BM-MSC (**p>0.01; Figure 2F). Human Gene Atlas
enrichment analysis suggested the T-500 proteome of both MSC sub-type was
statistically comparable to smooth muscle cells, reflected by high expression of α-SMA
(Figure 2G). On the other hand, BM-MSC were determined to harbor a T-500 proteome
that was statistically more comparable to adipocytes (*p<0.05), suggesting a distinct
propensity of BM-MSC to generate cells of the adipocyte lineage compared to PancMSC.
Next, we identified differential expressed proteins in the T-500 proteome
comparing BM and Panc-MSC (Figure 2H). As previously mentioned, expression
proteins associated with lipid metabolism such as Acetyl-CoA Acyltransferase 2
(ACAA2), Aldo-Keto Reductase Family 1 Member C2 (ARK1C1), or Hydroxysteroid
17-Β Dehydrogenase 4 (HSD17B4) were significantly increased in BM-MSC compared
to Panc-MSC. Conversely, Panc-MSC showed increased expression of the proliferation
marker Ki67 (MKI67), progenitor cell marker nestin (NES) and intermediate filament
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keratin 18 (KRT18). Collectively, these proteomic fingerprints established a unique
protein expression signature distinguishing each MSC sub-types that correlated with key
functional distinctions including growth kinetics and adipogenic potential.
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Figure 4.4 Label-free mass spectrometry reveals unique proteomic signatures
comparing Panc-MSC and BM-MSC. (A) >7500 unique proteins were identified in the
proteome of MSC subtypes. (B) PCA analysis demonstrated the unique proteomes of
BM-MSC and Panc-MSC. (C) Top 500 proteins based on LFQ intensities identified
vimentin as the most highly expressed protein in both MSC populations. (D) Top 500
proteins were matched to Panther Pathway enrichment annotations and revealed a
significant enrichment of integrin signaling components (P00034), (E) including the
expression of ITGB1 and ITGA2 in both MSC sub-types. (F) Extracellular matrix proteins
were comparably expressed between MSC subtypes, with the exception of FN1 with
increased expression in BM-MSC. (G) Human Gene Atlas enrichment analyses
determined the BM-MSC proteome was comparable to adipocytes, whereas both MSC
populations showed similarities to smooth muscle cells with comparable expression of
alpha-SMA. Representative confocal photomicrographs of alpha-SMA expression in BMand Panc-MSC. (H) Out of the top 500 proteins, 8 proteins were upregulated in PancMSC, including Nestin (NES), Ki67 (MKI67) and cytokeratin 18 (CK18). Selected
enrichment annotations contained >3 protein hits with p-value cutoff of p<0.01 and
minimal overlap of 1.5-fold. Data represented as Mean ± SEM (N=3).
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4.3.4

Panc-MSC demonstrate accelerated competency to pro-neurogenic
stimuli.

To further investigate the relevance of elevated Nestin expression in Panc-MSC, we
determined whether additional neural-lineage markers were detected by mass
spectrometry that fell below our initial T-500 cut-off. Surprisingly, we identified 15
additional proteins, expressed in Panc-MSC, associated with the neural lineage (Figure
3A). This included markers of neurons (Tubulin 3, TUBB3), oligodendrocytes (Myelin
Binding Protein, MBP) and astrocytes (Glial Fibrillary Acidic Protein, GFAP). GFAP
and MBP were detected at comparable levels within both MSC-types, however detection
of TUBB3 was increased 2-fold in BM-MSC. Flow cytometry validated the expression of
TUBB3, MBP, and GFAP in both MSC subtypes cultured under MSC-expansion
conditions (Figure 3B).
To assess the competency of Panc-MSC to respond to pro-neurogenic stimuli in
vitro, MSC were cultured in Neurocult media for up to 10 days. Compared to
maintenance in AmnioMax C-100 media, both MSC populations significantly increased
expression of TUBB3, MBP, and GFAP after 10 days of culture in Neurocult media,
measured by flow cytometry. Interestingly, Panc-MSC showed significantly elevated
TUBB3 and GFAP expression within 4-days culture in Neurocult (Figure 3C-E).
However, the frequency of cells expressing TUBB3 or GFAP remained high when BM or
Panc-MSC were cultured in either MSC-growth media (AmnioMax C-100) or Neurocult
(Figure 3F). In contrast, the frequency of MBP+ MSC was significantly increased when
ether MSC subtype was cultured in pro-neurogenic media (**p<0.01). Collectively, these
results confirmed both MSC populations expressed neural-lineage markers; albeit, PancMSC were initially more competent to pro-neural stimuli compared to BM-MSC.
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Figure 4.5 Panc-MSC express neural-lineage markers and respond to neurogenic
stimuli. (A) Volcano plot of neural lineage-associated proteins expressed within Pancand BM-MSC. (B) Representative flow cytometry plots validate the expression of neurallineage markers Tubulin-3/TUBB3 (neuron), Myelin Binding Protein/MBP
(oligodendrocyte) and Glial Fibrillary Acidic Protein/ GFAP (astrocyte) during culture in
Aminomax C-100. After culture in Neurocult, Panc-MSC increased expression of (C)
TUBB3, (D) MBP and (E) GFAP between 4 – 10 days post-induction. (F) Representative
confocal photomicrographs of TUBB3, MBP, and GFAP expression in BM- and PancMSC cultured in Aminomax or Neurocult at 10 days. Bar graphs demonstrate the
frequency of cells positive for TUBB3, MBP, or GFAP under each condition. Expression
was measured by geometrical mean fluorescence intensity (MFI) and normalized to
expression levels of MSC cultured in Aminomax C-100. Data represented as Mean ±
SEM (n=3). Statistical analyses were determined by unpaired Student’s t-test.
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4.3.5

Panc-MSC upregulate cell-cycle proteins driving cellular division
while BM-MSC upregulated proteins associated with lipid
metabolism.

Differential protein expression between MSC populations may translate to functional
characteristics 10. Accordingly, Panc-MSC demonstrated unique functional characteristics
compared to BM-MSC, including increased growth kinetics and restricted adipogenic
competency. Our mass spectrometry analyses identified 483 and 383 significantly
upregulated in BM-MSC and Panc-MSC, respectively (Figure 4A). Pathway enrichment
analysis on differentially expressed proteins was performed using Gene Ontology (GO)
pathway, and Reactome (R-HSA) annotations, uncovered distinguishable molecular
signatures when comparing the BM- and Panc-MSC populations (Figure 4B). Notably,
BM-MSC upregulated proteins involved in the metabolism of lipids (R-HSA-556833,
Figure 4C), whereas Panc-MSC upregulated proteins involved in the control of cell cycle
and mitosis (R-HSA-1640170, Figure 4D). More specifically, BM-MSC also upregulated
proteins with small molecule biosynthetic functions, including members of retinoic-acid
signaling pathways such as ALDH1A3, ALDH2, and STRA6 (Figure 4E). On the other
hand, Panc-MSC upregulated proteins associated with cell cycle complexes; including
origin of replication components such as ORC2/6, MCM2/5, GMNN, CCNB1 (Figure
4F). Collectively, Panc-MSC and BM-MSC demonstrated protein expression signatures
that drive distinctive cellular functions such as cell division and lipid metabolism,
respectively.
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Figure 4.6 Panc-MSC proteome was enriched for cell cycle proteins and BM-MSC
proteome was enriched for proteins involved with lipid metabolism. (A) Volcano plot
of 418 and 383 proteins significantly increased in the proteome of Panc-MSC (purple dots)
and BM-MSC (red dots), respectively. Upregulated proteins from BM-MSC and PancMSC were matched to GO- pathway, Reactome, and BioCarta enrichment annotations. (B)
10 annotations with smallest adjusted p-values from each cell-type were plotted against the
number of unique proteins identified within each annotation. (C) Proteins upregulated in
BM-MSC were strongly associated with the metabolism of lipids annotation (R-HSA556833), which included small molecule biosynthetic pathways (i.e. retinoic acid
production, ALDH1A3). In contrast, (D) Panc-MSC upregulated proteins associated with
cell cycle annotation (R-HSA-1640170), specifically with (F) mitotic function. Selected
enrichment annotations contained >3 protein hits with p-value cutoff of 0.01 and minimal
overlap of 1.5-fold. N=3, p<0.05.
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4.3.6

Panc-MSC and BM-MSC share common phenotypic proteins,
however each harbour distinct expression levels and unique surface
protein expression.

It is well established that cultured human MSC classically express surface markers
including CD73, CD105, CD90, however, cell surface marker expression selective for
tissue specific MSC subtypes is much less well established. We directly compared
surface marker expression of both Panc-MSC and BM-MSC using mass spectrometry. In
addition to classical MSC surface marker expression, we identified an additional 64 CD
surface markers with similar expression levels in both MSC populations, validated by
flow cytometry (i.e. CD109) using both MSC subtypes (Figure 5A). 15 CD-markers were
differentially expressed (Figure 5B). Specifically, Panc-MSC showed upregulated
expression of 7 surface markers, including CD142, CD9, CD168, CD55, CD166, CD97,
and CD49d (Figure 5B). In contrast, BM-MSC showed upregulated expression of 8
surface markers including CD63, CD74, CD146, CD318, CD297, CD230, CD304, and
CD276 (Figure 5B). Interestingly, our mass spectrometry and flow cytometry analyses
identified the expression of CD14 and HLA-DR (Figure 5C), previously reported to be
absent from plasma membrane of MSC. Specifically, 6 isoforms of HLA-DR were
upregulated in the proteome of BM-MSC (Figure 5D-E), albeit only HLA-DRA was
significantly elevated compared to Panc-MSC. Collectively, these results validated that
Panc-MSC possessed a unique surface marker profile compared to BM-MSC.
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Figure 4.7 Panc-MSC demonstrate a unique CD marker expression profile
compared to BM-MSC. (A) 67 CD markers were detected by label-free mass
spectrometry that showed comparable expression levels on both Panc- and BM-MSC.
Validated detected of CD109 using flow cytometry. (B) Volcano plot of CD markers
significantly upregulated in Panc-MSC (i.e. CD9) and BM-MSC (i.e. CD146). (C)
Expression of CD14 and HLA-DR surface expression was validated by flow cytometry
compared to isotype control (green line). (D-E) Several isoforms of HLA-DR were
upregulated by BM-MSC, compared to Panc-MSC. Horizontal dashed line is
representative of p<0.05. N=3
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4.3.7

Panc-MSC exhibit dampened CD146 expression and retinoic acidsignaling.

We sought to further investigate the phenotypic profile of Panc-MSC compared to BMMSC generated using label-free mass spectrometry. We determined pericyte marker
(CD146) expression was reduced at the level of protein translation (25.60±11.19 versus
76.25±4.02 % of MSC, *p<0.05; Figure 5A-B) and mRNA transcription (0.53±0.05 foldincrease, *p<0.05; Figure 5C) in Panc-MSC compared to BM-MSC, respectively.
Furthermore, Panc-MSC expressed dampened levels of ALDH-activity (7.58±2.54 versus
54.2±9.51 % of MSC, *p<0.05; Figure 6A,6D), measured by cytoplasmic Aldefluor
accumulation. Aldefluor is reduced to a cell-impermeable product primarily by several
ALDH family members, which was confirmed at both the level of ALDH1A3 mRNA
transcription (0.34±0.15 fold-increase, *p<0.05; Figure 6C) and ALDH1A3 protein
expression (Figure 4E) in Panc-MSC. Interestingly, Panc-MSC had elevated ALDH1A1
mRNA transcription (59.54±37.13 fold-increase, *p<0.05; Figure 5C) that was detected
in the proteome (Figure 6E). Furthermore, mass spectrometry detected differential
expression of several components and/or targets of the retinoic acid signaling pathway
(Figure 6F-G). In addition to increased ALDH-activity, we identified an increased
detection of increased detection of retinol transporter (STRA6), alcohol dehydrogenase
(RDH11), and regulators of retinoic signaling (i.e. DGAT1, DHRS3) in BM-MSC.
Collectively, a mosaic of phenotype differences, such as dampened CD146 expression
and retinoic acid-signaling pathways, can distinguish Panc-MSC from BM-MSC in vitro.
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Figure 4.8 Panc-MSC exhibit reduced expression of pericyte marker CD146 and
reduced aldehyde dehydrogenase-activity. (A) Representative flow cytometry plots for
BM-MSC (red) or Panc-MSC (purple) co-stained for pericyte marker CD146 and
cytosolic ALDH-activity. (B) Compared to BM-MSC, Panc-MSC demonstrated reduced
expression of pericyte marker CD146, and (C) reduced MSAM (CD146) mRNA
expression. Panc-MSC also demonstrated increased expression of ALDH1A1 mRNA,
however ALDH1A3 mRNA expression was reduced compared to BM-MSC. βglucuronidase (GUSB) was used as a housekeeping gene. (D) Panc-MSC demonstrated
(D) reduced ALDH-activity by flow cytometry. (E) CD146 and ALDH1A protein
expression was confirmed in BM- and Panc-MSC by confocal microscopy.
Immunofluorescent images were acquired under 40x oil-immersion, scale bar = 20𝝁m.
(F) Schematic highlighting retinoic acid signaling pathway components with (G)
differential expression in BM-MSC. Data represented as Mean ± SEM (*p<0.05; N=3-5).
Statistical analyses were determined by Student’s t-test.
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4.3.8

Adipogenic potential of Panc- and BM-MSC is independent of
microenvironment stiffness.

We sought to further investigate functionally relevant phenotypic differences between
Panc-MSC compared to BM-MSC generated using label-free mass spectrometry. Pericyte
marker (CD146) expression was reduced at the level of protein translation (25.60±11.1
versus 76.25±4.02 % in Panc- versus BM-MSC, *p<0.05; Figure 6A-B) and mRNA
expression (0.53±0.05 fold difference in Panc- versus BM-MSC, *p<0.05; Figure 6C) .
Panc-MSC also demonstrated a reduced frequency of cells with high ALDH-activity
(7.58±2.54 versus 54.2±9.51 % of cells, *p<0.05; Figure 6A,6D), measured by flow
cytometric assessment of AldefluorTM accumulation. AldefluorTM reagent is reduced to a
cell-impermeable product primarily by several cytosolic ALDH isoforms, primarily
ALDH1A family members. ALDH1A3 mRNA expression (0.34±0.15 fold difference in
Panc- versus BM-MSC, *p<0.05; Figure 6C) and ALDH1A protein expression (Figure
6E) was decreased in Panc-MSC. Interestingly, Panc-MSC demonstrated elevated
ALDH1A1 mRNA expression (59.54±37.13 fold-increase, *p<0.05; Figure 6C). Indeed,
our mass spectrometry data confirmed differential expression of several components of
the retinoic acid signaling pathway (Figure 6F-G). In addition to increased ALDH1A3
expression in BM-MSC, we identified an increased expression of retinol transporter
(STRA6), retinol dehydrogenase 11 (RDH11), alcohol dehydrogenase 2 (ADH2), cellular
retinoic acid binding protein 2 (CRABP2), and other regulators of retinoic signaling (i.e.
DGAT1, DHRS3) in BM-MSC. Collectively, a mosaic of phenotype differences, such as
reduced pericyte marker CD146 expression and retinoic acid-signaling, can distinguish
Panc-MSC from BM-MSC in vitro.
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Figure 4.9 Soft culture stiffness increased growth kinetics but did not enhance
adipogenic differentiation in BM- or Panc-MSC. (A) A schematic briefly describing
MSC culture on substrates with a range of Young’s Modulus (2-100kpa) in MSC-growth
(solid line) or pro-adipogenic media (dashed line). (B) Both MSC subtypes generated
greater cell numbers after 5 days expansion culture on soft substrate compared to TCP.
(C) CD105 or (D) CD146 or (E) vimentin expression was not altered when MSC were
cultured on softer substrates compared to TCP. Similarly, (F) the frequency of cells with
high ALDH-activity was not changed when MSC were cultured on softer substrates,
compared to TCP. (G) ∝-SMA expression was not altered by expansion of either MSC
subtype on soft substrates. (H-J) In response to adipogenic stimuli, Panc-MSC cultured
on softer substrates reduced (H) ∝-SMA expression compared to TCP, whereas (I)
vimentin expression was increased in Panc-MSC cultured on 10kPa or 100kPa. Although
BM-MSC were capable of robust adipocyte formation quantified by adiponectin
expression (MFI), Panc-MSC cultured on soft substrates remained resistant to adipogenic
differentiation in vitro. Horizontal dashed lines represent MFI of adiponectin in BMMSC or Panc-MSC cultured under expansion conditions in AmniomaxTM media. Data
represented as Mean ± SEM (*p<0.05; N=3-5). Statistical analyses were determined by
repeated measures one-way Anova with post-Hoc Tukey’s t-test, comparing MSC
subtypes across varying substrate stiffness.
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4.4 Discussion
This study employed label-free mass spectrometry and multiparametric flow cytometry to
determine the proteomic and phenotypic profile of human Panc-MSC, a MSC subtype
that can be readily isolated from cultured human pancreatic tissue. Using BM-derived
MSC as the ‘gold standard’ for therapeutic MSC, this study provides novel evidence that
distinguished Panc-MSC as a tissue-specific MSC population with unique phenotypic,
molecular, and functional characteristics in vitro. Specifically, Panc-MSC harbour a
proteome that drives robust expansion kinetics, defines a surface marker profile with
reduced CD146 and ALDH1A3 expression, and increases competency towards proneurogenic stimuli. Additionally, Panc-MSC were resistant to adipogenic differentiation,
a feature independent of vimentin expression, or decreased ∝-SMA expression in
response to decreased microenvironmental stiffness. Collectively, we provide
foundational proteomic, phenotypic and functional characterizations in vitro, towards a
tissue-specific MSC whose therapeutic potential has yet to be determined.
The prospective purification of MSC from human tissues has been complicated by
the lack of a selective cell surface marker expression 4 that permits efficient purification
of MSC. As a result, MSC cultures are highly heterogeneous due to dependence on
clonogenic expansion using selective media(s) and autonomous adherence to TCP
dependent on adhesion protein expression and ECM deposition 17. Accordingly, PancMSC readily adhered to TCP and our proteomic analyses demonstrated diverse integrin
expression accompanied by robust ECM production. Integrins detected on Panc-MSC
were expressed at comparable levels to BM-MSC, albeit integrin 𝛼-4 (CD49d) was
upregulated in Panc-MSC. Integrins heterodimers play a vital role in cell migration,
survival, and proliferation through the prorogation of intracellular signaling networks 1719

. We did not directly assess the functional relevance of integrin expression in this study.

Regardless, Panc-MSC exhibited accelerated growth kinetics in vitro compared to BMMSC. Further studies are warranted to elucidate the functional roles of integrin
expression and ECM molecule deposition in the coordination of pro-mitotic signaling in
Panc-MSC.
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To elucidate phenotypic characteristics that distinguish MSC subtypes from
different tissue sources, we investigated differential CD-marker expression between
Panc-MSC and BM-MSC. Both MSC subtypes highly expressed cell surface markers
CD73, CD90, and CD105; and were devoid of CD45 and CD31 expression. These
characteristics satisfy the minimal criteria to identify MSC colony formation adherent to
plastic, however our proteomic detection of cell surface marker expression conflicted
with the current ISCT guidelines 5, which suggest that MSC should be devoid of CD14
and HLA-DR expression. Here, we validated expression of CD14 on both MSC subtypes
and elevated HLA-DR expression on BM-MSC. These results and previous reports 6,20,21,
demonstrate highly sensitive proteomic approaches are required to establish surface
marker expression within heterogeneous MSC populations. Nonetheless, Panc-MSC and
BM-MSC demonstrated mesodermal multipotency, vimentin and α-SMA expression, and
STRO-1 surface marker expression 22,23. Additionally, 64 CD-markers were detected at
comparable levels between Panc-MSC and BM-MSC, suggesting that a uniform
phenotype between tissue-specific MSC likely exists. Conversely, we demonstrated
differential expression of 15 CD-markers, whose functional roles on MSC remain
undetermined. For example, CD9 is a multifunctional tetraspanin family member that is
upregulated in Panc-MSC. Halfon et al. previously reported CD9 was enriched on the
surface of fibroblasts compared to BM-MSC and was upregulated on BM-MSC with
extended culture 24. On the other hand, we observed increased expression of the pericyte
marker CD146 on BM-MSC. Nestin+/CD146+ MSC have been shown to maintain
hematopoietic stem cell pools in the perivascular niche of bone marrow 25 and
purification of CD146+ cells from several human tissue sources can enrich for MSC
colony forming cells 26. However, the functional relevance of CD146 expression on
MSC in vitro remains undetermined. Collectively, we have reported a unique surface
“fingerprint” for Panc-MSC that reflects a different tissue source of origin. Thus, future
studies are warranted to elucidate the functional roles of CD-markers identified in this
study.
Directed differentiation of MSC in vitro is currently the standard assay for
assessing progenitor cell multipotency, yet these assays remain primarily reliant on
qualitative histology. Accordingly, Panc-MSC demonstrated robust osteogenic and
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chondrogenic potential in vitro, however adipogenic potential was notably restricted with
Panc-MSC showing small lipid-droplet formation and infrequent Oil Red O staining. We
build upon these qualitative observations to demonstrate adipogenesis was quantitatively
restricted in Panc-MSC at the transcriptional and translational level. Proteomic analysis
revealed BM-MSC demonstrated protein expression patterns similar to adipocytes with
functions involved in lipid metabolism. Notably, we also detected expression of
progenitor cell marker Nestin, in Panc-MSC alongside accelerated response to proneurogenic stimuli compared to BM-MSC. It has been proposed that some MSC may
arise from non-mesodermal tissues, such as the neural crest 27. In addition, it has been
previously suggested that pancreas-derived MSC may be generated from a ductal
epithelial-to-mesenchymal transition initiated by culture in vitro 12. Our proteomic
findings support both these hypotheses, as Panc-MSC also highly expressed epithelial
cell markers such at KRT18. Conversely, Kubo et al. found that KRT18 was transcribed
>30-fold higher in BM-MSC 28 compared to fibroblasts, osteoblasts or adipocytes,
suggesting a better understanding of the functional relevance in Panc-MSC is warranted.
These observations amongst other studies suggest the multipotency of MSC may be
tissue-specific and likely entails epigenetic, transcriptional, and translation regulation
tightly controlled alongside extrinsic microenvironmental cues. Ultimately, the
development of in vivo functional testing will be required to further understand the true
multipotent potential of MSC.
Pathways activated by lipid metabolites drive cellular functions including tissue
patterning, cell division, cell survival, and differentiation 29. We identified that BM-MSC
up-regulated several members of the RA-signaling pathway, including ALDH1A3,
ALDH2, STRA6 and RDH10. ALDH-activity has been reported to be differentially
expressed by cells with high proliferative capacity, engraftment, and/or multipotency in
tissues such as blood, pancreas, or cancer 30,31. We have previously demonstrated
selection of high ALDH-activity can isolate hematopoietic progenitors with multifaceted
regenerative functions in vivo 30,32; in addition to enhanced multipotency and growth
kinetics in vitro. Conversely, BM-MSC with high ALDH-activity did not demonstrate
enhanced multipotency but instead generated a pro-angiogenic secretome with provascular functions in vivo 9. Here we report Panc-MSC, with dampened ALDH-activity,
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demonstrated accelerated growth kinetics in addition to reduced adipogenic potential.
Thus, the functional role of ALDH-activity in Panc-MSC in vitro remains elusive and the
pro-angiogenic potential of Panc-MSC in vivo is currently undetermined.
It is well established that microenvironmental properties in vitro can affect MSC
functional characteristics; including, lineage-differentiation and surface marker
expression 4,16. Talele et al. demonstrated ∝-SMA expression could be linked to
microenvironmental stiffness and was upregulated in BM-MSC with reduced adipogenic
capacity. In our studies, we observed comparable ∝-SMA expression between BM- and
Panc-MSC subtypes with restricted adipogenesis and reduced cell size in Panc-MSC.
Similar to Talele we observed reducing ∝-SMA expression when Panc-MSC were
cultured on a softer substrate, however adipogenesis was not recovered by Panc-MSC
cultured on a microenvironmental stiffness <100kPa. Notably, microenvironmental
stiffness appeared to have a minimal impact on CD105, CD146, vimentin expression or
ALDH-activity in both BM or Panc-MSC, suggesting alternate control mechanisms may
govern the multipotent capacity of MSC in vitro.
In summary, we employed label-free mass spectrometry and multiparametric flow
cytometry to characterize the proliferative and multipotent functions of Panc-MSC in
vitro. The foundational knowledge acquired in this study will support our future
investigations comparing the regenerative potential of distinct MSC subtypes in vivo, a
characteristic considered exclusive to MSC populations 33,34. Moreover, proteomic and
functional differences observed in this study would benefit from complementary
epigenetic and transcriptional profiling, with specific-focus on RA-signaling pathways,
adipogenesis, and the functional role(s) of surface marker expression.
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Chapter 5

5

Human Pancreas-derived Multipotent Stromal Cells Secrete
Extracellular Vesicles that Stimulate Microvessel Formation

5.1 Introduction
Human multipotent stromal cells (MSC) have been described as regenerative
‘biofactories’ or ‘sentinals’ of the regenerative response 1,2. However, clinical translation
of promising preclinical studies utilizing MSC has not fulfilled expectations 3, due to the
transfer of heterogeneous cells showing transient engraftment 4, poor survival and
biodistribution 5-7, and/or the loss of pro-regenerative functions after exposure to a
diseased or inflamed microenvironment 8-11. We recently demonstrated bone marrow
(BM) MSC may be employed as ‘biofactories’ in vitro to generate a serum-free and cellfree mixture of effectors that stimulate islet regeneration in hyperglycemic mice
following intrapancreatic delivery 12,13. Moreover, pharmaceutical manipulation of BMMSC in vitro successfully tailored a secretome enriched for pro-regenerative stimuli that
improved islet regenerative capacity in vivo. Collectively, development of cell-free
biotherapeutic approaches for regenerative medicine mitigates many of the translational
barriers associated with allogeneic MSC transplantation, yet in-depth investigation of the
biotherapeutic products secreted by various MSC subtypes are required to better
understand and stimulate the regenerative response.
We recently conducted an in-depth proteomic and phenotypic characterization of
MSC derived from human pancreatic islet preparations (Panc-MSC) that shared classical
MSC characteristics with BM-MSC. Panc-MSC demonstrated reduced aldehyde
dehydrogenase (ALDH)-activity and CD146 pericyte marker expression, compared to
BM-MSC, suggesting functional differences may exist between tissue specific human
MSC subtypes that can be exploited for therapeutic gain. Although identification of a
selective cell surface or functional phenotype to distinguish MSC from differentiated
progeny has been met with limited success 14; the capacity for MSC isolated from
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different tissues to coordinate complex regenerative processes, such as angiogenesis, may
arguably segregate therapeutic MSC from non-therapeutic sources 15. Because Panc-MSC
are derived from healthy islets containing an intricate microvascular network 16, we
hypothesized Panc-MSC would possess a vascular supportive or pro-angiogenic
secretome.
The secretome generated by MSC contains a complex mixture of regenerative
stimuli, in the form of protein, bioactive lipids and nucleic acids that contribute to tissue
regeneration in vivo 17,18. Notably, extracellular vesicles (EVs) secreted into the
peripheral microenvironment or circulation facilitate the transportation of regenerative
stimuli from tissue-specific MSC subtypes to target cells 19-21. EVs can be subclassified
based on their size and cellular-origin; moreover, MSC-derived EVs are phenotypically
distinct from apoptotic bodies 22. Small extracellular vesicles or exosomes (30nm-100nm)
are generated through the endosomal pathway and are actively released through
exocytosis. In contrast, larger EVs referred to as microparticles (100nm-1µm) are
generated by blebbing of the cytoplasm and localized ‘pinching’ of the plasma
membrane, leading to the direct release of microparticles to the surrounding
microenvironment or systemic circulation. Despite containing the parent cell cytoplasmic
components, EVs are packaged with a unique set of cargo (bioactive proteins, lipids and
RNA moieties) within an intact a bilayer membrane. Although generation of both
exosomes and microparticles represents a highly regulated cellular process,
understanding of the mechanisms by which MSC organize the generation and delivery of
EVs to areas of tissue damage is warranted for regenerative medicine applications. We
have recently demonstrated EVs-derived from Panc-MSC contain a diversity of cargo
including proteins, lipids, and nucleic acids using surface-enhanced Ramen spectroscopy
18

, although the functional significance of this cargo remains to be determined.
Collectively, the contribution of EVs to the regenerative functions of MSC

requires further investigation to: 1) better understand cellular communication
mechanisms driving tissue regeneration 2) to identify vascular regenerative stimuli that
may improve therapeutic applications in regenerative medicine. Herein, we demonstrate

182

that Panc-MSC generate a unique pro-angiogenic secretome that promoted endothelial
cell recruitment, proliferation and microvessel formation in vitro and in vivo. Notably,
these functions were transmitted primarily within Panc-MSC EV-enriched subfraction
which accelerated the recovery of blood perfusion in mice with femoral artery ligationinduced unilateral hindlimb ischemia.

5.2 Methods
5.2.1

BM-MSC and Panc-MSC Isolation and Culture

BM-MSC:
Human BM aspirates were obtained from healthy donors with informed consent from the London
Health Sciences Centre (London, ON). BM-MSC were established and cultured in AmniomaxC100TM media + AmnioMax C100 (Life Technologies) supplement as previously described 23.

Panc-MSC:
Ricordi-chamber isolated human islets were obtained through the Integrated Islet Distribution
Program (IIDP) funded by the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). Panc-MSC were established by plastic adherence during islet suspension cultures and
expanded as previously described37.

5.2.2

Enrichment of EVs from MSC Conditioned Media

Conditioned media (CM) was generated by culturing BM-MSC and Panc-MSC to ~80%
confluency, rinsed twice with pre-warmed PBS, switched to basal Aminomax C100
media without supplement and media was collected after 24-hours culture. CM was
subsequently processed in one of three ways (Supplemental Figure 2). 1) Cell-free CM
was concentrated (~20-fold by volume) by centrifugation in 3kDa centrifuge filter unit
for 45 minutes at 2800g. This fraction contained both EVs and soluble proteins >3kDa
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and is referred to as bulk CM. 2) Cell-free CM was concentrated in 100kDa centrifuge
filter units for 20 minutes at 2800g. This fraction (EV+) was enriched with EVs and
proteins complexes larger than 100kDa This fraction was referred to as EV+ CM or EVenriched CM. 3) CM which passed through the 100kDA filter was centrifuged in 3kDA
centrifuge filter units for 40 minutes at 2800g to concentrate soluble proteins between
>3kDa and <100kDA size. This fraction was referred to as EV- CM or EV-depleted CM.
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Figure 5.1 Concentration of MSC CM and segregation of EV+ versus EV- CM
subfractions.
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5.2.3

Pierce 660nm protein quantification

CM fractions BM- and Panc-MSC subtypes were analyzed for total protein content using
the detergent compatible reagent to measure 660nm absorbance using a micro-plate
reader. The membranes of EVs were dissociated using a urea-based lysis buffer
containing ammonium bicarbonate, DTT, and 20% SDS. Lysed CM was then diluted
200-fold with an ionic detergent compatibility reagent (Thermo Fisher) incubated for 5
minutes at room temperature.

5.2.4

Mass Spectrometry

Methodological details of protein precipitation, digestion, SFX peptide fractionation,
liquid chromatography-tandem mass spectrometry, and proteomic data base analysis are
described thoroughly in Supplemental Methods and previous studies 13,38.

5.2.5

Directed in vivo Angiogenesis Assay (DIVAA)

The directed in vivo angiogenesis assay (DIVAA) was performed as per manufacturer’s
instructions (Trevigen, Gaithersburg, MD, www.trevigen.com). DIVAA angioreactors
were loaded with 2.0x105 Panc-MSC, 2.0x105 BM-MSC, or with 10𝜇g of BM-MSC or
Panc-MSC bulk CM suspended in 20𝜇l basement membrane extract. Angioreactors were
incubated at 37⁰C ex vivo for 10 days prior to subcutaneous implantation into the upper
dorsal ﬂank of 10-12-week-old nonobese diabetic/severe combined immunodeﬁciency
(NOD/SCID) mice. After 10 days, the recruitment of murine endothelial cells into
implanted angioreactors was quantiﬁed by lectin-uptake, detected with a SpectraMax
plate reader (MolecularDevices, Sunnyvale, CA, www.moleculardevices.com).

5.2.6

Assessment of HMVEC Survival and Proliferation

Human Microvascular Endothelial Cells (HMVEC) were seeded at 104 cells/cm2 in
complete endothelial growth media, EGM-2 (EBM-2 + 5%FBS, IGF, bFGF, EGF, and
VEGF) for 24 hours. HMVEC were washed twice with pre-warmed PBS and switched to
serum/growth factor-deprived EBM-2 for up to 48 hours. 40µg total protein of BM-MSC
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or Panc-MSC CM was supplemented into EBM-2 without serum or growth factors (<5%
of total culture volume), and 750nM of EdU was added 24 prior to harvest to label
proliferating cells. HMVEC were harvested at 48-hours and enumerated using automated
hematocytometer counts (Life Technologies). Harvested HMVEC were divided in half
prior for detecting EdU incorporation in fixed (10% Formalin) and permeabilized (1x
Saponin Buffer) cells using the Click-It system with Alexfluor 594 (Life Technologies),
according to manufacturer’s instructions. Nonpermeabilized HMVEC were co-stained
with BV421- Annexin V and 7-AAD to assess early apoptosis or cell death, respectively.
man Microvascular Endothelial Cells (HMVEC) were seeded at 104 cells/cm2 in
complete endothelial growth media, EGM-2 (EBM-2 + 5%FBS, IGF, bFGF, EGF, and
VEGF) for 24 hours. HMVEC were washed twice with pre-warmed PBS and switched to
serum/growth factor-deprived EBM-2 for up to 48 hours. 40µg total protein of BM-MSC
or Panc-MSC CM was supplemented into EBM-2 without serum or growth factors (<5%
of total culture volume), and 750nM of EdU was added 24 prior to harvest to label
proliferating cells. HMVEC were harvested at 48-hours and enumerated using automated
hematocytometer counts (Life Technologies). Harvested HMVEC were divided in half
prior for detecting EdU incorporation in fixed (10% Formalin) and permeabilized (1x
Saponin Buffer) cells using the Click-It system with Alexfluor 594 (Life Technologies),
according to manufacturer’s instructions. Nonpermeabilized HMVEC were co-stained
with BV421- Annexin V and 7-AAD to assess early apoptosis or cell death, respectively.

5.2.7

Nanoscale Flow Cytometry

Bulk, EV+, and EV- CM from Panc- or BM-MSC were analyzed for the number of
microparticles/𝜇l. 20𝜇l of each concentrate was diluted to 300𝜇l with 0.22um-filtered
PBS at room temperature. Microparticles secretion were detected using the A-50
nanoscale flow cytometer (Apogee), capable of multi-parametric analyses on
microparticles between 150nm-1000nm diameter 24. 150𝜇l of diluted CM was injected
and analyzed at 10.5𝜇l/min for 1 minute. The size of secreted microparticles was
estimated using silca beads ranging 110nm-1300nm using properties of large-angle light
scatter (LALS) and small-angle light scatter (SALS). Silica beads provide a refractive
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index (λ=1.42) that is similar to cells (λ=1.35-1.39). The resolution of exosomes
(<100nm) or large protein complexes compared to background noise was not reliably
attained based on the limitations of the A-50 nanoscale flow cytometer.

5.2.8

Atomic Force Microscopy

EV+ and EV- CM fractions were washed with 0.22um filtered PBS twice, diluted 1:20,
and CM fractions were pipetted as 10uL microdroplets onto sterile glass coverslips and
allowed to dry at room temperature in a sterile biological safety cabinet in preparation for
atomic force microscopy (AFM) imaging. AFM measurements were performed using a
BioScope Catalyst AFM (Bruker) equipped with NCL tips (NanoWorld) and Nanoscope
software. Images were recorded in noncontact mode at a line rate of 0.5 Hz and processed
using post-acquisition software Gwyddion.

5.2.9

Visualization of EVs derived from Panc-MSC

CM generated by BM-MSC or Panc-MSC was incubated for 40 minutes at room
temperature with 1uM of Cell Tracker CTMPX, a fluorescent dye that becomes a
membrane intercalated product. CTMPX-labelled CM was used to visualize EVs and
semi-quantify uptake by HMVEC using flow cytometry and confocal imaging.
Specifically, CTMPX-labelled CM was processed to generate EV+ and EV- CM. EVCM was used as a negative control, as this fraction is devoid of membrane structures that
retain CTMPX fluorescence. CMPTX+ EVs were visualized using oil immersion
confocal imaging at 63X with 4x digital zoom (Leica TSP8).

5.2.10

EV Uptake by Human Endothelial Cells

To confirm EV- CM was devoid of EVs, HMVEC were cultured in EBM-2 with equal
volumes of CMTPX labelled CM separated into EV+ and EV- fractions. Geometric mean
fluorescent intensity (MFI) was measured at 0.5, 1, and 12 hours using a LSRII flow
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cytometer. Furthermore, CTMPX-labelled EV+ CM uptake was spiked at increasing
doses into single-cell suspensions of 1.0 x 106 HMVEC and immediately measured using
MFI via flow cytometry.
Additionally, CTMPX+ EV uptake was visualized by adding CTMPX+ EV+ or
EV- CM to serum-free HMVEC cultures for up to 12 hours. Confocal images were
acquired at 1 or 12 hours after CFMPM-labelled HMVEC were fixed using 10% formalin
and counterstained with DAPI. EV and CMPTX internalization were visualized through
the Z-plane at 0.1𝜇m increments under 63x oil immersion and 2x digital zoom (Leica
TSP8).

5.2.11

HMVEC Tubule Formation

To assay for tubule forming function in vitro, 1.2x105 HMVEC were cultured on growth
factor-reduced Geltrex matrices (LifeTechnologies) in EGM-2, EBM-2 or EBM-2
supplemented with 30ug of bulk, EV+ or EV- CM generated by BM-MSC or Panc-MSC.
After 24 hours, four photo-micrographs were taken per well, and complete tube formation
was quantiﬁed by manual counting in a blinded fashion using open-source Fiji Image
Analysis Software.

5.2.12

Femoral Artery Ligation and Transplantation

Unilateral hind limb ischemia was induced in anesthetised (100mg/kg ketamine/xylazine,
maintain with 2% isoflurane, 0.8L/min) NOD/SCID mice via surgical ligation and
cauterization of the femoral artery and vein (FAL), as previously described 39. Mice with
unilateral hind-limb ischemia (perfusion ratio <0.1), were transplanted 24-hours after
surgery (Day 0) with 40𝜇g total protein intramuscularly (i.m) injected (20𝜇L) at 3 sites in
the thigh muscle and one site in the calf muscle. As a vehicle control, mice received i.m.injections of 80𝜇l of basal AminomaxTM C100 media.

5.2.13

Laser Doppler Perfusion Imaging

Anesthetised mice were warmed to 37ºC for 5 minutes and hindlimb blood perfusion was
measured using Laser Doppler perfusion imaging (LDPI) as previously described 39.
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Recovery of blood flow was quantified on 3-, 7-, 14- and 21-days post-transplantation by
quantifying the perfusion ratio (ischemic/non-ischemic limb) of transplanted mice.

5.2.14

Endothelial Cell Density

Adductor muscle from ischemic and non-ischemic thighs were harvested at Day 28,
embedded in OCT, and cryosectioned (14𝜇m) to obtain three sections per slide ≥100𝜇m
apart. Cryosections were fixed in 10% formalin (Sigma) and blocked with 5% serum.
CD31+ area was quantified at 21-days post-transplantation using rat anti-mouse CD31
(BD Biosciences; 1:100) detected with alkaline phosphatase-labelled rabbit anti-rat
secondary antibodies (Vector; 1:200) stained with Vector Blue (Vector). CD31+ cell area
was enumerated using 3 randomly selected fields of view per section, totaling 9 images
per limb. Images were converted to RBG stack and threshold of was set between 180-210
using Fiji Image Analysis Software.

5.2.15

Statistical Analyses

Analysis of significance was performed by one-way ANOVA with Tukey’s multiple
comparisons tests for all in vitro or in vivo experiments and enumeration of histological
analyses. Outliers were identified using Grubb’s test; *p<0.05.

5.3 Results
5.3.1

The secretome of Panc-MSC was enriched for proteins that
contribute to vascular development, wound response, and
chemotaxis

We recently demonstrated Panc-MSC express tissue-specific MSC characteristics,
however, the therapeutic potential of Panc-MSC is currently undetermined. We
considered BM-MSC as the gold-standard of therapeutic MSC and utilized the secretome
of BM-MSC as a comparator for the secretome of Panc-MSC. Using label-free mass
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spectrometry we detected >1700 proteins in bulk CM generated by both MSC-types
(Figure 1A), and 540 proteins were considered secreted effectors based on GOterminologies. 343 of the 540 secreted proteins were detected at equivalent levels in both
MSC subtypes (Figure 1B), referred to herein as the shared MSC secretome. GO-pathway
enrichment analyses determined the majority of shared MSC secretome (182/343) were
associated with wound response, vascular development, and/or inflammation
(Supplemental Figure 1A-B). Specifically, 54 of these 182 proteins were associated with
overlapping (>1) GO-pathway annotation (Figure 1B), and 12 proteins were associated
with all 3 GO-pathway terminology and included pleiotropic signals including WNT5A,
TIMP1, HGF, TGFB1, IL-6 and CCL2. Alternatively, Panther pathway enrichment
analysis determined the shared MSC secretome was enriched with proteins associated
with integrin signaling and angiogenesis (Supplemental Table 1-2).
Of the 540 shared secreted proteins, 115 and 82 were significantly upregulated
(total=197 differentially expressed) in the secretome of Pan-MSC or BM-MSC,
respectively (Figure 1C; Supplemental Figure 1C). GO-pathways enrichment analyses
suggested there was a significant representation (95/197=48%) of differentially expressed
proteins that have functional contributions towards wound response (GO:0009611),
chemotaxis (GO:0006935), and/or blood vessel development (GO:0001568). 54 of these
proteins were exclusively associated with a single GO-pathway annotation term (Figure
1D), 27 of which were significantly upregulated in Panc-MSC. Moreover, 41 differential
proteins were associated with 2 or more GO-pathway annotations (Figure 1E), 27 which
were significantly enriched in the secretome of Panc-MSC. Specifically, the secretome
of Panc-MSC was significantly enriched with proteins that contribute to chemotaxis and
blood vessel development (i.e. Platelet-derived Growth Factor D/PDGFD).
We previously demonstrated the secretome of BM-MSC with high ALDHactivity can stimulate robust endothelial cell recruitment in a murine model of endothelial
cell chemotaxis 23. Accordingly, we used the directed in vivo angiogenesis assay
(DIVAA) methodology to assess the capacity of BM-MSC or Panc-MSC to recruit
endothelial cells in vivo (Figure 1F). Interestingly, BM-MSC or Panc-MSC seeded in
angioreactors did not stimulate endothelial cell recruitment, compared to vehicle controls.
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In contrast, concentrated CM generated by Panc-MSC significantly stimulated the
recruitment of murine endothelial cells, compared to vehicle controls (Figure 1G).
Collectively, these results suggest the secretome of Panc-MSC is enriched for proteins
involved in chemotaxis, wound response and vascular development compared to BMMSC; however, there exists a comparable functional capacity to stimulate endothelial cell
chemotaxis in vivo.
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Figure 5.2 The secretome of Panc-MSC was enriched for pro-vascular proteins that
stimulate endothelial cell recruitment in vivo. Conditioned Media (CM) generated by
BM-MSC or Pan-MSC was analyzed by label-free mass spectrometry. (A) Mass
spectrometry identified 1912 and 1872 unique proteins in the secretome of BM-MSC and
Panc-MSC, respectively. Identified proteins filtered using GOCC analysis identified 540
secreted proteins were shared in the secretome of BM-MSC and Panc-MSC. Of the
secreted proteins identified, 343 secreted proteins were equally expressed, 115 secreted
proteins were upregulated in the secretome of Panc-MSC, whereas 82 secreted proteins
were upregulated in the secretome of BM-MSC (*p<0.05). (B) Of the 343 shared
proteins, 182 were associated with Inflammation, Response to Wounding, or Blood
Vessel Development. Specifically, 8 of the 182 shared proteins were associated with all 3
GO-terms. (C) Differentially expressed proteins cross referenced to GO-pathway
database revealed a significance enrichment of pro-vascular proteins in the secretome of
Panc-MSC. Specifically, (D) differentially expressed proteins associated with one GOpathway annotation or (E) multiple annotations were enriched in Panc MSC CM. (F)
Schematic of 2.5 x105 MSC or 20µg MSC CM-loaded DIVAA angioreactor implantation
into NOD/SCID mice. (G) Panc-MSC CM significantly increased endothelial cell
recruitment compared to vehicle or cellular controls. Data represented as Mean ± SEM
(*p<0.05; N=3, n=3). Statistical analyses were determined by one-way ANOVA with
Tukey’s post-hoc test.
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Figure 5.3 GO-Pathways Analysis of Panc-MSC and BM-MSC Conditioned Media.
Label-free mass spectrometry was performed on concentrated conditioned media
generated by human BM-MSC or Panc-MSC. (A) Pathways networks and (B) pathway
enrichment analyses demonstrate the secretome of both MSC-types are enriched with
proteins that have functional roles in wound response, blood vessel development and
chemotaxis.
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Table 5.1 Protein enrichment analysis on the secretome of of Panc-MSC crossreferenced to the Panther 2016 Database.

Table 5.2 Protein enrichment analysis on the secretome of BM-MSC crossreferenced to the Panther 2016 Database.
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5.3.2

Panc-MSC CM increased HMVEC proliferation and survival.

Blood vessel regeneration requires fine-tuned orchestration of endothelial cell
recruitment, proliferation, and tube formation. We have previously demonstrated the
secretome of BM-MSC can support HMVEC survival, proliferation, and tube formation
in vitro 23. Accordingly, we sought to investigate whether CM generated by Panc-MSC
similarly supported HMVEC survival and/or proliferation under serum and growth
factor-starved conditions in vitro. After 48 hours culture under starvation conditions in
EBM-2 without serum or growth factors, HMVEC supplemented with 40𝜇g of CM
generated by BM-MSC or Panc-MSC demonstrated increased cell survival (**p<0.05,
Figure 2A) and proliferation (**p<0.01; Figure 2B). The frequency of HMVEC
undergoing apoptosis (Annexin V+/7-AAD-) was reduced when EBM-2 was
supplemented with BM-MSC or Panc-MSC CM (**p<0.01; Figure 2C). Moreover, the
frequency of dead cells (Annexin V+/7-AAD+) was also reduced when HMVEC were
supplemented with BM- or Panc-MSC generated CM (Figure 2D). As a result, the total
number of viable HMVEC was significantly increased after 48 hours, when HMVEC
cultures were supplemented with BM- or Panc-MSC CM under starvation conditions
(**p<0.01; Figure 2E). Collectively, these results demonstrated the capacity of PancMSC CM to support HMVEC survival and proliferation in vitro was comparable to BMMSC CM.
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Figure 5.4 Panc-MSC CM promoted endothelial cell survival and proliferation
under growth-factor and serum-starved conditions in vitro. HMVEC were cultured up
to 48 hours in EBM-2 without serum or growth factors with or without 40µg of BM-MSC
CM or Panc-MSC CM. As a control for optimal HMVEC growth, HMVEC were also
cultured under EGM-2 conditions. (A) Panc-MSC increased the frequency of EdU+
HMVEC after 48 hours. Panc-MSC CM increased (B) viable HMVEC frequency by
decreasing the frequency of (C) apoptotic and (D) dead HMVEC after 48 hours. (E) Total
viable HMVEC cell number was increased after 48 hours. Data represented as Mean ±
SEM (*p<0.05; n=3). Statistical analyses were determined by one-way ANOVA with
Tukey’s post-hoc test
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5.3.3

Panc-MSC CM contains extracellular vesicles

We have recently demonstrated using custom fabricated nano-hole trapping and surface
enhanced Ramen-spectrometry that the secretome of Panc-MSC contains vesicle-like
structures with packaged cargo including proteins, lipids, and nucleic acids 18. Because
this technique does not assess vesicle size or distinguish the identity of common markers
in the EV membrane (i.e. CD9, CD63, or CD81), we identified an enrichment of proteins
associated with exosomes within bulk Panc-MSC generated CM, according to the
ExoCarta database (exocarta.org) and FunRich (funrich.org) functional enrichment
analyses (Figure 3A). Accordingly, we detected a high abundance of the EV membrane
markers CD9, CD63, and CD81 in the secretome of Panc-MSC (Figure 3B). EVassociated proteins such as Pyruvate Kinase M1/2 (PKM) or Tumor susceptibility gene
101 (TSG101) were also detected. The detection of EVs by conventional flow cytometry
is limited by resolution of particle size and obscuration from sample debris,
underestimating EV concentrations in analyzed samples 24. To address this, we employed
nanoscale flow cytometry to measure microparticle content in EV-enriched (EV+) and
EV-depleted (EV-) CM (Figure 3C). The number of detectable microparticles (170nm1𝜇m) was increased above media control only in EV+ CM, whereas the number of events
in EV- CM did not exceed background measurements (Figure 3D). Interestingly, the
majority of total protein by mass for both BM-MSC and Panc-MSC was contained within
the EV- CM fraction (Figure 3E). The majority of microparticles detected were relatively
small (170-250nm) and aligned with the size range of microparticles (Figure 3F). Atomic
force microscopy (AFM) was used to visualize the enrichment of EVs after ultrafiltration
(Figure 3G). EV+ CM contained many vesicle-like structures demonstrating appropriate
microparticle dimensions and morphology, whereas vesicle-like structures were not
observed in EV- CM. Collectively, these results demonstrate Panc-MSC secrete EVs and
ultrafiltration is sufficient to segregate EVs from vesicle-free proteins.
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Figure 5.5 Panc-MSC secrete extracellular vesicles that can be detected by nanoscale flow cytometry. (A) Mass spectrometry analysis identified 1298 unique proteins in
the secretome of Panc-MSC and BM-MSC that were associated with exosomes using
FunRich enrichment analysis. (B) Mass spectrometry detected proteins associated with
extracellular vesicles, including CD63, CD81, CD9, PKM or TSG101 in the secretome of
both BM-MSC and Panc-MSC. (C) Representative nanoscale flow cytometry plots,
acquired using Apogee A-50 and calibrated using silca beads ranging from 178 to
1300nm, demonstrated only bulk and EV+ CM fractions exhibited detectable
microparticle detection. (D) On the other hand, levels of microparticles in EV- CM was
not detectable above background levels observed with media (horizontal dashed line). (E)
Total protein measured by 660nm spectrophotometry revealed the majority of bulk mass
was contained within EV-CM. Tot. Vol = Volume of CM after typical ultrafiltration
when 10mL of CM was concentrated. (F) Size distribution of EVs detected by nanoscale
flow cytometry. (G) Representative atomic force microscopy image demonstrating
enrichment of EVs within EV+ CM. Data represented as Mean ± SEM (*p<0.05; n=3-4).
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5.3.4

HMVEC demonstrate uptake of EVs generated by Panc-MSC

EVs contain bioactive cargo enclosed by a plasma membrane that can up taken by target
cells either through endocytosis or fusion with the plasma membrane 25. To assess
whether endothelial cells were competent to EVs generated by Panc-MSC, we incubated
cell-free CM with a fluorescent label (CMTPX red) that is metabolized to a membrane
impermeable by-product (Figure 4A). This approach ensures that only vesicles with
enzymatic activity would retain CTMPX and free CTMPX(<3kDa) would be removed
during CM concentration and purification into EV+ and EV- subfractions. CTMPX+
vesicle-like structures were observed using oil-immersion confocal microscopy and
diameters validated EV sizes detected by nanoscale flowcytometry and AFM (Figure
4B). HMVEC cultured with CMTPX-labelled EV+ CM demonstrated distinct
accumulation of CMTPX after 12 hours whereas, HMVEC supplemented with EV- CM
did not accumulate CTMPX fluorescence above non-supplemented HMVEC controls
(Figure 4C). Furthermore, rapid accumulation of CMTPX+ fluorescence was observed
within 400ms of exposure to labelled EV+ CM, and accumulation of CMTPX
fluorescence occurred in a dose-dependent manner (Figure 4D). Next, we wanted to
determine whether CTMPX+ accumulation in HMVEC was a result of vesicle
internalization or vesicle fusion to the plasma membrane. Accordingly, HMVEC were
first labelled with CMFPR (green) to define cytoplasmic contents and incubated with
either CMTPX-labelled EV+ or EV- CM. Robust CMTPX internalization was observed
after HMVEC were cultured with EV+ CM for 1 hour, suggesting active EV uptake in
HMVEC via an endocytotic mechanism. In contrast, CMTPX internalization was not
observed in HMVEC cultured with EV- CM for up to 12 hours (Figure 4E). High
resolution oil-immersion confocal microscopy detected the presence of CMTPX+ vesiclelike structures in both the plasma membrane and cytoplasm of HMVEC (Figure 4F).
Thus, HMVEC EV uptake demonstrated characteristics consistent with EV
internalization to the cytoplasm and fusion at the plasma membrane.
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Figure 5.6 HMVEC uptake EVs generated by Panc-MSC. (A) Panc-MSC and BMMSC CM was stained with Cell Tracker CTMPX, allowing for the labelling of EVs. (B)
Representative oil immersion confocal photomicrograph of Panc-MSC EV+ CM
labelled with Cell Tracker CTMPX. (C) Representative flow cytometry plots
demonstrate that only the EV+ CM fraction was able to increase the Cell Tracker
CTMPX fluorescence in HMVEC, as measured by geometric mean fluorescence
intensity (MFI). (D) HMVEC in single cell suspension were exposed to increasing
amounts of CTMPX-labelled EVs and immediately analyzed for CMTPX accumulation
up to 400s by MFI. (E) CMTPX-labeled EVs were detected within HMVEC at 1 hour
and (F) visualized in the Z-plane using oil immersion confocal imaging at 63x oil and
2x digital zoom. Data represented as Mean ± SEM (*p<0.05; n=3).

5.3.5

Classical EV-markers were exclusively detected in EV+ CM

It is well established that EVs contain specific cargo distinct from the parent cytoplasm.
However, currently undetermined is the identities of proteins exclusively released within
EVs versus conventional vesicle-free exocytosis from the parent cell. We employed an
additional label-free mass spectrometry screen on EV+ versus EV- CM generated by
Panc-MSC to investigate proteomic make-up of each compartment. Although we have
previously demonstrated EV- CM contained the majority of bulk protein content based on
660nm spectrophotometry, we determined the EV+ CM fraction contained a significantly
more protein diversity compared to EV- CM. Specifically, we detected 1458±63.02
versus 877.30±78.19 proteins in EV+ CM versus EV- CM, respectively (Figure 5A).
PCA analysis demonstrated a clear distinction between the proteomic profile of EV+
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Figure 5.7 Panc-MSC EV+ CM demonstrates a diverse proteomic profile with
exclusive enrichment of EV-associated proteins. Panc-MSC CM was processed into
EV+ CM and EV- CM and analyze by mass spectrometry. (A) ~1450 and 870 proteins
were quantified in EV+ or EV- CM, respectively. (B) PCA analysis demonstrates distinct
composition between EV+ and EV- CM. (C) Specifically, expression levels of 1047
proteins were equally detected, whereas 637 proteins were exclusively detected in at least
1 EV+ CM. On the other hand, 74 proteins were exclusively detected in at least 1 EVCM. (D) Volcano plot of comparably detected proteins. EV+ CM was significantly
enriched for ECM molecules, such as FN1, and POSTN. (F) Of the 637 proteins
exclusive to 1 of 3 EV+ CM, 142 were detected in 3 of 3 EV+ CM samples. (G) Of the
74 proteins exclusive to EV- CM, 18 were detected in 3 out of 3 EV- CM. Data
represented as Mean ± SEM (*p<0.05; n=3).
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versus EV- CM (Figure 5B). Although 1047 common proteins were detected in both EV+
or EV- CM (Figure 5C), 322 of these proteins were significantly enriched in the EV+ CM
fraction, whereas 180 proteins were significantly enriched in the EV- CM fraction (Figure
5D). Proteins with increased abundance in EV+ CM included several ECM
molecules (i.e. COL1A2, COL6A2, COL5A, FN1) and two isoforms of Periostin
(POSTN). On the other hand, EV- CM was significantly enriched for proteins including
SERPINB6/7, CD201/PROCR, and Tissue Factor/TF.
Next, we investigated which proteins were robustly and exclusively detected in
each CM fraction. 637 proteins were detected in at least 1 of 3 EV+ CM sample and
exclusively absent from 3 out of 3 EV- CM samples. We filtered these 637 unique
proteins to include only those which were detected in 3 out of 3 EV+ CM samples. These
subsequent analyses identified 142 proteins that are robustly expressed and exclusively
detected in the Panc-MSC EV+ CM fraction (Figure 5E). Proteins exclusive to EV+ CM
included classical EV markers such as CD9, CD81, CD63 and PKM; and
regenerative/pro-angiogenic proteins ALDH1A1, ANGPT1, and WNT5A. In contrast, 74
proteins detected in at least one EV- CM sample and excluded from EV+ CM were
identified. We filtered these 74 unique proteins to only those detected in 3 of out 3 EVCM samples, in return identifying 18 proteins with robust expression that exclusively
detected in EV- CM (Figure 5F). Collectively, these results confirmed the segregation of
EVs using ultrafiltration and provide novel insight into proteins which may be
exclusively secreted within EVs by Panc-MSC.
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5.3.6

HMVEC tubule formation was enhanced by CM fractions
generated by Panc-MSC

CM generated by Panc-MSC supported endothelial cell proliferation and survival (Figure
2). To determine whether Panc-MSC CM could support HMVEC tubule formation,
HMVEC in seeded on Geltrex media and treated with Panc-MSC CM subfractions in
vitro. After 24 hours, we observed a significant increase in the number of tubules formed
by HMVEC supplemented with Panc-MSC bulk CM (Figure 6A), compared to EBM-2
without supplements (*p<0.05). Furthermore, when Panc-MSC CM was segregated into
EV+ CM and EV- CM, both subfractions enhanced tubule formation compared to EBM-2
conditions (*p<0.05; Figure 6A). Collectively, the soluble and EV secretome
compartments from Panc-MSC equally supported endothelial tubule formation under
serum-deprived culture conditions in vitro.

5.3.7

Intramuscular-injection of Panc-MSC EV+ CM enhanced recovery
of blood perfusion in mice with hindlimb ischemia

Although MSC demonstrate diverse pro-regenerative functions in vitro, transplantation of
MSC has produced modest and often inconsistent results due to culture-induced
functional heterogeneity, poor cell engraftment and transient cell survival. We recently
demonstrated direct injection of MSC-generated CM can facilitate tissue regeneration in
a model of 𝛽-cell regeneration, eliminating the requirement for cell transfer to stimulate a
regenerative cascade 12. Therefore, we investigated the vascular regenerative potential of
Panc-MSC CM following direct intramuscular injection and determined if vascular
regenerative stimuli were contained in EV+ and/or EV- CM compartments. Mice with
unilateral hind-limb ischemia received 4 x 20𝜇g injections of bulk, EV+ or EV- CM
(Figure 6B) 24 hours following femoral artery/vein ligation and excision. Specifically,
two injections were proximal to site the site of ligation, one immediately distal to
ligation, and one into the calf muscle. Unconditioned media of equal volume was injected
as a vehicle control. Interestingly, only EV+ CM significantly increased blood perfusion
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(days 14 and 21), compared to vehicle control (*p<0.05; Figure 6C). Recovery of blood
perfusion (Figure 6C, insert), measured by area under the curve (AUC), was significantly
improved in mice that received bulk (*p<0.05) or EV+ CM (**p<0.01). Accelerated
recovery of perfusion was not observed in mice that received i.m. injections of EV- CM
and was statistically comparable to the injection of vehicle control. Collectively, these
results provide foundational evidence that the secretome of Panc-MSC contains vascular
regenerative stimuli contained primarily within extracellular vesicles.
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Figure 5.8 Panc-MSC CM supports HMVEC tubule formation in vitro and supports
the recovery of hindlimb blood perfusion in vivo. (A) Representative
photomicrographs at 24-hours of HMVEC tubule formation following culture with
(30µg) of bulk, EV+, or EV- CM generated by either Panc-MSC or BM-MSC. PancMSC bulk, EV- and EV+ CM significantly increased HMVEC tubule formation under
EBM-2 conditions. (B) Schematic of femoral artery ligation (x) and cauderization (c)
sites and laser doppler perfusion imaging following intramuscular transplantation of
Panc-MSC CM fractions into NOD/SCID mice. (C) Intramuscular injection of bulk or
EV+ CM significantly improved hindlimb perfusion over 28 days (insert). Specifically,
EV+ increased hind limb blood perfusion at days 14 and 21 post-transplantation. Data
represented as Mean ± SEM (*p<0.05; n=3-6). Statistical analyses were determined by
one-way ANOVA with post-hoc tukey’s t-test.
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5.3.8

Injection of Panc-MSC CM increased vessel density in ischemic
thigh muscle.

Microvascular density was assessed in the thigh muscles of mice 28 days after Panc-MSC
CM injection (Figure 7A). Consistent with improved perfusion induced by Panc-MSC
subfractions, mice I.M.-injected with bulk or EV+ CM showed significantly increased
CD31+ cell area (3.13±0.46 or 3.53±0.40 CD31+ % of area, respectively), compared to
mice injected with unconditioned media control (1.83 ± 0.35 CD31+ % of area; Figure
7B). In contrast, mice injected with EV- CM fraction did not demonstrate significant
recovery of blood vessel area (2.39 ± 0.28 CD31+ % of area). Collectively, bulk and EV+
CM generated by Panc-MSC stimulated the recovery of hind-limb blood perfusion which
coincided with increased vessel density in the ischemic thigh muscles of NOD/SCID
mice with femoral artery ligation-induced unilateral hindlimb ischemia.
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Figure 5.9 Revascularization of thigh muscle tissue is stimulated after i.m. injection
of Panc-MSC CM. Thigh muscles were harvested at Day 28 from NOD/SCID mice with
hindlimb ischemia that received intramuscular injections of Panc-MSC CM. (A)
Representative photomicrographs demonstrate Panc-MSC bulk and EV+ CM
significantly increased CD31+ area in ischemic thigh muscles, compared to vehicle
control. Conversely, i.m. injection of EV- CM did not significantly increase CD31+ area,
compared to vehicle control. Data represented as Mean ± SEM (*p<0.05; N=5).
Statistical analyses were determined by one-way ANOVA with post-hoc tukey’s t-test.
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5.4 Discussion
MSC hold notable therapeutic potential and can be isolated from a diverse selection of
tissue sources. However, it is currently undetermined whether a pro-vascular secretome is
uniform across MSC isolated from different tissue types. We provide novel evidence that
human Panc-MSC possess a unique secretome containing vascular regenerative stimuli,
primarily packaged into EVs, that demonstrates proangiogenic function when injected
into ischemic muscle. These characteristics combined with ease of MSC expansion after
cadaveric islet harvest suggests that Panc-MSC CM may serve as a biotherapeutic agent
to support vascular regenerative therapy. We demonstrated: 1) Panc-MSC generate a
secretome composition distinct to BM-MSC, albeit CM generated by BM MSC also
demonstrated pro-vascular functions in vitro and in vivo; 2) EVs generated by Panc-MSC
contained a diverse portfolio of protein cargo that supported the recovery of blood
perfusion and stimulated revascularization after im-injection into ischemic murine
hindlimbs. Collectively, this study has provided foundational knowledge to further
understand proteomic and functional characteristics which may be uniform across MSC
from different tissue-types. In addition, we provide proof-of-concept and continuing
evidence that the cell-free delivery of MSC biotherapeutics (i.e. MSC CM) may represent
a useful tool for applications of regenerative medicine.
We recently characterized the total proteome of human Panc-MSC and conducted
a parallel molecular and functional comparison with BM-MSC in vitro, demonstrating
Panc-MSC were enriched for cell division protein machinery and depleted for proteins
involved in lipid metabolism compared to BM-MSC. Panc-MSC also demonstrated
phenotypic differences such as reduced ALDH1A3 and CD146 expression and
adipogenic competency compared to BM-MSC. Considering, the secretome of both Pancand BM-MSC harbour pro-vascular stimuli and demonstrated comparable functions in
vitro and in vivo, the phenotypic differences previously reported (i.e. CD146 or ALDHactivity) may not correlate with a pro-vascular secretome 23. Other MSC subtypes,
including adipose-derived MSC, have also demonstrated the secretion of pro-vascular
stimuli alongside differential cell surface phenotypes 26. Whether the production of proangiogenic stimuli is a uniform characteristic across tissue specific MSC subtypes
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remains to be established. However, fibroblasts from several tissues did not demonstrate
pro-vascular effects in a comparable in vitro or in vivo model 15,27, therefore future
studies are warranted.
Extracellular vesicles contain a diverse range of cargo that ‘communicate’ with a
target cells at levels of transcriptional, translational, or directly as ligands to activate
target receptors 20. Panc-MSC generated extracellular vesicles with diverse protein
content compared to EV- CM, despite representing <50% of the bulk protein mass
secreted. Nonetheless, cargo within Panc-MSC EVs was readily incorporated by
HMVEC and stimulated endothelial tubule-formation in vitro. Importantly, EV+ CM
generated by Panc-MSC accelerated the recovery of hindlimb blood perfusion after
femoral artery ligation in vivo. We cannot conclude that proteomic stimuli were
exclusively responsible for the pro-vascular effects observed in this study. Losordo and
colleagues recently demonstrated that human CD34+ hematopoietic progenitors
generated exosomes that transfer miR-126-3p to reduce SPRED1 mRNA and increase
revascularization in a murine model of hind-limb ischemia 28. The potential role of
miRNA content within Panc-MSC EVs was not assessed in this study. Moreover, several
studies have demonstrated secreted MSC signals alter the infiltration hematopoietic cell
populations, such as promoting a pro-regenerative M2 macrophage recruitment opposed
to pro-inflammatory M1 macrophages 29. Thus, future studies are needed to investigate
the functional role of nucleic acid content within EVs and to elucidate the roles of
infiltrating hematopoietic cell populations in angiogenesis. Nonetheless, we demonstrate
a relatively uncostly method to concentrate and enrich EVs from MSC in an injectable
volume (<100ul). Future work designed to investigate the functional role of protein
stimuli that exert pro-vascular benefits in a pre-clinical models of critical limb ischemia
are needed.
Utilizing the secretome of vascular regenerative MSC subtypes, we envision the
creation of a cell-free biotherapeutic ‘tailored’ to combat a pathological condition. For
instance, stimuli with known pro-regenerative functions were detected in MSC CM
and/or exclusively in the EV+ CM fraction. Wnt5a signals through both the canonical and
non-canonical signaling pathways to activate pro-angiogenic pathways in vivo through
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endothelial cells or through M2-polarization of infiltrating monocytes 30,31. Likewise,
VEGF-A, ANGPT1 and POSTN have also demonstrated pro-angiogenic and regenerative
function in previous studies 32-34. Although we did not assess the contribution of
individual proteins, or defined protein mixtures detected in EV+ CM to the recovery of
hind-limb blood perfusion, this study provides a foundation to explore targetable
pathways during MSC expansion to ‘tailor’ the secretome towards a specific regenerative
response. For example, we have recently demonstrated activation of canonical Wntsignaling during BM-MSC expansion (via GSK3-inhibition) can enhance islet
regenerative secretory function in vivo 12. Other studies have demonstrated genetic
modification 35 or hypoxic priming 36 may improve the regenerative or proangiogenic
functions of MSC respectively. Therefore, our future studies will address whether
pharmaceutical or genetic manipulation of specific MSC subtypes can enhance the provascular secretome of MSC to generate therapeutics for vascular regenerative therapies.
In conclusion, this study provides foundational insight to elucidate vascular
regenerative potential of MSC-generated CM. Moreover, we further defined the central
role of EVs generated by Panc-MSC and conducted two proteomic screens that identified
future biological targets. Collectively, vascular regenerative medicine has demonstrated
pre-clinical potential to treat macro- and micro-vascular pathologies, however direct cell
transplantation has endured several setbacks during translation to clinical studies. Our
recent studies suggest regenerative MSC populations may be used as ‘biofactories’ to
generate a cell-free biotherapeutics, although future research is crucial to determine the
‘therapeutic ceiling’ of these approaches.
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Chapter 6

6

Pancreatic MSC secrete islet regenerative stimuli*

*This chapter was primarily incorporated to supplement Chapters 4 and 5 as foundational
evidence to 1) establish a common multifaceted secretome across MSC populations 2)
demonstrate the therapeutic potential of cell-free biotherapeutics for complex tissue
regeneration. Additionally, this chapter provides preliminary experimental evidence to
establish discussion points in Chapter 7.

6.1 Introduction
We have recently demonstrated that the secretome of BM-MSC harbours bioactive
stimuli capable of supporting beta-cell proliferation and survival in vitro1. Notably,
intrapancreatic (iPan) injection of concentrated BM-MSC CM stimulated complex islet
regenerative programs, including characteristic consistent with the induction of islet
neogenesis, increased β-cell proliferation, and accelerated 𝛽-cell maturation in STZinduced hyperglycemic NOD/SCID mice2. Currently, we are utilizing this reproduceable
injection platform combined with thorough secretome analyses to identify stimuli that
mediate islet regenerative processes in pre-clinical models which may be translated to
human application for diabetes treatment2,3. To this end, mass spectrometry-based
analyses of BM-MSC revealed active canonical Wnt-signaling was a conserved
characteristic of islet-regenerative BM-MSC that significantly lowered hyperglycemia
following intravenous cell transplantation3. Inhibition of GSK3 activity (CHIR99021),
resulting in the stabilization of β-catenin during ex vivo cell expansion led to enrichment
of islet regenerative effectors in the secretome of BM-MSC that could be injected as a
cell-free biotherapeutic to reverse hyperglycemia in NOD/SCID mice. Taken together,
these studies suggested that 1) the secretome of MSC may determine islet regenerative
functions in vivo and 2) cell-biotherapeutics can be ‘tailored’ to enhance the induction of
islet regenerative programs.
Considering Panc-MSC are derived from the islet microenvironment, I hypothesized that
Panc-MSC will generate a secretome that demonstrates islet regenerative function after
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direct iPan-delivery. In chapter 6, I present functional evidence that the Panc-MSC
secretome of also capable of inducing islet recovery and reducing STZ-treated
hyperglycemic mice, similar to BM-MSC. The knowledge acquired within this chapter
will serve as preliminary proof-of-concept for future studies aiming to utilize the
secteome of Panc-MSC as a cell-free biotherapeutic for the treatment of diabetes.

6.2 Methods
6.2.1

BM-MSC and Panc-MSC Isolation and Culture

BM-MSC:
Human BM aspirates were obtained from healthy donors with informed consent from the
London Health Sciences Centre (London, ON). BM-MSC were established and cultured in
Amniomax-C100 media + C100 supplement (Life Technologies) as previously described
in Chapter 4.
Panc-MSC:
Ricordi-chamber isolated human islets were obtained through the Integrated Islet
Distribution Program (IIDP) funded by the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK). Panc-MSC were established by plastic adherence during
islet suspension cultures and expanded in Amniomax-C100 media + supplement as
previously described in Chapter 4.

6.2.2

Enrichment of EVs from Panc-MSC CM

Conditioned media (CM) was generated by culturing BM-MSC and Panc-MSC to ~80%
confluency, rinsed twice with pre-warmed PBS, switched to basal Aminomax C100
media without supplement and media was collected after 24-hours culture. CM was
subsequently processed in one of three ways (Supplemental Figure 2). 1) Cell-free CM
was concentrated (~20-fold by volume) by centrifugation in 3kDa centrifuge filter unit
for 45 minutes at 2800g. This fraction contained both EVs and soluble proteins >3kDa
and is referred to as bulk CM. 2) Cell-free CM was concentrated in 100kDa centrifuge
filter units for 20 minutes at 2800g. This fraction (EV+) was enriched with EVs and
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proteins complexes larger than 100kDa This fraction was referred to as EV+ CM or EVenriched CM. 3) CM which passed through the 100kDA filter was centrifuged in 3kDA
centrifuge filter units for 40 minutes at 2800g to concentrate soluble proteins between
>3kDa and <100kDA size. This fraction was referred to as EV- CM or EV-depleted CM
(also see Chapter 5 Methods).

6.2.3

Intrapancreatic or Intravenous Transplantation of Panc-MSC in
hyperglycemic NOD/SCID mice

Pancreatic β-cell ablation was induced in NOD/SCID mice aged 8- to 10-weeks by
intraperitoneal injection of STZ (35 mg/kg/ day) for 5 consecutive days. All animal
procedures were approved by the Animal Care Committee at Western University Canada
(AUP 2015-033). On day 10, hyperglycemic (15–25 mM) mice were sublethally
irradiated (300 cGy) prior to intrapancreatic transplantation of 5.0x105 Panc-MSC (20µl).
Alternatively, 5.0x105 Panc-MSC were intravenously infused within 500ul of Basal
Aminomax C-100 via tail vein injection. Equal volumes of Basal Aminomax C-100 were
used as vehicle control for both injection modalities. Systemic blood glycemic levels
were monitored in a blinded fashion weekly for 42 days.

6.2.4

Intrapancreatic or Intravenous Injection of MSC-derived CM in
hyperglycemic NOD/SCID mice

Hyperglycemic NOD/SCID mice, generated as described above were transplanted on day
10 by intrapancreatic or intravenous injection of MSC-derived CM fractions.
Specifically, hyperglycemic mice received a single intrapancreatic injection of bulk, EV+,
EV- CM (6μg total protein in 20ul) derived from Panc-MSC or bulk CM (6μg total
protein 20µl) derived from BM-MSC. In addition, STZ-treated NOD/SCID mice received
i.v. injection of 100μg total protein of Panc-MSC CM via the tail vein, as described
above. Equal volumes of Basal Aminomax C-100 were used as vehicle control for both
routes of CM injection. Systemic blood glycemic levels were monitored in a blinded
fashion weekly for 42 days.
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6.3 Results
6.3.1

Intravenous or intrapancreatic transplantation of Panc-MSC did not
reduce hyperglycemia in STZ-treated mice

We have previously demonstrated that BM-MSC can lower hyperglycemia and stimulate
islet regeneration when infused into the systemic circulation4-6. However, regenerative
functions were variable and donor specific. Furthermore, direct intrapancreatic transplantation of islet-regenerative UCB ALDHhi cells augmented the reduction in
hyperglycemia7, compared to intravenous transplantation. Therefore, I sought to
investigate if Panc-MSC could stimulate islet regeneration following intravenous infusion
or after intrapancreatic transplantation. Accordingly, we demonstrated that neither
intravenous or intrapancreatic transplantation of Panc-MSC reduced hyperglycemia in
STZ-treated NOD/SCID mice (Figure 6.1), compared to mice injected with vehicle
control.
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Figure 6.1 Intravenous or Intrapancreatic-injection does not reduce hyperglycemia
in STZ-treated NOD/SCID mice. 8-10-week-old NOD/SCID mice were injected with
STZ days 0-5 to induce β-cell ablation. On day 10, hyperglycemic mice (>15mmol/mL)
received 5.0x105 Panc-MSC by either intravenous (i.v.) infusion or intrapancreatic (iPan)
transplantation. Basal Aminomax C-100 was injected as vehicle control. (A) i.v. or iPan
transplantation of Panc-MSC did not significantly reduce blood glucose levels in
NOD/SCID mice, compared to vehicle injected control mice. Data represented as Mean +
SEM (n=3-4 mice per group). Statistical analyses were performed by two-way ANOVA
with Tukey’s post-hoc test.
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6.3.2

Panc-MSC CM reduced hyperglycemia in STZ-treated NOD/SCID
mice after intrapancreatic-injection but not after intravenous
injection

STZ-treated mice injected with concentrated CM generated by BM-MSC demonstrated
reduced hyperglycemia via the stimulation of potent islet regenerative and islet neogenic
programs following direct injection into the pancreas2. However, it has yet to be
determined if the intravenous infusion of CM generated by MSC could similarly
stimulate islet regeneration. Accordingly, I sought to determine if 1) intrapancreatic
injection of Panc-MSC CM could stimulate islet regeneration similar to BM-MSC and 2)
if intravenous infusion of Panc-MSC CM via tail-vein injection could stimulate islet
regeneration in hyperglycemic NOD/SCID mice.
First, I injected hyperglycemic mice with CM (3 or 6μg total protein) generated by BMMSC or Panc-MSC. To serve as a vehicle control, non-conditioned media was iPan
injection. Compared to vehicle control, 6𝜇g CM generated by both BM-MSC and PancMSC significantly reduced (*p<0.05) hyperglycemia in STZ-treated NOD/SCID mice
(Figure 6.2). In contrast, 3μg of BM-MSC or Panc-MSC CM did not reduce
hyperglycemia in vivo, compared to vehicle control. To assess whether secreted stimuli
could induce murine islet from distant sites, I tested whether tail vein-injection of 100μg
total protein of Panc-MSC CM could reduce hyperglycemic in STZ-treated mice.
Compared to vehicle control, intravenous-infusion of Panc-MSC CM did not
significantly decrease hyperglycemia in vivo (Figure 6.3). Collectively, I demonstrated
CM generated by Panc-MSC reduced hyperglycemia in NOD/SCID mice, albeit direct
injection into the pancreas was required.
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Figure 6.2 Intrapancreatic injection of MSC-derived CM reduced resting
blood glucose levels in STZ-treated NOD/SCID mice. 8-10-week-old
NOD/SCID mice were rendered hyperglycemic by STZ-induced β-cell ablation
between days 0-5. On day 10, hyperglycemic mice (>15mmol/mL blood glucose)
received 3 or 6𝝁g of Panc-MSC or BM-MSC derived CM. Basal Aminomax C100 served as vehicle control. (A) Collectively, iPan transplantation of 6ug CM
derived from Panc-MSC or BM-MSC significantly reduced resting blood glucose
levels, (B) as measured by area under the curve (AUC). Conversely, 3μg of
Panc-MSC CM did not demonstrate hyperglycemic reduction. Data represented
as Mean +/- SEM (n=5-8). Statistical analyses performed by one-way ANOVA
with post-hoc Tukey’s t test (*p<0.05).
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Figure 6.3 Intravenous infusion of Panc-MSC CM did not reduce
hyperglycemia in STZ-treated NOD/SCID mice. 8-10-week-old NOD/SCID
mice were treated with STZ for 5 consecutive days to induce β-cell ablation
between days 0-5. On day 10, hyperglycemic mice (>15mmol/mL blood glucose)
received 100ug total protein of Panc-MSC by either intravenous (i.v.) infusion.
500𝝁l of basal Aminomax C-100 served as vehicle control. (A) i.v. infusion of
Panc-MSC CM did not significantly reduce resting blood glucose levels in
NOD/SCID mice, compared to vehicle control. Data represented as Mean + SEM
(n=3-4 mice / group). Statistical analyses were performed by one-way ANOVA
with Tukey’s post-hoc test.
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6.3.3

Islet regenerative stimuli are haboured throughout the secretome of
Panc-MSC

In Chapter 5, I demonstrated that EVs generated by Panc-MSC contained pro-angiogenic
stimuli able to stimulate the recovery of hindlimb blood perfusion in mice with femoral
artery ligation induced hindlimb ischemia. To investigate the role of Panc-MSC secreted
EVs in islet regeneration, EV+ and EV- CM was generated in a similar fashion as
described in Chapter 5. Interestingly, intrapancreatic injection of both the EV+ and EVCM fractions reduced hyperglycemia in NOD/SCID mice compared to vehicle control
and the extent of hyperglycemia reduction was comparable after EV+ and EV- CM
injection, suggesting islet regenerative stimuli were found in the soluble fraction of the
Panc-MSC secretome and in EV-bound vesicles secreted by Panc-MSC.
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Figure 6.4 Islet regenerative stimuli contained in the soluble and EV+ fractions
generated by Panc-MSC. 8-10-week-old NOD/SCID mice were rendered
hyperglycemic by STZ-induced β-cell ablation between days 0-5. On day 10,
hyperglycemic mice (>15mmol/mL blood glucose) received iPan-injection of 6ug EVCM or EV+ CM generated by Panc-MSC. Basal Aminomax C-100 served as vehicle
control. (A) Collectively, iPan transplantation of both EV- and EV+ CM was able to
significantly reduce resting blood glucose levels, (B) as measured by area under the
curve (AUC). Conversely, iPan-injection of 3ug of Panc-MSC CM did not induce
hyperglycemia reduction. Data represented as Mean +/- SEM (n=4-8 mice per group).
Statistical analyses were performed by one-way ANOVA with post-hoc Tukey’s t test.
(*p<0.05).
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6.4 Discussion
Endogenous regeneration of β-cells may hold the promise of providing sustained glucose
control without exogenous insulin in patients with diabetes8-10. We have previously
shown to islet regeneration could occur in response to the direct injection of BM-MSC
CM2. Using an alternative source, we predicted Panc-MSC may provide a ‘fine-tuned’
secretome for islet regeneration, albeit islet regenerative stimuli could also be a
conserved characteristic ‘common’ to the secretome MSC populations from different
tissue sources. Herein, I provide preliminary evidence that islet regenerative stimuli are
contained within both BM-MSC and Panc-MSC CM with comparable capacity to reduce
hyperglycemia in STZ-treated NOD/SCID mice. Thus, these data suggest that secretion
of pro-regenerative stimuli may be a shared characteristic across different MSC from
different tissue sources.
Furthermore, I demonstrated islet regenerative stimuli were contained within both EV+
and EV- CM fractions of the Panc-MSC secretome. Further studies are needed to
elucidate specific stimuli contained within either fraction, or whether similar regenerative
proteins were present in both EV+ and EV- CM. Conversely, it remains possible that EVand EV+ CM contain unique stimuli which activate a common regenerative mechanism.
In addition to proteins, EVs may also contain nucleic acid or lipid effectors that can
influence recipient cell populations (Figure 1.11). Losordo and colleagues demonstrated
that EVs isolated from CD34+ HPC could activate VEGF pathways in recipient
endothelial cells through the transfer of miRNA that repressed translation of VEGFpathway inhibitors11. Collectively, future studies will need to characterize a vast array of
stimuli collectively responsible for the activation of biological pathways in recipient
cells.
Nonetheless, islet regeneration only occurred when stimuli generated by Panc-MSC were
delivered directly to the site of injury (intravenous versus intrapancreatic) at a high
therapeutic dose (3μg versus 6μg). The results highlight the generation of a “therapeutic
islet microenvironment” that may tip the balance in favour of regeneration versus
inflammation and destruction12-14. In continuation with Chapter 4 and 5, Chapter 6
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supports the thesis that Panc-MSC generate a multifaceted secretome with potential as a
cell-free biotherapeutic. This work will lead us to better unravel the mechanisms of islet
regeneration using transgenic model systems to identify activated cell populations
resident within the pancreas, discussed below.
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Chapter 7

7

Summary of Objectives

The global objective of this thesis was to investigate scalable biotherapeutic approaches
of regenerative medicine utilizing post-natal progenitor cells to stimulate endogenous
islet regeneration and/or revascularization of ischemic tissue. In Chapters 2 and 3, I
focused on enhancing the ex vivo expansion of human UCB ALDHhi hematopoietic cell
progeny that retain vascular and islet regenerative functions after transplantation.
Furthermore, I provide the first comprehensive proteomic and regenerative function
analyses of human Panc-MSC (Chapter 4) demonstrating extracellular vesicles generated
by Panc-MSC harbor vascular (Chapter 5) and islet regenerative protein cargo (Chapter
6). Below, I briefly summarize the significant findings of each chapter to highlight the
contributions of this work to the field of regenerative medicine and to outline intellectual
and technical limitations encountered throughout these studies. Subsequently, I propose
future experimentation required to further refine the breadth of knowledge obtained
within this thesis. Finally, I will discuss the implications of these findings, with specific
focus on regenerative medicine strategies to treat diabetes and related cardiovascular
pathologies.
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7.1 Summary of Findings
In chapter 2, I determined that expanded hematopoietic progeny from UCB ALDHhi cells
retained a characteristic of pro-angiogenic secretome, despite reduced capacity to
stimulate angiogenesis in vivo. Moreover, I discovered that UCB ALDHhi cells will
primarily differentiate towards the megakaryocyte lineage during expansion as primitive
progenitor cell phenotype is diminished in vitro. Accordingly, I demonstrated that
preventing HPC differentiation by temporally inhibition of RA-production (via DEABtreatment) enhanced the expansion of hematopoietic progeny retaining primitive
phenotype in vitro and vascular regenerative function in vivo (Figure 7.1). Mass
spectrometry analyses suggested the inhibition of ALDH-activity enriched the proteome
of expanded HPC with a pro-survival signature which coincided with improved cell
engraftment. In chapter 3, I sought to determine if expanded hematopoietic progeny
reselected for high ALDH-activity (ALDHhi) after DEAB-treatment culture conditions
retained islet regenerative function, analogous to freshly-isolated UCB ALDHhi cells.
Surprisingly, only ALDHlo cells reselected after culture demonstrated islet regenerative
stimuli, despite ALDHhi cells retaining progenitor cell characteristics. DEAB-treated
ALDHlo cells were significantly enriched for cells of the megakaryocyte-lineage, albeit
the mature hematopoietic cell marker CD38 was significantly reduced.
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Figure 7.1 Inhibition of Retinoic Acid Production Enhances the Expansion of
Hematopoietic Progeny with Multifaceted Regenerative Functions.
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In chapter 4, I characterized the proteome on an understudied MSC population
from human pancreatic tissue, Panc-MSC (Figure 7.2). In this study, I conducted a direct
comparison of Panc-MSC versus BM-MSC using mass spectrometry, flow cytometry,
and functional differentiation assays in vitro. The proteome of Panc-MSC was enriched
with increased pro-mitotic protein expression, coinciding with accelerated growth
kinetics in vitro. Adipogenic pathways were restricted within Panc-MSC, whereas the
proteome of BM-MSC was ‘primed’ for adipogenic differentiation, lipid metabolism, and
RA-induced differentiation. Nonetheless, I detected 15 differentially expressed CD
markers between Panc- and BM-MSC as candidates for future investigation to reduce the
heterogeneity of potentially therapeutic MSC subpopulations based on surface marker
expression (i.e. CD146+ versus CD146- Panc-MSC). In Chapter 5 and 6, I demonstrated
the secretome of Panc-MSC was enriched for pro-regenerative stimuli capable of
promoting vascular or islet regeneration in vivo. Furthermore, extracellular vesicle
protein content of Panc-MSC proved pro-regenerative and provided a foundation for the
development of cell-free biotherapeutics employing Panc-MSC as mini ‘bio-factories’ for
regenerative medicine applications.
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Figure 7.2 Human Pancreas-derived Multipotent Stromal Cells Secrete
Multifaceted Pro-Regenerative Stimuli.

241

In summary, I have demonstrated human HPC and MSC possess multifaceted therapeutic
functions in murine models of vascular or islet regeneration. Unfortunately, previous
clinical use of autologous therapeutic cell populations has led to modest efficacy in
patients with critical limb ischemia presumably limited by poor cell engraftment in the
ischemic limb post-transplantation and/or a diminished pro-regenerative secretome
following extensive expansion ex vivo. Thus, allogenic cell sources such as healthy BM
or UCB combined with cell-free biotherapeutic approaches may help circumvent many of
the limitations of autologous cell transplantation. Further understanding of central
regenerative pathways and functional synergies through future research is warranted.
Towards this end, improving the capacity to expand therapeutic cell populations while
retaining regenerative secretory function is essential to refining our current regenerative
medicine approaches for treating diabetes and cardiovascular comorbidities.

7.1.1

Limitations of Progenitor Cell Isolation and Hematopoietic Cell
Expansion

In chapter 2 and 3, I isolated and expanded ALDHhi cells from UCB mononuclear cell
samples in serum-free conditions supplemented with TPO, FLT-3L, SCF. Leading up to
transplantation, several notable limitations were encountered with UCB ALDHhi cell
expansion. Firstly, lineage-depletion of UCB samples was achieved with a tetrameric
antibody system that binds multiple mature hematopoietic cell surface markers and
allows for depletion of mature cell populations during mononuclear cell isolation. After I
discovered that expanded ALDHhi cells preferentially differentiate towards the
megakaryocyte lineage, it was established this methodology did not deplete cells of the
megakaryocyte lineage using an antibody for CD41 or CD42. At the time of this study,
the initial enrichment of Lin- cells may have biased UCB ALDHhi cells towards
megakaryopoiesis by indirectly enriching for cells expressing these megakaryocytelineage markers. This limitation can easily be addressed in future studies by performing a
secondary depletion of CD41+ cells during FACS or simply using current lineagedepletion kits that include depletion of CD41+ cells.
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Paradoxically, TPO is a known driver of megakaryopoiesis1,2 and through pleiotropic
functions is also required for maintenance for human HSC pool3,4. Furthermore, HPC
express the thrombopoietin receptor Mpl, and can be directed to a megkaryocyte fate
when cultured with TPO in vitro4. I demonstrate in chapters 2 and 3 that exogenous TPO
drives UCB ALDHhi cell expansion, albeit at the cost of progenitor cell differentiation
(Figure 7.3). Developing megakaryocytes also secrete additional factors that further
promote progenitor cell differentiation in vitro. Given that UCB ALDHhi cells are
enriched with megakaryocyte-precursors and culture under conditions supplemented with
known drivers of megakaryopoiesis, the outcome of HPC expansion observed in this
study were likely predisposed by the aforementioned factors. Future studies will need to
individually address the influence of Lin- selection and culture conditions utilized for the
expansion of therapeutic ALDHhi cells.
Throughout this thesis, ex vivo expansion of UCB ALDHhi cell was performed in static
suspension culture and bulk media changes were performed every 3 days. Integration of
additional technologies, such as real-time bioreactor expansion chambers developed by
Zandstra and colleagues5-8, is expected to further enhance the expansion therapeutic HPC
by permitting a dynamic and control of culture conditions. Nevertheless, knowledge
acquired within this study provides insight towards targetable pathways that further
enhance the expansion of therapeutic HPC for applications of regenerative medicine.
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Figure 7.3 UCB ALDHhi cell Expansion and Differentiation is Paradoxically driven
by TPO.
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7.1.2

Elucidating the Complexity of ALDH-activity and Retinoic Acid
Signaling Pathways

Retinoic acid signaling exerts regulatory functions through the complex network of
upstream cytosolic effectors and nuclear receptors9-12, each containing distinct and
redundant isoforms. For example, genetic deletion of ALDH1A1 within transgenic mice
is rescued by increased ALDH1A3 expression and leads to normal fetal and adult
hematopoiesis13. An intellectual limitation encountered in chapter 2 was we did not
directly quantify the abundance of individual ALDH isoforms which contribute to
cannonical RA-signaling. Instead, we measured ALDH-activity using AldefluorTM
substrate which acts as a substrate for multiple ALDH isoforms. ALDH-activity is also
regulated through post-translation modifications, such as acetylation or deacetylation.
Thus, further quantification of specific ALDH isoforms will be needed to support future
studies utilizing AldefluorTM. Furthermore, ALDH-activity also measures a regulatory
function independent of RA-production, including the reduction of ROS production and
detoxification of reactive aldehydes14. DEAB-inhibition in chapters 2 and 3 inhibits
several isoforms of ALDH15,16, thus future studies using selective inhibitors or siRNA
interference would be better suited to address individual roles of ALDH isoforms and
subsequent ROS production during UCB ALDHhi cell expansion.
RA can be produced in cis- or trans- isoforms and is capable of activating receptors aside
from canonical RAR/RXR heterodimers, such as the PPAR17,18 or RAR-related orphan
receptors isoforms11,12,19. Likewise, the canonical RAR/RXR heterodimer complex can be
activated by additional ligands that selectively bind sites on either RAR or RXR subunits
bound to RA response elements11,20. RAREs are genetic loci of canonical RAR/RXR
regulatory complexes and exists at 100s of genes throughout the human genome, thus
active RA-signaling networks can provide a considerable amount of transcriptional and
epigenetic regulation within expanding ALDHhi cells21. Collectively, these properties
highlight the complexity of the RA-signaling network, that was largely understudied in
Chapters 2 and 3 as a result of technical limitations. Specifically, the future use of global
transcriptional (microarray or RNAseq) and proteomic analyses would provide more
fruitful insight into the ability of DEAB-supplementation to modify the complete RA-
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signaling network. To this end, concurrent manipulation of additional effectors and/or
receptors of may provide further regulation of complex RA-signaling networks in vitro.

7.1.3

Current Limitations of Murine Model of CLI

In Chapter 2 and 5, I utilized a murine model of hindlimb ischemia to assess distinct
biotherapeutic approaches to stimulate revascularization. Hindlimb ischemia in this
model is induced by surgical removal of the femoral artery and vein to induce acute
localized ischemia22,23. Unfortunately, acute ischemia induced in healthy NOD/SCID
mice does not fully reflect the pathogenesis observed in human patients with severe
atherosclerosis developed over a prolonged cardiometabolic imbalance24-26. Specifically,
the surgical model employed in this study does not reflect the gradual atherosclerotic
occlusion of peripheral arterioles that leads to distal tissue ischemia, inflammation and
necrosis in human patients. Therefore, inducing cardiometabolic imbalances within
preclinical models will improve translation of novel regenerative medicine approaches
towards reproduceable clinical efficacy in human patients.
Mice are highly resistant to atherosclerosis when fed a high-fat ‘Western’ diet,
thus modeling PAD/CLI in a standard rodent model is nearly impossible without genetic
perturbation. Single or dual transgenic knockouts of Apolipoprotein E/APOE or
Lipoprotein Lipase/LPL in mice provide models for the pathogenesis of atherosclerosis2730

, albeit even these genetic models do not entirely reflect the pathophysiology or

secondary complications of human CVD. Additional exogenous insults would be
necessary to model concurrent cardiometabolic syndromes such as diabetes. Ultimately,
the physiology of murine models limit our capacity to accurately model human PAD/CLI
with or without concurrent cardiometabolic syndromes. The physiology of large animals,
such as porcine or non-human primates, more accurately reflect human physiology,
although financial and logistical limitations must be considered with these models31-34.
Furthermore, the necessity of using immunodeficient models to study human cell
transplantation limits the relevance of an intact immune system that would likely require
larger animal models combined with immunosuppressive therapies. Later in this chapter,
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I will briefly discuss the theoretical use of human organoids as a complimentary model to
study human PAD/CLI.

7.1.4

Limitations of Using Mouse and Human Tissues to Elucidate Islet
Regenerative Mechanisms

In chapters 3 and 6, we employed a murine model of hyperglycemia induction through
STZ-induced 𝛽-cell ablation in immune deficient NOD/SCID mice that permit the
survival of transferred human cells35-37. Pathogenesis in this model was induced by the
administration of STZ, a glucose analog which specifically targets and damages β-cells
with high Glut2 expression. Therefore, autoimmune pathogenesis of human Type 1 DM
is not accurately reflected in the murine model employed38. Furthermore, NOD/SCID
mice provide a functional platform for human cell transplantation studies39, however the
lack of functional lymphocytes responsible for autoimmune destruction of β-cell in
human subjects. The initiation of autoimmunity is proceeded by a chronic infiltration of
inflammatory cells (insulitis) that will change the inflammatory microenvironment within
islets38. Future studies will need to employ more immunocompetent mice to better model
T1D and to assess the critical question whether β-cell regeneration can occur in the face
of ongoing autoimmunity? NOD mice spontaneously develop diabetes through a
pathogenic insulitis similar to human subjects40-42, however β-cell regeneration may not
be feasible without immunosuppression or reversal or autoimmunity. Our future studies
aim to explore whether human-derived cell-free biotherapeutics can be injected into
autoimmune NOD mice as described in chapter 6. If proof-of-concept can be established,
cell-free biotherapeutic delivery would be required to address whether islet regeneration
can occur in the face of autoimmunity and whether biotherapeutics generated by PancMSC can also dampen local autoimmunity in pre-clinical models of Type 1 DM.
The molecular and morphogenic mechanisms underlying endogenous islet regeneration
observed in Chapter 3 and 6 remain elusive. Specifically, putative signal-receiving cells
within the NOD/SCID pancreas can only be inferred through antibody-based histological
analyses following euthanasia, thus lacking fate-mapping capabilities captured using
current transgenic reporter systems (i.e. lineage-tracing). Several mechanisms for
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endogenous islet regeneration have been proposed and each require inducible lineagespecific transgenic systems to fully determine the origin of regenerating islet cells. For
example, the Melton laboratory used a tamoxifen-inducible transgenic human placental
alkaline peroxidase-reporter system driven by the insulin-promoter to suggest that mature
β-cell duplication was the primary source of regenerated β-cell mass following partial
pancreatomy43. In contrast, several cell alternative populations within rodent and human
pancreata have been suggested to possess a facultative capacity to transdifferentiate to βcells (α cells, exocrine cells, ductal epithelial cells) following specific pancreatic injury
(partial pancreatectomy, ductal ligation, STZ-treatment) to generate new 𝛽-cell mass
during pregnancy or early stages of Type 2 DM44-51. The ductal epithelium has been
repletely suggested to dedifferentiate into a bipotent progenitor cell that transiently
expresses NEUROG3 prior to endocrine cell neogenesis52,53. For example, the Collombat
lab used inducible expression of PAX4 to expand β-cell mass through the
transdifferentiation of Glucagon+ or Somatostatin+ cells cells54-57. Accordingly,
replacement of depleted glucagon cell populations was also suggested by this group to
occur through ductal epithelial cell transdifferentiation through a peusdo-mesenchymal
state. These novel findings demonstrate endocrine plasticity within the adult mouse
pancreas is possible, however further studies are required to determine the functional
relevance of this phenomea in humans without genetic manipulation. Liu et al recently
demonstrated inducible dual-lineage fate-mapping system, utilizing Dre- and Crerecombinase, to identity a multipotent stem cell population within the lungs activated
after injury58. With this system in mind, future fate-mapping studies investigating islet
regeneration can be designed using MSC-derived biotherapeutic approach in
sophisticated lineage-tracing models that selectively label cells with ‘transitional’
phenotype (i.e. Insulin/Glucagon; see Figure 7.4).
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Figure 7.4 Working model of Dual-lineage transgenic system utilizing Cre- and
Dre-recombinase to labelled potential cells with polyhormonal expression.
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7.1.5

EV isolation and transplantation to identify pro-regenerative subfractions

Several approaches are currently used to effectively purify EVs60-62, however I employed
a simple ultrafiltration fractionation in chapters 5 and 6 to enrich for EVs from CM
generated by Panc-MSC. I demonstrated ultrafiltration was sufficient to separate EVs
from soluble proteins of 3-100kDa using biological validation by mass spectrometry and
physical validation using nanoscale flow cytometry and atomic force microscopy. As
such, the purity of EVs within EV+ CM was limited by co-enrichment with large ECM
molecules (i.e. fibronectin) or large protein complexes. Generally, ECM components are
typically integrated as large heteromeric complexes selectively bound to additional
proteins63,64. Therefore, ECM molecules and large proteins complexes would be
concentrated with EVs using the ultrafiltration employed in chapters 5 and 6. Potential
contamination with large protein/complexes within the EV+ CM subfraction limited the
ability to demonstrate regenerative pathway stimulation in vivo was exclusive to EVs
secreted by Panc-MSC. Proteomic analysis of Panc-MSC CM encountered similar
limitations, such that effectors detected within the EV-enriched fraction were ‘most
likely’ contained within the lumen or membrane of EVs. Future studies would benefit by
using ultrafiltration to obtain pure EV preparations prior to transplantation64,65.
Alternatively, the implementation of siRNA interference or CRISPR-mediated genetic
modifications to Panc-MSC would provide insight towards the effectors secreted by
Panc-MSC that may provide multifaceted regenerative functions in vivo.

7.2 Clinical Applications
Throughout my thesis, I have demonstrated that both HPC and MSC demonstrate
multifaceted therapeutic potential using two pre-clinical models. Likewise, HPC and
MSC have been used previously in clinical trials for vascular or islet regenerative
applications66-68. Unfortunately, current clinical efficacy using these progenitor cell
population in the autologous has been modest at best. Several primary explanations for
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the lack of translational efficacy have been postulated including: (1) autologous
progenitor cells exposed to a harsh microenvironment shaped by chronic disease have
shown diminished therapeutic function and decreased engraftment following
transplantation69, and (2) extensive expansion ex vivo is often required to generate
sufficient cell numbers for transplantation yet expansion paradoxically drives the loss of
progenitor cell identify and therapeutic functions in vivo70, Thus, refinement of expansion
protocols to generate high cell number with therapeutic functions provide the greatest
clinical benefit. Results obtained in chapters 2 and 3, provide insight towards targetable
pathways (i.e. RA-signaling) to enhance expansion of regenerative progeny retaining
multifaceted therapeutic functions; potentially through the enrichment of pro-survival
signaling pathways which improves engraftment after transplantation.
Transplantation of biotherapeutic stimuli holds potential to activate specific
regenerative signaling pathways without many of the regulatory limitations encountered
by direct cell transplantation71,72. MSC demonstrate multifaceted regenerative functions
primarily mediated by a paracrine secretion of regenerative stimuli. Thus, MSC have
been previously used in numerous clinical trials68,73 for their secretory profile, however
clinical efficacy utilizing direct MSC transplantation into tissues has been limited by low
engraftment in an unfamiliar or harsh microenvironment. In chapters 4-6, I provide the
first in-depth and functional characterization of human Panc-MSC. Within the context of
clinical applications, I demonstrated Panc-MSC are an accessible cell population with
robust expansion kinetics and a pro-regenerative secretome. Future studies are now
warranted to determine whether cell-free biotherapeutics generated by Panc-MSC can be
used to directly stimulate endogenous regeneration or to better support regenerative cell
types after transplantation into relevant pre-clinical models.
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7.3 Future Studies and Proposed Experimentation
7.3.1

Enhancing the Engraftment of Therapeutic HPC

UCB provides a readily accessible source of allogenic progenitor cells used for
regenerative medicine applications74,75. Although efficacy following transplantation is
often limited by transient engraftment, in chapter 2, I identified that DEAB-treatment
during culture expansion enriched for HPC that generated proteins associated with prosurvival functions. To further elucidate the functional roles of these proteins, I would
implement siRNA interference prior to intramuscular transplantation to knockdown
identified proteins effectors in UCB ALDHhi cells expanded under DEAB-treated
conditions. Histological analyses performed shortly after transplantation would provide
insight into pathways that influence the engraftment of transplanted cell populations.
Alternatively, proteins of interest could also be upregulated through ectopic vector
expression or pharmaceutical activation of up/downstream effectors.

7.3.2

Do cells of the megakaryocyte-lineage possess multifaceted
therapeutic potential?

It was discovered in chapters 2 and 3 that UCB ALDHhi cell expansion was biased
towards generation of progeny from the megakaryocyte lineage. Interestingly, expanded
cells with low ALDH-activity were enriched for committed megakaryocytes with
previously unrecognized islet regeneration in vivo. Unfortunately, I was not able to
determine potential contribution of megakaryocytes to islet regeneration, although FACS
purification based on CD41 and/or CD42 could be employed to enrich for cells at
different stages of megakaryopoiesis. Direct FACS purification of megakaryocyte-related
cell populations could be transplanted into murine models of Type 1 diabetes or severe
CLI utilized throughout this thesis. Furthermore, platelet-rich plasma (PRP) has recently
emerged as a source of pro-angiogenic or anti-inflammatory stimuli with therapeutic
benefit for treating articular cartilage osteoarthritis in early clinical trials76-80. Platelets are
anucleated fragments generated by megakaryocyte burst is essential for wound healing
and vascular homeostasis81-83. Notably, it has been recently demonstrated that platelets
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can transfer potent vascular and tissue regenerative stimuli to exposed cell
populations77,84. Thus, future research would benefit from investigation of the therapeutic
potential culture-generated platelets transplanted into pre-clinical models of Type 1 DM
or PAD/CLI.

7.3.3

Identification of Panc-MSC during human pathology and
regeneration

The true phenotype of MSC in human tissues remains controversial and represents a
persistent limitation to the advancement of regenerative medicine approaches using
MSC85. Further fate-mapping studies are necessary to elucidate MSC hierarchies within
human tissues, however clinical use of native human Panc-MSC will ultimately rely on
elucidating unique functional benefits not demonstrated by BM-derived MSC. Here, I
demonstrated Panc-MSC demonstrated a unique proteome and enriched expression
progenitor cell markers, such as vimentin and nestin. Furthermore, I provided a surface
marker profile of Panc-MSC, including over 70 CD markers which may potentially serve
as candidate markers for further subset purification and functional analyses (Figure 7.5).
As observed in this study, heterogenicity is a current limitation of MSC culture. Until this
heterogeneity is minimized, functional variation between tissue-specific MSC will limit
consistent therapeutic benefit. Fibrosis following wounding is mediated by MSC-like
progeny, such that fibroblasts or myofibroblasts, robustly deposit ECM components that
comprise scar tissue and formation of an inflammatory microenvironment that generally
inhibits regeneration of functional cell populations86-88. Other groups have demonstrated
that tissue-specific MSC exist using fate-mapping in mice, however their multipotency
was facultative to injury and potency was restricted to fibroblast or adipocyte-lineages
when exposed to a pro-inflammatory microenvironment88. In the context of diabetes, the
BM niche becomes populated with MSC-derived adipocytes due to local metabolic
imbalances89,90. Although mesoderm-derived BM-MSC effectively differentiates into
adipocytes within this thesis, I demonstrated human Panc-MSC were restricted from
adipogenic differentiation in vitro. Adipocyte formation can occur within the pancreas;
however, the origin of these adipocytes remains elusive and requires further
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investigation. Lastly, several groups have proposed that select MSC populations may not
be derived from a mesodermal origin during embryogenesis91-96, but are
developmentally-derived from the neural crest. Collectively, future studies will need to
investigate the pathogenesis of human Panc-MSC during established Type 1 and Type 2
diabetes. Moreover, fate-mapping studies using pluripotent ESCs or iPSCs may be
required to elucidate the developmental origins of human Panc-MSC and their
contributions to endogenous islet regeneration.
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Figure 7.5 Working model to elucidate the phenotype and function of Panc-MSC in
situ in humans and mice. Pancreas concurrently harvested from (Ai) human or (Aii)
murine donors would be used to isolate single cells from (Bi) whole pancreas digests or
(Bii) dissociated islet preps. (C) Single cells would be FACS purified based on CD
candidates identified in Chapter 4 and (D) tested for single- cell colony formation and
MSC characteristics in vitro. MSC-like cells would be subjected to further molecular and
functional experimentation. (E) Transgenic mouse models could be created based on
relevant MSC-phenotypes, albeit (F) refinement of purification strategies may be
required. (G) Ultimately, the pathological role and therapeutic function of Panc-MSC
could be tested in stitu and used to develop of Panc-MSC could be tested in clinical trials
for regenerative medicine applications.
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7.3.4

Elucidating the pro-regenerative microenvironment generated by
cell-free biotherapeutics
The recent advancement in human organoid generation and culture may provide

an sustainable high-throughput platform to accurately model human disease in vitro and
after organoid implantation in vivo97,98. Furthermore, iPSC technologies offer the
opportunity to assess genetic and epigenetic differences encountered between human
patients with a given pathology. As eluded to in Chapter 1, designer cells would allow for
patient-specific organoids that reflect complex and concurrent pathogenesis, such as Type
2 DM or atherosclerosis. Although these technologies hold undoubtable potential,
standardized generation of human organoids is in its infancy and further development is
necessary before organoids are routinely used as translational models of disease. The
Penniger lab recently demonstrated the generation of human vascular organoids which
effectively modelled diabetes-induced vasculopathy in a multi-well culture system97. In
theory, we could use a cell-free biotherapeutics generated from ‘designer’ MSC and test
regenerative functions on similar organoid systems to elucidate targetable pathways that
reverse pathogenesis99. For example, periostin and Wnt5a was significantly enriched
within EV+ CM generated by Panc-MSC. Results for previous studies suggest Wnt5a100103
103

and periostin104-106 has proangiogenic and islet proliferative functions, respectively100. Additionally, global proteomic analyses and biotherapeutic agent transfer into

immunocompetent or inducible lineage-specific lineage tracing models suggested in this
thesis could provide additional insight towards understanding how ECM and
microenvironmental architecture influences both vascular and islet regenerative
mechanisms. It is essential to consider the signaling contribution of the 3D
microenvironment, as many studies have demonstrated the role of the extracellular matrix
on progenitor cell survival and differentiation8,107-109. Ultimately, the success of
biotherapeutic approaches, aiming to stimulate endogenous regeneration, will rely on the
ability to generate and sustain a ‘development-like’ microenvironment in the face of
chronic disease.
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Appendix 2 Animal Use Protocol Ethics Approval: β-cell Regeneration
AUP Number: 2015-033

AUP

Title:

Transplantation

of

Novel

Stem

Cells

for

the

Regeneration of B-Cell Function

Yearly Renewal Date: 07/01/2019

The YEARLY RENEWAL to Animal Use Protocol (AUP) 2015-033
has been approved by the Animal Care Committee (ACC), and
will be approved through to the above review date.

Please at this time review your AUP with your research team to ensure
full understanding by everyone listed within this AUP.

As per your declaration within this approved AUP, you are obligated to
ensure that:

1) Animals used in this research project will be cared for in alignment
with:
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a)

Western's

Senate

MAPPs

7.12,

7.10,

and

7.15

http://www.uwo.ca/univsec/policies_procedures/research.html
b) University Council on Animal Care Policies and related Animal
Care

Committee

procedures

http://uwo.ca/research/services/animalethics/animal_care_and_use_p
olicies.html

2) As per UCAC's Animal Use Protocols Policy
a) this AUP accurately represents intended animal use;
b) external approvals associated with this AUP, including permits
and scientific/departmental peer approvals, are complete and accurate;
c) any divergence from this AUP will not be undertaken until the
related Protocol Modification is approved by the ACC; and
d) AUP form submissions - Annual Protocol Renewals and Full
AUP Renewals - will be submitted
timeframes

outlined

and attended to within
by

the

ACC.

http://uwo.ca/research/services/animalethics/animal_use_protocols.ht
ml

3) As per MAPP 7.10 all individuals listed within this AUP as having any
hands-on animal contact will
a) be made familiar with and have direct access to this AUP;
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b)

complete

all

required

CCAC

mandatory

training

(

training@uwo.ca); and
c) be overseen by me to ensure appropriate care and use of
animals.

4) As per MAPP 7.15,
a) Practice will align with approved AUP elements;
b) Unrestricted access to all animal areas will be given to ACVS
Veterinarians and ACC Leaders;
c) UCAC policies and related ACC procedures will be followed,
including but not limited to:
i) Research Animal Procurement
ii) Animal Care and Use Records
iii) Sick Animal Response
iv) Continuing Care Visits

5) As per institutional OH&S policies, all individuals listed within this AUP
who will be using or potentially

exposed to hazardous materials will

have completed in advance the appropriate institutional OH&S training,
facility-level

training,

and

reviewed

related

http://www.uwo.ca/hr/learning/required/index.html

(M)SDS

Sheets,

267

Submitted by: Copeman, Laura on behalf of the Animal Care Committee
University Council on Animal Care

The University of Western Ontario
Animal Care Committee / University Council on Animal Care
London, Ontario Canada N6A 5C1
519-661-2111 x 88792 Fax 519-661-2028
auspc@uwo.ca�
http://www.uwo.ca/research/services/animalethics/index.html
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Appendix 3 Animal Use Protocol Ethics Approval: Hindlimb Ischemia
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